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INTRODUCTION 
Nausea and emesis are entities that have been recognized as 
such for many years. The former was derived from the greek 
word "naus" meaning ship, and originally meant seasickness. 
Until the middle of this century research in this field has 
mainly focussed on the physiology of vomiting. Early 
investigators such as Openchowski (188Θ), Thumas (1891), 
Hatcher (1924), and Koppanyi (1930) all agreed on the 
existence of a central vomiting centre, which they believed 
played the most important role in the emetic reflex. The 
exact location of the vomiting centre remained unclear 
until Borison and Wang identified the chemoreceptor trigger 
zone and the vomiting centre as two separate, but adjacent 
zones in the brainstem (1949). Later it was demonstrated 
that the gastrointestinal tract also played a major role in 
the emetic reflex. 
Since the early 1940's there has been an increasing use 
of chemotherapeutic agents for the treatment of cancer. 
Unfortunately, the increasing potency of cytotoxic regimens 
tends to be associated with more severe side effects. From 
the patient's point of view, nausea and vomiting have long 
been among the most distressing toxicities, often resulting 
in postponement or refusal of further chemotherapy, and 
possibly interfering with a potential cure. It was 
therefore of no surprise that effective anti-emetics were 
first demanded by patients and physicians alike. As in most 
areas of medical science progress in this field has been 
erratic. In this respect the history of metoclopramide is a 
good example. In the anti-emetic trials carried out between 
1965 and 1980 metoclopramide failed to show any control of 
cisplatin-induced emesis. In 1981 Gralla demonstrated that 
a good anti-emetic effect was achieved when metoclopramide 
was used at high doses. During the last decade this drug 
has been the cornerstone of most effective anti-emetic 
combinations. However, due to dopamine antagonism high-dose 
metoclopramide can induce extrapyramidal reactions, and 
these remain a major drawback, activating further research. 
Recently developed serotonin 5-HT3 receptor antagonists 
such as ondansetron, granisetron, and tropisetron showed 
promising results in the prophylaxis of cytotoxic drug-
induced emesis in animals. The first clinical experiences 
with ondansetron in the Netherlands were obtained at the 
University Hospital St Radboud in Nijmegen by P.H.M. De 
Mulder and colleagues. These early trials demonstrated that 
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ondansetron was able to prevent chemotherapy-induced 
emesis, and sufficiently supported the initiation of 
further anti-emetic trials which were carried out in 
Nijmegen and Rotterdam, and later also in other centres. 
Results of these different studies are described in this 
thesis. 
After it was established that ondansetron was effective 
in the prophylaxis of nausea and vomiting induced by 
cisplatin chemotherapy (chapter 4), it was also found that 
ondansetron could re-establish control in refractory emesis 
induced by non-cisplatin chemotherapy (chapter 6). 
Subsequently, the anti-emetic efficacy of a continuous 
infusion schedule of ondansetron was compared with a high-
dose metoclopramide regimen (chapter 7), and with single 
doses of ondansetron (chapter Θ). A pharmacodynamic study 
was carried out to investigate whether a relationship 
between a plasmaconcentration of ondansetron and anti­
emetic control could be determined (chapter 5). In order to 
put the data of ondansetron into proper perspective the 
pathophysiology of chemotherapy-induced emesis, treatment 
related aspects and modalities are reviewed (chapter 1 and 
2) and a comparison of the results of the 5-HT3 receptor 
antagonists ondansetron, granisetron and tropisetron was 
made (chapter 3 and 9). 
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Chapter 1 
PATHOPHYSIOLOGY OF CYTOTOXIC DRUG-INDUCED EMESIS: 
FAR FROM CRYSTAL-CLEAR. 
C. Seynaeve1, P.H.M. de Mulder2, J. Verweij1 
Department of Medical Oncology, 
Rotterdam Cancer Institute/Dr. Daniel den Hoed Kliniek, 
the Netherlands. 
Department of Medical Oncology, 
University Hospital St Radboud, Nijmegen, the 
Netherlands. 
Pharm Weekbl [Sci] 1991, 13:1-6. 
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Abstract 
Both radiotherapy and chemotherapy for cancer are capable 
of causing severe nausea and vomiting, which formerly often 
interfered with the patient's compliance to treatment. The 
basic pathways and pharmacological mechanisms herewith 
involved are still poorly understood. The recent discovery, 
however, that 5-HT3 receptor antagonists can prevent or 
greatly reduce chemotherapy-induced emesis led to a re-
evaluation of the sequence of events occurring in the 
protective emetic reflex, which are reviewed in this paper. 
The vomiting centre co-ordinates the incoming and outgoing 
information, and is thought to be represented by complex 
interactions between different adjacent areas in the brain-
stem. Whether the main role in the emetic reflex arch is 
accomplished by either the central part (chemoreceptor 
trigger zone) or the peripheral part (gastro-intestinal 
tract) needs further confirmation. A more important role, 
however, of the vagal nerve and the gastro-intestinal tract 
is generally accepted. The neurotransmitter serotonin 
appears to play a major role in chemotherapy-induced emesis 
via the 5-HT3 receptor. These indications could form the 
basis for further investigation into the involvement of 
other neurotransmitters, and the character of their 
interactions. 
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INTRODUCTION 
Cytotoxic cancer treatment frequently causes nausea and 
vomiting, and in doing so interferes with the patient's 
compliance to curative or palliative treatment. The anti-
emetic drugs currently available lack complete efficacy and 
can produce unwanted side-effects. Clearly more effective 
anti-emetics, preferably without side-effects, are needed. 
The rational design and selection of new anti-emetics 
requires an understanding of the causative mechanisms of 
nausea and vomiting. This involves a knowledge of the 
anatomy, physiology and pharmacology of the process of 
emesis. Comprehension of the emetic reflex is, however, 
hampered by the frequently inaccessible pathways and its 
complex neurophysiology and neurotransmitter interactions. 
Most fundamental knowledge of emesis comes from studies 
in dogs, cats, ferrets and incidental observations in man. 
Furthermore, there is little research into the reasons why 
cytotoxic agents cause emesis. Thus, to date there is much 
ignorance and speculation with regard to the patho-
physiology of emesis. However, the development of serotonin 
(5-HT3) receptor antagonists and their application in 
preventing or reducing severe radiotherapy- or chemo-
therapy-induced emesis, has renewed interest and activated 
further research into this clinically important field. 
Thus, it seems appropriate at this time to review the 
pathophysiology of emesis in the light of old and recent 
findings. 
FUNCTION AND ORGANIZATION OF THE EMETIC REFLEX 
In strict biological terms the vomiting act is a primitive 
function, through which living creatures can reject 
endogenous or exogenous toxic materials. Many stimuli are 
known to evoke emesis, such as motion, pregnancy, drugs, 
pain, anxiety, gut obstruction, uraemia, hyperglycaemia and 
hypercalcaemia, and increased intracranial pressure. 
Because of the variety of the emetic stimuli it comes as no 
surprise that this defence system consists of several 
mechanisms, in an attempt to ensure maximal protection 
(Table 1) [1]. A suggested hierarchy of these mechanisms is 
based on their temporal appearance: 
- the smell and taste of substances can lead to the 
avoidance of ingestion due to innate or previously 
learned behaviour; 
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- the detection of toxins by receptors in the gut results 
in an appropriate response: nausea prevents further 
consumption; decreased gastric motility limits the toxin 
to the stomach and reduces absorption; vomiting evacuates 
the ingested toxins; 
- the detection of toxins by receptors located in the 
central nervous system is the protective mechanism of 
last resort, also leading to an emetic response. 
If some line of defence is highly developed, it renders 
some of the other protective levels redundant or non­
functional. The absence of vomiting in laboratory rats can 
so be explained, since they develop a pronounced 
conditioned taste aversion to a wide range of emetic 
stimuli. 
Table 1. The hierarchical organization of the defence 
mechanism for protection of the organism against 
toxins *. 
Level of 
defence 
1 
2 
3 
Location 
of toxin 
outside 
the GI 
tract 
Intra­
gastric 
Intra­
vascu­
lar 
Type of Sensor 
location 
1.smel1 and taste 
2.peripheral 
1.chemoreceptors 
2.near absorptive 
site 
1.chemoreceptor 
trigger zone 
2.central ner­
vous system 
Effect 
a.avoidance 
b.nausea 
a.nausea 
b.motility 
c.avoidance 
d.vomiting 
a.nausea 
b.motility 
с vomiting 
Resultant 
action 
.learned 
aversion 
for potential 
toxins 
.learned 
aversion 
.confining 
toxin to one 
area 
.ejection of 
toxin 
•ejection of 
toxin 
.confining 
toxin 
.learned 
aversion 
* Adapted with permission from reference 1. 
Early investigators already recognized that emesis is a 
complex act involving co-ordinated activities of the 
gastro-intestinal tract, and the respiratory and abdominal 
musculature [2]. Others concentrated on the centrally 
occurring processes [3]. Induction of vomiting seems 
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unlikely to be governed by one common mechanism, although 
three components appear to be general : 
- Afferent pathways relay the signals of the emetic stimuli 
from the periphery to the central nervous system; 
- Central reception, recognition and processing areas 
integrate the emetic stimuli and orchestrate the 
appropriate response in the vomiting centre; 
- Efferent pathways co-ordinate, in an unique spatio-
temporal sequence the changes in the involved organs to a 
vomiting act and the accompanying emetic epiphenomena. 
We will discuss the different elements separately. 
AFFERENT PATHWAYS 
The different regions thought to detect an emetic stimulus 
are the vestibular sensory apparatus, the higher cortical 
regions, the chemoreceptor trigger zone and the 
gut/pharynx. The latter two are the most important 
detection sites in chemotherapy-induced emesis (Fig. 1 and 
2). 
Vestibular sensory apparatus 
The hair cells in the labyrinth are the receptors of 
motion-emetic stimuli. The connections with the vomiting 
centre are thought to go via the vestibular nerve and 
nuclei, via the cerebellum and the chemoreceptor trigger 
zone. It has been demonstrated in animals that the removal 
of the cerebellum or the area postrema abolishes motion-
induced vomiting. Many neurotransmitters appear to be 
involved, although individually they have not, as yet, been 
identified [4]. An argument for a role of the labyrinth in 
chemotherapy-induced emesis comes from the observation that 
patients, sensitive to motion sickness, experience more 
severe emesis after chemotherapy [5]. 
Higher cortical regions 
Exact connections of the higher cortical regions with the 
vomiting centre or a specific neurotransmitter have not yet 
been identified. Afferent input to the vomiting centre 
seems to come from subcortical forebrain nuclei, from 
hypothalamic and mesencephalic regions. Conditioned taste 
aversion and anticipatory emesis are thought to originate 
in these regions. 
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Chemoreceptor trigger zone 
In 1953, Borison and Wang identified the chemoreceptor 
trigger zone as a region separate from the vomiting centre 
[6]. The chemoreceptor trigger zone, which functions as a 
detector of circulating emetic agents, is a group of 
specialized cells located in the area postrema on the floor 
of the fourth ventricle and belongs to the circumventri-
cular organs. Morphologically, the following are 
distinguished in the area postrema: the parenchyma, the 
blood compartment and the perivascular spaces. The 
vasculature mainly consists of sinusoidal fenestrated 
capillaries enabling direct access to blood components. 
Furthermore, there is also a direct link with the cere-
brospinal fluid through a permeable membrane and by means 
of free flow through the pericapillary spaces continuous 
with the subarachnoid fluid space [7]. 
Afferent pathways to the chemoreceptor trigger zone pass 
through the tractus solitarius and its nucleus and come 
probably from the hypothalamus and other cortical regions. 
Vagal afférents from the gut (sensory information) and 
glossopharyngeal afférents (baroreceptor information) 
project directly to the area postrema [1,8]. Efferent 
signals from the chemoreceptor trigger zone are probably 
involved in gastro-intestinal tract motility [9]. 
Evidence for an involvement of the chemoreceptor trigger 
zone in the emetic reflex was generated by the observation 
that ablation of the area postrema abolishes the vomiting 
response to several (e.g. apomorphine, cisplatin, 
radiation), but not all emetic stimuli [3,9,10]. 
Destruction of the area postrema in 5 patients with 
intractable emesis due to irresectable brain tumours, 
resulted in a relief from vomiting and no response to 
apomorphine [12]. Neurochemical studies of the chemo-
receptor trigger zone/area postrema in animals and man 
demonstrated the presence of several putative neuro-
transmitters: dopamine, norepinephrine, somatostatin, 
substance P, vasoactive peptide (VIP), enkephalins, chole-
cystokinin (CCK), γ-aminobutyric acid (GABA) and serotonin 
(5-HT); as well as receptors or binding sites for dopamine 
(D2), histamine (H2), norepinephrine (a2), cholecystokinin, 
enkephalins and acetylcholine [9,13-15]. Recently 5-HT3 
receptors were also demonstrated in the chemoreceptor 
trigger zone of the ferret and man [16,17]. 
In summary, it seems likely that the chemoreceptor 
trigger zone indeed plays a major role, though not the only 
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one, in emesis [2,11]. Probably the activation occurs in 
two ways: by vagal afférents and by exogenous or endogenous 
emetic agents [9]. Precise knowledge of the relevant 
receptors and transmitters is lacking. 
Visceral afférents 
In the hierarchical organization of the emetic reflex the 
first line of defence is situated in the gastro-intestinal 
tract, which is an important source of sensory stimuli 
collected from several neural intestinal plexuses. The 
afferent signals are conveyed mainly via the vagal and to a 
lesser extent via the splanchnic nerves. It has been shown 
that abdominal vagotomy abolishes or suppresses emesis 
induced by radiation, chlormethine, cisplatin and cyclo-
phosphamide, and inhibits both the gastric relaxation and 
the retroperistalsis [6,18,19]. 
It is not exactly known which of the gastro-intestinal 
effects, induced by cytotoxic treatment, activate the 
different receptive afférents. Observed changes are: 
alteration of gastro-intestinal motility (cisplatin) [2]; 
an altered morphology of the intestinal wall (chlormethine, 
cyclophosphamide, fluorouracil, methotrexate, cisplatin) 
[20-22]; increased levels of 5-HT and 5-hydroxyindole 
acetic acid (5-HIAA) in the ileal mucosa (not in gastric 
mucosa and the hypothalamic region) (cisplatin) [21]. 
Recently it has been demonstrated that the urinary 
excretion rate of 5-HIAA in man increased considerably in 
the 4-to-6-h period after cisplatin infusion. This rise 
parallels the onset and development of emesis [23]. 
Moreover, some agents (e.g. 5-HT, cholecystokinin), placed 
in the intestinal lumen, evoke a changed motor activity or 
activate mechanoreceptors via local reflexes [9]. 
Hence, it seems likely that cancer chemotherapeutic drugs 
damage the intestinal mucosa, releasing neuroactive agents 
which in turn activate the respective receptors (Fig. 1 ) . 
Apart from 5-HT, other neurotransmitters appear to have a 
role in this process, e.g. adenosine triphosphate (ATP), 
dopamine, vasoactive peptide, histamine, acetylcholine. 
Despite the anti-emetic properties of some of their 
antagonists, the phenomenon cannot be explained by one 
unique neurotransmitter. 
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Emetics in CNS ^-»-_ 
•·$*** \\^±. Area Postrema 
^т^гт&ъК Vertebral artery 
Diaphragm 
Intercostals 
Tongue 
Abdominal 
muscle 
Heart 
Airways 
Salivary glands 
Gut mucosa 
Gut muscle 
Portal vein 
Luminal stimuli (e.g. CuSOi) 
Systemic cytotoxics (e g cisplatm) 
Radiation 
Figure 1. 
A summary of the major pathways involved in cytotox ic- and radiation-induced 
emesis. Emetic agents are suggested to cause the release of neuroactive agents in 
the upper gut mucosa, act ivat ing via the vagal nerve the "vomiting centre", 
d i r e c t l y or v ia the chemoreceptor t r i g g e r zone. Entering the bloodstream these 
agents could be detected by hepatic afférents or chemoreceptors in the chemo-
receptor t r i gger zone, (published with permission from Andrews [ re f .19 ] ) 
CENTRAL INTEGRATING COMPLEX 
With the d e s c r i p t i o n by Thumas in 1891 of a l o c a l i z e d 
c e r e b r a l reg ion in which emesis was i n i t i a t e d with l o c a l l y 
app l ied apomorphine, the concept of a vomiting cen t r e has 
been p o s t u l a t e d . A s e r i e s of papers publ ished in the 1950s 
has provided the cu r r en t knowledge on t h i s s u b j e c t . 
In 1949 Borison and Wang e l i c i t e d emesis in decerebra ted , 
unanaes thes ized c a t s by e l e c t r i c a l s t i m u l a t i o n of the 
d o r s o l a t e r a l p a r t of the r e t i c u l a r formation in the b r a i n -
stem. Damage t o t h i s a rea by implan ta t ion of radon seeds 
made the animals r e l a t i v e l y r e f r a c t o r y to previous emetic 
s t i m u l i [ 6 ] . Adjacent a reas a re the r e s p i r a t o r y , vasomotor 
and s a l i v a t o r y c e n t r e s ; and the c r a n i a l nerves VIII and X 
t r a v e l c lo se by. Recent e l e c t r i c a l s t imu la t i on s t u d i e s have 
f a i l e d t o d u p l i c a t e these r e s u l t s and no defined vomiting 
c e n t r e could be loca ted [24] . Although t h e r e a re important 
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technical limitations in this kind of studies, it is 
premature to conclude that the vomiting centre does not 
exist. 
Further studies led to the identification of the 
parvicellular reticular formation which has an extensive 
network of neuroanatomical connections with several brain-
stem nuclei. This could be consistent with the role of an 
integration centre [25]. Nowadays, it is thought that the 
vomiting centre, rather than being a single anatomical 
entity, is represented by complex interactions between the 
nucleus tractus solitarius, the parvicellular reticular 
formation and the visceral and somatic motor nuclei 
involved in the efferent reflex arch (Fig. 2) [9,25]. 
Accordingly, instead of a "parallel" activation model 
with the vomiting centre functioning as a central black box 
giving rise to the different reflex components, a 
"sequential" activation model has been suggested. The 
different triggered effector nuclei would then act in 
concert to elicit an emetic response if the threshold for 
activation was reached [1]. 
Vomiting centre 
higher 
CNS areae 
Veatlbular 
apparatus 
Area postrema 
n.vagua 
Figure 2 . 
The central integrat ing complex, represented by interact ions between the nucleus 
tractus so l i t a r i us (NTS), the parv ice l lu lar re t i cu la r formation (PCRF) and the 
visceral-somatic motor nucle i , and i t s connections. 
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EFFERENT PATHWAYS 
The efferent impulses to the effector organs travel through 
the hypoglossal, glossopharyngeal and trigeminal nerves 
(innervating the mouth and pharynx), through the vagal 
nerve (pharynx, airway, gastro-intestinal tract), from the 
respiratory centre to the phrenic and intercostal nerves, 
and through some sympathetic efferents (gastro-intestinal 
tract). Activation of these pathways induces many changes. 
Outside the gastro-intestinal tract associated phenomena 
occur: including vasoconstriction, cold sweat, salivation, 
increased upper airway secretion, increased heart rate, 
lowered blood pressure and increased depth of respiration. 
The observed intestinal changes are mainly related to 
altered motility. Prior to emesis the proximal stomach 
relaxes, mainly due to an increased activity in the non-
adrenergic, non-cholinergic inhibitory vagal neurons. 
Possible neurotransmitters involved are ATP, dopamine, 
vasoactive peptide and 5-HT. Secondly, the slow wave 
activity (basic electrical rhythm) and the normally 
superimposed spiking activity are decreased or abolished in 
the antrum, duodenum and jejunum, leading to a period of 
"electrical silence". Hereafter, an intense spiking 
activity occurs in these regions, resulting in an orally 
propagated contraction. 
Table 2. Different phases of the emetic act. 
1. NAUSEA: the feeling of a need to vomit, associated with prodromal signs 
and coincided with proximal gastric relaxation and intestinal 
retroperistalsis (pre-ejection phase) 
2. RETCHING: synchronized movements of the diaphragm and the respiratory and 
abdominal muscles against a closed glottis, with coinciding upper 
oesophageal sphincter relaxation (ejection phase) 
3. VOMITING: forceful expulsion of gastric contents by the contraction of the 
abdominal muscles and the diaphragm, in coordination with opening 
of the gastric cardia and a relaxation of the upper oesophageal 
sphincter (ejection phase) 
In several animal studies an identical change in motility 
has been observed after the administration of apomorphine 
and cisplatin [2]. In patients with unexplained emetic 
complaints and motion-induced sickness disturbed electrical 
rhythms (tachygastrias, tachyarrhythmias) have been 
described [26,27]. The exact nature of the mechanism or 
neurotransmitter involved is unknown. Dopamine, adrenaline, 
prostaglandin, enkephalins, glucagon and 5-HT are possible 
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agents [2,9,18]. 
An integration of all these changes results in the 
vomiting act, which can be divided into three stages, as 
shown in Table 2. 
NEUROPHARMACOLOGY OF CYTOTOXIC DRUG-INDUCED EMESIS 
It is clear from the preceding paragraph that many stimuli 
interfere at different points in the emetic reflex, and at 
any point there is a potential role for numerous neuro-
transmitters. The traditional anti-emetics with their 
antagonistic activity for histamine, acetylcholine and 
dopamine have led to the study of their involvement in 
chemotherapy-induced emesis. Receptors for histamine, 
acetylcholine and dopamine have been identified in the area 
postrema/chemoreceptor trigger zone and in other cerebral 
regions [14,15,28]. However, a blockade of all these 
receptors by a combination of different anti-emetics did 
not result in the expected complete anti-emetic control 
[29]. Moreover, there are no indications of an interaction 
of cytotoxic drugs at these receptors [30]. 
Evidence for a central involvement of dopamine D2 
receptors in chemotherapy-induced emesis includes the 
abolition of emesis induced by dopamine antagonists by the 
ablation of the area postrema [6] and the activation of 
area postrema neurons by dopamine [1,13]. On the other 
hand, the most effective anti-emetic metoclopramide has the 
lowest affinity for D2 receptors in comparison with other 
dopamine antagonists and is also active at 5-HT3 receptor 
sites unlike other anti-emetic dopamine antagonists (Table 
3) [29,31]. Little evidence has been found for a major role 
of dopamine outside the central nervous system. D2 
receptors have been found in the oesophagus, the stomach 
and the duodenum. However, no dopamine is found in the 
gastro-intestinal wall after extrinsic denervation and a 
role as an intrinsic neurotransmitter seems unlikely 
[18,32]. Studies are, however, limited by the unselectivity 
of the available dopamine antagonists. 
The delayed onset of chemotherapy-induced emesis led to 
the suggestion that cytotoxic drugs probably inhibit the 
turnover of particular enzyme systems resulting in 
inhibition of neurotransmitter breakdown. The rate of 
neurotransmitter accumulation depends on the kind of chemo-
therapy and dictates the time of onset of emesis. Such 
likely neurotransmitters are enkephalins found in the area 
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postrema and probably acting via opiate receptors. 
Furthermore, these neuropeptides are linked with the dopa-
minergic system and can cause dopamine release [8,33,34]. 
Although this idea is interesting, the hypothesis has not 
been sufficiently tested. 
The role of endotoxins and ß-endorphins released after 
cellular damage has been studied, but similarly the 
available data are insufficient to support a major role in 
chemotherapy-induced emesis [19,35]. 
Renewed interest in the neuropharmacology of emesis, and 
especially for serotonin and its 5-HT3 receptor as a 
possible mediator of chemotherapy-induced emesis originated 
from the finding that the dopamine antagonist 
metoclopramide also blocked activity at 5-HT3 receptors 
[31,33,36]. Other 5-HT receptor types, 5-HT^like and 5-
HT2, appear not to be involved in chemotherapy-induced 
emesis. There is evidence that different affinities for 5-
HT3 receptors are found in different species [37]. These 
receptors have been demonstrated in large numbers on the 
afferent neurons of the gastro-intestinal tract (90% of the 
total body 5-HT is located in the intestinal entero-
chromaffin cells) and the central nervous system (cortical 
and limbic areas, area postrema) [17,38,39]. A possible 
hypothesis with the 5-HT3 receptor as a unifying concept in 
chemotherapy-induced emesis is outlined in Figure 1. Cyto-
toxic drugs can damage cells in the gut causing a release 
of 5-HT from the enterochromaffin cells. The increased 
amount of 5-HT can activate vagal afférents, either 
directly in the hepatic veins or indirectly by a disruption 
of gastro-intestinal motility, leading to an emetic 
response [9,17,23]. The role of the central parts of the 
pathway requires further investigation. Although serotonin 
can activate neurons in the area postrema [11], an intra-
cerebroventricular injection of the 5-HT agonist 2-methyl-
5HT did not evoke emesis, unlike apomorphine, and the 
duration of the anti-emetic control was unexpectedly short 
[17]. 
In view of these data, specific 5-HT3 receptor 
antagonists were tested for their anti-emetic potential. 
Several studies in animals and man demonstrated promising 
anti-emetic results against radiotherapy- and chemotherapy-
induced emesis [19,36,40,41]. Furthermore, 5-HT3 anta-
gonists have an anxiolytic activity and can reduce the 
hyperactivity caused by an increased mesolimbic dopa-
minergic activity [42]. These observations suggest that a 
synergism between 5-HT and another mediator is needed in 
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the initiation of the emetic reflex and that modulation 
between dopaminergic and serotonergic pathways may occur 
[43]. 
Table 3. Drug affinities for dopamine-, histamine-, 
muscarine choline- and serotonin-labelled sites 
in brain membranes. (K , nmol/D* 
Drug 
Dopamine 
P r o c h l o r p e ­
r a z i n e 
Chlorpromazine 
Oro p e n d o ! 
F luphenazine 
Dompen done 
S e r o t o n i n 
BRL43694 
ICS205-930 
Z a c o p n d e 
MDL72222 
Mixed Drug 
M e t o c l o p r a ­
mide 
Dopamine 
( D 2 ) 
7 . 3 
1Θ 
2.4 
4 . 8 
12 
>10,000 
>10,000 
>10,000 
>10,000 
240 
±1 
±5 
± 0 . 6 
±3 
±3 
±60 
Muscarine 
c h o l i n e 
2,100 
300 
130 
>10,000 
340 
-
-
-
-
-
>10,000 
H i s t a m i n e 
(V 
100 
2Θ 
2,500 
60 
-
-
-
-
-
1,100 
S e r o t o n i n 
(5-HT3) 
1,800 
1.900 
4,200 
>10.000 
>10,000 
0.30 
0.38 
0.42 
0.20 
120 
±200 
±30 
± 0 . 0 4 
±0.02 
±0.2 
± 1 . 0 
±30 
* Adapted from Peroutka [ref 30,33]. 
CONCLUSION 
Many questions remain unanswered with regard to the path­
ways and neurotransmission in chemotherapy-induced emesis. 
Recent work with 5-HT3 receptor antagonists has stimulated 
research and opened new perspectives into the mechanism of 
emesis. A more important role has been assigned to visceral 
systems, especially the gut, whereas the vomiting centre is 
probably represented by a complex network of interactions 
at adjacent areas rather than a single centre. Cytotoxic 
drugs are thought to induce peripheral intestinal changes 
activating vagal afférents projecting on the chemoreceptor 
trigger zone/parvicellular reticular formation. This 
results in emesis. The neurotransmitters involved in the 
activation of these pathways are not yet clear. Research 
has focussed on 5-HT and its type 3 receptor, which is 
believed to play an important, but not unique role in 
chemotherapy-induced emesis. 
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Furthermore, there is evidence for a possible modulation 
between 5-HT and dopamine or other unknown mediators. 
Knowledge of, and better insight in the neuropharmacology 
of chemotherapy-induced emesis may result in a more 
rational approach to the development of effective anti-
emetics and the final goal of completely controlling 
emesis. 
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Abstract 
Cytotoxic chemotherapy can induce acute, delayed and 
anticipatory nausea and vomiting. The efficacy and toxicity 
data of the available anti-emetics and their role in 
chemotherapy-induced emesis are reviewed. Moreover, some 
pitfalls in the methodology of anti-emetic trials as well 
as factors known to affect the individual sensitivity of 
patients for the emetic challenge are illustrated. So far 
high-dose metoclopramide (3-6 mg/kg/day) was the most 
effective single agent in the control of acute emesis. 
However, extrapyramidal reactions caused by its dopamine 
antagonism remained a major drawback. The addition of 
dexamethasone and/or lorazepam decreases the incidence of 
extrapyramidal reactions, and further improves anti-emetic 
control. In animals, serotonin type 3 receptor antagonists 
have demonstrated promising anti-emetic results against 
chemotherapy- and radiotherapy-induced emesis, the results 
of clinical studies are awaited. Delayed nausea and 
vomiting have been studied less. At present, the 
combination of metoclopramide and dexamethasone offers an 
optimal protection in ± 50% of patients on cisplatin chemo-
therapy. Anticipatory nausea and emesis remain major 
problems, and an effective pharmacological treatment is 
lacking. Attempts to control this type of emesis focus on 
drugs with amnesic properties and behaviour therapy. 
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INTRODUCTION 
Nausea and vomiting are well known side effects of cancer 
chemo- and radiotherapy, and one of the most prominent from 
the patients perspective [1,2]. These side effects may 
interfere with patient's compliance, and influence the 
outcome of potentially curative regimens [2,3]. Sometimes, 
serious problems can arise in the absence of good anti-
emetic control ranging from refusal of possibly curative 
treatment [2,3], the occurrence of oesophageal tears 
(Mallory Weiss), pathological bone fractures [3] or 
electrolyte disturbances exacerbating the possible 
nephrotoxicity of cytostatic agents [3,4], to anticipatory 
emesis [5], disruption of social life [2] and psychological 
depression [6]. 
The recognition of this problem, emphasized by the use of 
the highly emetogenic drug cisplatin [7], led to 
intensified research on anti-emetic agents and an over-
whelming amount of publications. At present an improved 
anti-emetic control in the acute phase can be achieved in 
70% of the patients, however, still 20-30% of them 
experience some degree of acute nausea/vomiting which in 
its turn can lead to refractory or anticipatory nausea and 
vomiting. Important parts of the anatomic structures and 
the neurotransmitters involved in the mediation of nausea 
and vomiting are known. However, the precise mechanisms by 
which cytotoxic agents induce emesis are not known, 
hampering a true rational approach. 
At the moment three chemotherapy related emetic entities 
have been identified: (1) Acute nausea and vomiting occur 
during the first 24 hours after the chemotherapy 
administration. (2) Delayed emesis are the prolonged emetic 
complaints occurring from day 2 up to day 6 inclusive after 
chemotherapy. (3) Anticipatory emesis occurs prior to the 
administration of chemotherapy. 
Obviously not all nausea and vomiting experienced by 
cancer patients is ascribable to chemotherapy. Other causes 
of emesis such as hypercalcaemia, uraemia, bowel 
obstruction, brain metastases and co-medication (e.g. 
morphinomimetics) should always be considered. 
The purpose of this paper is to outline some 
considerations in the anti-emetic approach supporting 
chemotherapy and to give a practical guide for use of the 
available anti-emetic agents. We will discuss variables 
affecting anti-emetic assessment, some methodological 
pitfalls, available and investigational anti-emetic drugs, 
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and validated anti-emetic regimens. 
VARIABLES AFFECTING ANTI-EMETIC ASSESSMENT 
Patient variables 
The incidence and course of cytotoxic drug-induced emesis 
differ greatly among patients and even among treatment 
courses in one patient. Recognized factors interfering with 
outcome are: age, sex, high chronic alcohol use, prior 
chemotherapeutic treatment, and susceptibility to motion 
sickness. 
Emesis appears to be easier to control in men [8-10] and 
in elderly (>60 yrs) [8,11]. Possible explanations for the 
sex difference are the different hormonal status or the 
endocrine changes induced by the anti-emetic drugs, it 
remains to be proven whether the apparently increased anti-
emetic control in the elderly can be explained by a reduced 
number of receptors, decreasing the sensitivity to the 
anti-emetic challenge [11]. Moreover the influence of 
several co-factors such as different diseases, greater 
likelihood of alcohol use and other chemotherapeutic 
regimens should be taken into account. 
Complete anti-emetic control is more difficult to achieve 
in patients who have received previous courses of chemo-
therapy than in chemotherapy naive patients [12-14]. 
Conflicting results are reported on the maintenance of 
anti-emetic control with subsequent chemotherapy courses 
[10,13,15]. Once treatment coincides with poor anti-emetic 
control it is well recognized that the patient is 
predisposed to vomit more with following chemotherapy 
cycles, underlining the importance of primarily adequate 
anti-emetic treatment. 
Patients with a history of chronic and significant 
alcohol use (> 80 g/day) appear to have a better anti-
emetic control [16,17]. There is not yet a clear 
explanation for this observation. 
Patients susceptible to motion sickness, on the other 
hand, are less easy to control. It is not yet proven 
whether this implies that the chemoreceptor trigger zone 
receives additional information from the vestibular system 
or higher cortical zones. 
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Cytotoxic drug variables 
All cytotoxic drugs can induce nausea and vomiting, to a 
degree dependent on the type of cytotoxic drug used. Harris 
mentioned hypothetically that this difference could be 
produced by inhibition of rapidly turning over enzyme 
systems, responsible for the breakdown of neurotransmitter 
substances being specific for each agent [19]. Other known 
variables are: the drug-dose [8,12,20], the rate of 
administration (e.g. adriamycin, cisplatin [20]), the route 
and time of administration [21]. The onset and duration of 
emesis is also drug dependent. Acute emesis generally 
starts within the first 4 hours, reaching a peak intensity 
between 4-10 hours after administration. On the contrary 
mustine hydrochloride can cause nausea/vomiting within 30-
120 min., while cyclophosphamide given intravenously often 
has a latency period of 9-18 hours before emesis occurs 
[22]. Delayed emesis after cisplatin may continue for upto 
6 days [23]. If chemotherapy is given over consecutive days 
tolerance can occur. Table 1 lists frequently used cyto-
toxic drugs in the order of increasing emetogenic 
potential. One should be aware that these data were not 
obtained from strictly controlled studies on the different 
agents, but from clinical observations. 
METHODOLOGY OF ANTI-EMETIC TRIALS 
Anti-emetic studies show great divergence in design and 
assessment, resulting in a difficult interpretation and 
comparison of the generated information and sometimes in 
the inability to draw conclusions. Undoubtedly, anti-emetic 
trials have to meet much requirements and an universal 
recepted standard to measure overall efficacy is lacking. 
This is partly caused by the difficulty of evaluating and 
quantifying the subjective nature of nausea [24]. The 
various issues of anti-emetic research have been outlined 
recently by Pater and Willan [25]. When judging the quality 
of anti-emetic studies, attention should be payed to: 
(1) which anti-emetic regimen was used for comparison 
(optimum dose schedule, route of administration). 
(2) was the study randomized, double-blind, with adequate 
sample size to detect differences? 
(3) was it a cross-over or a parallel design? A cross-over 
design may be more effective since utilization of the 
patient as his own control results in greater power 
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for the given sample size and allows for the 
assessment of patient's preference. However, in the 
analysis one has to take into account that the 
efficacy of a treatment may be different when used in 
the second period because of a carry-over effect. 
(4) was there a stratification for emetic potential, for 
an in/out-patient setting, for prior chemotherapeutic 
treatment? Were the groups balanced with respect to 
age, gender, alcohol use? 
(5) did the data collected include quantitative assessment 
of nausea (graded or visual analogue scale) and 
vomiting (number, time of episodes), duration of the 
evaluated period, data on post-treatment symptoms, 
anticipatory emesis and side effects. 
Table 1. Relative emetogenic potential 
therapeutic drugs. 
of several chemo-
Emetic Potential 
High Likelihood 
Low Likelihood 
Cytotoxic drug 
Cisplatin 
Dacarbazine 
Dactinomycine 
Mechlorethamme 
Cyclophosphamide 
Doxorubicin 
Daunorubicin 
Epirubicin 
Iproplatin 
Carboplatin 
Carmustine 
Lomustine 
Cytarabine 
Procarbazine 
Etoposide 
Mitoxantrone 
Mitomycine-C 
Methothrexate 
5-Fluorouracil 
Vinblastine 
Bleomycin 
Vincristine 
Chlorambucil 
Emesis 
onset 
1-6 
1-3 
2-6 
1/2-2 
6-12 
4-6 
2-6 
4-6 
4-6 
6-14 
2-4 
2-6 
6-12 
24-27 
3-8 
2-6 
1-4 
4-12 
3-6 
4-8 
3-6 
4-8 
48-72 
Emesis 
duration(hrs) 
24-72 
12-24 
12-24 
8-24 
4-24 
12-24 
<24 
12-24 
24-48 
24-48 
4-24 
4-6 
3-5 
diff 
24 
<24 
48-72 
3-12 
unknown 
unknown 
unknown 
unknown 
unknown 
With these guidelines anti-emetic trials can produce more 
clear-cut results and can be assessed for their true value. 
Unfortunately not all these conditions can be fulfilled. 
Only a few pharmacokinetic studies have been performed 
showing a great variability in serum drug-concentrations 
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and an absence of dose-response relationship [11,20,24,26]. 
Exact data on an optimum dose are not available for most 
anti-emetics. 
ANTI-EMETIC AGENTS 
The anti-emetic drugs can be classified according to the 
type of receptor blockade or site of action. We will focus 
on those anti-emetics with documented efficacy in chemo-
therapy-induced emesis and briefly discuss their pharma-
cology and toxicology. Some recommendations for doses and 
route of administration will be given. 
Dopamine antagonists 
Pheno thiazines 
The anti-emetic effect of these agents appears to be 
exerted through competitive antagonism on dopamine 
receptors predominantly in the chemoreceptor trigger zone. 
While it is uncertain whether the anti-histaminic and anti-
cholinergic activities contribute to the anti-emetic 
efficacy, they do so for the side effects. The drugs all 
have a similar base structure with 2 substituted positions, 
whereby the composition of the side chain at position 10 
has been suggested to affect the anti-emetic activity. In 
man however it was not observed that piperazine derivatives 
had a higher efficacy than aliphatic compounds. Major 
adverse events are autonomic dysfunction (hypotension, 
sedation) and extrapyramidal reactions [27]. 
Prochlorperazine, at a daily dose of 30-50 mg, has been 
found to be equivalent to droperidol and low-dose meto-
clopramide (MCP), equivalent or inferior to tetrahydro-
cannabinol (THC), inferior to high-dose MCP and dexa-
methasone in the control of acute emesis [27-30]. Recently 
significantly better anti-emetic results were obtained 
using higher doses (30-40 mg, tds, given i.v. over 20 
minutes), without an important increase in toxicity [31]. 
However, hypotension, occasionally severe, sedation and 
extrapyramidal reactions remain distressing side effects. 
As far as is known chlorpromazine has only limited anti-
emetic efficacy and is mostly used in the control of acute 
emesis in non-cisplatin chemotherapy [32]. In a recent 
pilot study chlorpromazine, at a dose of 120 mg/m , was 
given by continuous infusion (84-110hrs) to patients 
25 
receiving cisplatin 40 mg/m /day on 3 consecutive days. 
Although an acceptable complete anti-emetic control was 
achieved in 66% of the patients over the 3-daily period, 
unpleasant postural hypotension and sedation were observed 
in almost 100% of the patients [33]. 
Table 2. Doses and administration schedules of anti-emetics 
Antι-emetic 
Phenothiazines 
Proch1orperazι ne 
Chlorpromazine 
Butyrophenones 
Haloperidol 
Droperidol 
Dompen done 
Benzamides 
Alizapride 
Metoclopramide 
Corticosteroids 
Dexamethasone 
Methyl predni­
solone 
Benzodιazepines 
Lorazepam 
Serotonin antagonists 
Ondansetron 
Gramsetron 
Route 
oral 
rectal 
im/iv 
oral 
1m/iv 
oral 
im/iv 
IV 
oral 
rectal 
oral 
IV 
oral 
rectal 
IV 
oral 
IV 
iv 
oral 
IV 
oral 
Iv 
IV 
Dose range 
5 -
10-
10-
1 -
1 -
1 -
TO­
SO-
ΙΟ­
Ι -
4 -
250-
8-
10 
25 
30 
25 
15 
2, 
3 
3 
20 
60 
50 
150 
20 
20 
3 
4 
10 
500 
1 
1 
θ 
32 
40 
mg 
mg 
mg 
mg 
mg 
5 mg 
mg 
mg 
mg 
mg 
mg 
mg 
mg 
mg 
mg/kg 
mg 
mg 
mg 
mg 
mg/sq m 
mg 
mg 
цд/кд 
Frequency/day 
4-6x 
3-4x 
3-4x 
3-6x 
4-θχ 
3-4x 
3-6x 
3-6x 
3-4x 
3-4x 
3-6x 
3-6x 
3-6x 
3-4x 
2-5x 
2-4x 
1x, 3x 
1x, 3x 
3x 
1-3x 
3x 
1x 
1x 
To date, these agents have only a limited role in acute 
chemotherapy-induced emesis. They can be used with low-
emetogenic chemotherapy and irradiation, or in combination 
regimens (Tables 2 and 3). The associated sedation may be 
beneficial for inpatients, because it allows them to sleep 
instead of experiencing the feeling of nausea, and reduces 
anxiety known to affect emetic symptoms. The user should be 
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aware that the various preparations (tablets, sup-
positories, injections) differ largely in bioavailability. 
Butyrophenones 
Haloperidol and Droperidol, both neuroleptics, are 
structurally and pharmacologically similar to the pheno-
thiazines and probably act at the level of the chemo-
receptor trigger zone by blocking dopamine receptors. 
Several studies have indicated anti-emetic activity against 
acute chemotherapy-induced emesis [34,35]. In non-cisplatin 
containing regimens both drugs were found to be superior to 
phenothiazines [27,28]. In cisplatin containing regimens 
comparative trials with high-dose MCP showed haloperidol to 
be less effective [35], whereas conflicting results have 
been noted for droperidol [28,36]. Major side effects are 
hypotension (mainly with droperidol) and sedation, although 
for both to a lesser degree than with phenothiazines. 
Nevertheless, the optimal anti-emetic dose has not yet been 
defined and the drugs do not have a role as standard 
therapy against acute chemotherapy-induced nausea and 
vomiting. 
Domperidone is a benzimidazolinon derivative, chemically 
related to the butyrophenones with a similar anti-emetic 
pattern as MCP. The proposed mechanism of action is a peri-
pheral dopamine receptor antagonism and stimulation of 
gastric motility. It is known that the drug poorly passes 
the blood brain barrier, and therefore thought to be devoid 
of central nervous system side effects. Nevertheless 
several extrapyramidal reactions have been reported [37]. 
In non-cisplatin containing regimens oral administration 
has been shown similar efficacy in the control of acute and 
delayed emetic symptoms compared to low-dose MCP, and to be 
inferior to corticosteroids [38]. Domperidone given i.v. 
was inferior to both former mentioned drugs against acute 
emesis [39]. In cisplatin containing chemotherapy the 
control of acute emesis was poor and inferior to alizapride 
[40]. Higher doses of the drug did not improve the 
efficacy, but induced cardio-respiratory arrests. The 
parenteral dosage form has since been withdrawn [37,39]. 
Oral domperidone is a valuable drug for using with low 
emetogenic chemotherapeutic drugs or radiotherapy. Its role 
in delayed nausea and vomiting has insufficiently been 
studied. 
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Senza/ni de Derivative 
Alizapride, a methoxy-2-benzamide derivative, has similar 
dopamine antagonism at central sites as MCP but has no 
proven peripheral action. Its efficacy against acute chemo-
therapy-induced emesis is poor and inferior to high-dose 
MCP [41,42] or corticosteroids, but conflicting results 
have been reported [43]. The side effects are: mild 
sedation, diarrhea, extrapyramidal reactions and at higher 
doses orthostatic hypotension. If used, the drug can only 
appropriately be given in moderately emetogenic chemo-
therapy . 
Dopamine/5-HT3 Receptor Antagonist 
Metoclopramide (MCP), a procainamide derivative, has only 
poor anti-emetic activity at conventional doses (0.15-0.3 
mg/kg) but higher doses (10 mg/kg/8hrs) remarkably improve 
the anti-emetic efficacy in acute chemotherapy-induced 
emesis [29]. Since this observation MCP has been 
extensively studied to confirm its efficacy and to refine 
the dose, schedule and route of administration. During the 
last decade the drug has been generally considered the most 
effective single agent anti-emetic. 
Until recently MCP was thought to exert its anti-emetic 
action by a blockade of dopamine D2 receptors in the 
periphery and in the chemoreceptor trigger zone. However, 
it has been demonstrated that at higher doses MCP is also 
an inhibitor of 5-hydroxytryptamine type 3 (5-HT3) receptor 
sites. It is probably in this way that MCP alters gastro-
intestinal motility (increased gastric emptying, inhibited 
retroperistalsis) and mainly controls emesis [44,45]. 
Determining the affinity of 11 traditional and 
investigational anti-emetic drugs for D2 and 5-HT3 receptor 
sites in brain membranes, it has been demonstrated that 
only MCP showed less than micromolar affinity for both 
receptor sites. MCP was less potent at D2 receptors than 
the other tradional anti-emetics and less active at 5-HT3 
receptors than the recently developed 5-HT3 receptor anta-
gonists [46] . 
The toxicity of MCP at the effective high-dose, mainly 
relates on the dopamine antagonism. It consists of mild 
sedation, diarrhea (however, also possibly related to the 
concurrent chemotherapy, such as cisplatin [7,28]), 
akathisia (restlessness) and extrapyramidal reactions [28]. 
Occasional reports mentioned tardive dyskinesia and dys-
rhythmias [47]. The incidence of the extrapyramidal 
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reactions is not clearly dose-related, but appears related 
to age and route of administration. In a group of 452 
patients, these symptoms were noticed in 2% of patients 
over 30 years and in 27% under 30 years of age. After oral 
administration the frequency of acute dystonic reactions 
was increased in both age groups being 8% and 75%, 
respectively [48]. There is no clear explanation for this 
observation. The extrapyramidal reactions can be treated or 
prevented by either diphenhydramine or biperiden, whereas 
the latter appears to be some more effective (Table 3). 
Akathisia can be avoided by the additional administration 
of benzodiazepines or corticosteroids [49]. Diarrhea can be 
reduced by concomittant dexamethasone [50]. 
In randomized studies, high-dose MCP given i.v. was 
superior to prochlorperazine, THC, butyrophenones, 
alizapride and dexamethasone in the control of acute emesis 
induced by cisplatin-based chemotherapy [28,35,36,41,42, 
51]. Different pharmacokinetic analyses failed to establish 
a clear relationship between the MCP serum level and the 
anti-emetic control [20,52]. The lack of such a dose-
response relationship might explain why the almost endless 
number of different MCP schedules not really show 
significantly different results. A similar overall complete 
response of 60% in acute emesis has been reported with the 
combination of high-dose MCP, dexamethasone and lorazepam, 
irrespective of the MCP schedule (single dose of 4-6 mg/kg 
or twice 3 mg/kg) [49,53]. After high-dose MCP, taken 
orally (2-3 mg/kg), a therapeutic serum level and a good 
anti-emetic result are also noticed [48,54]. The efficacy 
of MCP in the control of acute and delayed nausea and 
vomiting by non-cisplatin containing regimens has been 
studied less extensively. The reported complete responses 
vary between 50 and 90% and are no better than for cortico-
steroids [39,55]. Recommended doses and schedules are 
outlined in Tables 2 and 3. 
Corticosteroids 
Of this group mainly dexamethasone and methylprednisolone 
are used as anti-emetics in cancer chemotherapy. The exact 
mechanism of the anti-emetic action remains unknown. One 
hypothesis mentioned an inhibition of prostaglandin 
synthesis, another suggested an action on the cortical 
pathways influencing the vomiting centre, leading to an 
altered subjective perception regarding the distress of the 
emetic symptoms [15]. Whether these drugs do promote tumor-
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growth or negatively influence immune status has not been 
proven, although only a few reports on this subject are 
available. 
In comparative studies dexamethasone is superior to 
prochlorperazine and appears to be equivalent to high-dose 
MCP in the control of acute emesis induced by moderately 
emetogenic cytotoxic regimens (low-dose cisplatin, doxo-
rubicin, cyclophosphamide) [30,38,51,56]. In high-dose 
cisplatin regimens the drug is inferior to MCP [51]. 
Methylprednisolone is as effective as moderate-dose MCP 
in the prevention of acute emesis after moderately emeto-
genic chemotherapy [39,55,56]. 
The addition of corticosteroids to other anti-emetics 
generally improves anti-emetic control, but the difference 
is not always significant [8,15,56]. Patient's preference, 
however, was then found in favour of the combination 
regimen [15,55]. Different doses of both drugs have been 
studied, for methylprednisolone ranging between 250 and 
1000 mg, for dexamethasone between 10 and 50 mg. There 
appears to be no definite evidence in favour of using the 
higher dosages. 
The known side effects are: mood changes (euphoria, 
weakness, psychosis), fluid retention and perineal itching 
(the latter disappears with a slower infusion-rate). 
Because there is still no consensus on the interference 
of corticosteroids with tumourgrowth, they should 
preferentially not be used as single agent anti-emetics. As 
short term therapy they can be used in combination with 
other anti-emetics, especially for patients experiencing 
severe post-chemotherapy emesis despite an adequate dose of 
MCP. Recommended doses are given in Tables 2 and 3. 
Benzodi azepines 
Diazepam and Lorazepam have anxiolytic, sedative and 
amnesic effects, next to some minor anti-emetic activity 
[8]. Recently, lorazepam has shown better control of acute 
emesis in cisplatin containing chemotherapy compared to 
methylprednisolone [57]. The combination of lorazepam with 
prochlorperazine, dexamethasone [8] or MCP [58,59] shows an 
improved acute anti-emetic control. If lorazepam is added 
to a combination of MCP and dexamethasone the anti-emetic 
results may remain unchanged, but anxiety and akathisia are 
observed less often and sedation allows the inpatient to 
sleep through periods of nausea. This is greatly 
appreciated by the patients mirrored by a significant 
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preference for the lorazepam combination [49]. The exact 
contribution of sedation to the anti-emetic effect is 
unclear, but since there was no correlation between the 
degree of sedation and the anti-emetic control it is very 
unlikely that sedation alone accounts for the total anti-
emetic effect [58]. 
Undoubtedly lorazepam has a place in an anti-emetic 
combination against cytotoxic drug-induced emesis; sedation 
being the drawback which limits the drug for use in an out-
patient setting. 
Table 3. Anti-emetic regimens in different chemo-
therapeutic schedules. 
Chemotherapy Anti-emetics Frequency/day 
Cisplatin MCP 2-3í!ig/kg iv 2-3x 
>99mg/m + Lorazepam Img/m lx 
± Dexamethasone 10-15mg 
40-B0mg/m2 MCP 2-3mg/kg 2-3x 
ρ 
+ Lorazepam 0,5-1mg/m 1-2x 
t Dexamethasone 10mg 
< 40mg/m2 MCP 1-2mg/kg 2-3x 
ρ 
+ Lorazepam 0,5-1mg/m 1-2x 
± Dexamethasone 10mg 
Non C i s p l a t i n Regimens 
I n - P a t i e n t s MCP 1-2nig/kg 2-3x 
+ Lorazepam 1mg 1-2x 
* 
± Dexamethasone 5mg 
Out-Patients MCP 1-2mg/kg iv 1x 
+ MCP 10-20 mg oral 4x 
- extrapyramidal reactions can be prevented by diphenhydramine 50-100mg i.v., or 
biperiden 2-5mg i.v. 
dexamethasone should be added to the anti-emetic regimen in patients who are 
poorly controlled with standard anti-emetic. 
Cannabinoids 
Tetrahydrocannabinol (THC), nabilone and levonantradol are 
chemical constituents of marijuana which have some anti­
emetic activity. The mechanism of action is unknown. Also 
because of their toxic profile on the central nervous and 
cardiovascular system, consisting of sedation, dysphoric 
reactions, orthostatic hypotension and increased heart 
rate, these drugs should not be used [26]. 
* 
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5-HT, Receptor Antagonists 
Serotonin (5-HT) is a neurotransmitter stored in and 
released from central and peripheral neurons, blood 
platelets and enterochromaffin cells of the gastro­
intestinal tract. Recent work indicated that especially the 
5-HT3 receptor seems to be involved in the emetic reflex 
and these receptors have been identified in the gastro­
intestinal tract and in the area postrema [60,61]. In 
ferrets selective 5-HT3 receptor antagonists completely 
abolish emesis induced by chemotherapy and radiation, not 
the apomorphine-induced vomiting [44]. To date several 
compounds with varying degrees of 5-HT3 antagonism are 
under investigation in man, such as MDL72222, Ondansetron 
(GR38032F), Granisetron (BRL43694), ICS205-930 and Batano-
pride (ΒΜΥ25Θ01-01). 
Ondansetron showed in phase I studies complete control of 
acute cisplatin-induced emesis (cisplatin 60-120 mg/m ) in 
44-58% of the patients which is equivalent with the results 
of high-dose MCP in its phase I studies [17,62]. The 
results of 2 double-blind studies comparing ondansetron 
(loading dose + 24-h infusion) with MCP (loading dose + 8-h 
infusion) in naive cisplatin-treated patients, showed a 
complete response of 45% with ondansetron and 22% with MCP 
(P<0.001) [9,63]. Recent data demonstrate that a single 
dose of ondansetron (32 mg) is as effective as a continuous 
infusion (CR: 58% and 57% respectively) [64]. Other studies 
indicated anti-emetic efficacy against ifosfamide, multiple 
days cisplatin and refractory emesis in non-cisplatin 
regimens [65-67]. Reported side effects are mild, 
consisting of headache and constipation. 
In high-dose cisplatin regimens one single dose of 
granisetron, 40 ug/kg or 160 цд/кд, completely controls 
acute emesis in 57% and 60% of the patients respectively 
[68]. In a double-blind study the single 40 цд/кд dose was 
as effective as the combination of high-dose MCP and dexa­
methasone against acute cisplatin emesis, showing a 
complete response of 70% and 69% respectively [69]. An 
additional intravenous dose is able to restablish control 
of the breakthrough emesis in 85% of the patients [68]. The 
main reported side effect is headache. 
With a single dose of ICS 205-930 a complete control of 
acute emesis is achieved in 40-50% of patients receiving 
cisplatin chemotherapy [70]. The comparison of the anti­
emetic activity of a single dose of ICS 205-930 (5 mg) with 
a combination regimen of MCP, dexamethasone and optionally 
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lorazepam in cisplatin regimens showed a complete response 
of acute emesis in 63% of patients in both arms, whereas 
delayed emesis was prevented in more than 65% of patients 
(P>0.05) [71]. Side effects are headache and sedation. 
Multiple dose regimens of batanopride show superiority to 
placebo in cisplatin-treated patients (CR 67%) [72]. 
Interim results of a double-blind study comparing the 
efficacy of batanopride and MCP (3 χ 2mg/kg) in cisplatin 
chemotherapy showed a similar complete response rate in 54% 
and 49% of the patients respectively [73]. Because of major 
side effects consisting of QT prolongation and hypotension, 
this drug will not undergo further investigation. 
Although definitive data from randomized, double-blind 
studies of many of these drugs are not yet available, it 
appears from the data so far that these drugs offer an 
advantage over the traditional anti-emetic drugs. The 
absence of extrapyramidal reactions is a major advance, 
next to the ease of administration. The good anti-emetic 
efficacy and the lack of serious adverse events will make 
them potential first line anti-emetic agents. 
OTHER EMETIC PROBLEMS 
Delayed Emesis 
This phenomenon has received less attention. It is thought 
to be a separate entity next to acute emesis, with probably 
a different mechanism of action. In high-dose cisplatin 
regimens (>100 mg/m ) an incidence of 50-90% has been 
reported and can last up to 120 hrs after chemotherapy 
administration. The greatest incidence and severity occurs 
during the period between 4Θ-72 hrs [23,74]. For non-
cisplatin chemotherapy the reported frequency is 15-20% and 
symptoms occur mainly between 24-72 hrs [75]. 
Identified factors influencing the incidence of delayed 
nausea and vomiting are: emetogenic potential (dose of 
cisplatin) [74], control of acute emesis [23] and female 
gender [74] . 
Single agent MCP, dexamethasone or ondansetron are not 
sufficiently effective [9,23,74]. Moreover the use of oral 
MCP on consecutive days exacerbates the problem of dystonic 
reactions, especially in younger patients [76]. It is not 
yet known whether lorazepam gives some additional effect. 
The combination of MCP and dexamethasone protects 50% of 
the patients, and appears to be the best schedule at this 
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moment [23]. 
Anticipatory Nausea and Vomiting 
The occurrence of nonpharmacological nausea/vomiting 
beginning before the cytotoxic treatment has been reported 
in different frequencies, ranging from 18 to 57% [5]. The 
phenomenon is considered to be the result of a classical 
conditioning process, wherein chemotherapy is the un-
conditioned stimulus, nausea/vomiting the unconditioned 
response and the various stimuli in the environment in 
which chemotherapy is administered are considered the 
conditioned stimulus. The result of this multifaceted 
process is that various cues (visual, auditory, olfactory 
etc.) can elicit emesis. Identified variables in the 
development of anticipatory nausea/ vomiting are: severity 
and incidence of post-chemotherapy emesis, emetogenic 
potential, duration of infusion, age <50 yrs, anxiety, 
history of motion sickness and taste or odour sensations. 
Because of the lack of effective pharmacological anti-
emetic treatment modalities the importance of an initial 
effective anti-emetic regimen should be emphasized. Drugs 
with amnesic properties such as lorazepam might reduce the 
risk to develop anticipatory symptoms; however no hard data 
are available to prove this. Behaviour therapy may 
alleviate complaints to some extent [5,6]. 
CONCLUSION 
The continual attempts to improve the therapeutic remedies 
for cancer patients are often associated with pronounced 
toxicities. The alleviation of nausea and vomiting 
contributes to the psychological and physical well-being of 
the patients and diminishes the risk of poor compliance and 
suboptimal efficacy. In view of the present knowledge and 
available therapeutic modalities this goal can be reached 
in about 70% of the patients. It is clear that correct use 
of each anti-emetic is therefore mandatory and the anti-
emetic regimen should tune in to the multiple variables for 
that specific condition. 
High-dose MCP is the most effective "traditional" agent 
in the prevention of acute chemotherapy-induced emesis. 
Combinations of MCP with corticosteroids and/or benzo-
diazepines improve anti-emetic control, alleviate some of 
the unpleasant side effects of high-dose MCP, and moreover 
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offer more subjective benefit. Anti-emetic studies with the 
new 5-HT3 receptor antagonists show promising anti-emetic 
results in cisplatin regimens, without the distressing 
dystonic reactions. It is the expectation that these 
agents, being investigated in comparative studies, will 
become first line agents in the near future. 
At the moment a combination of MCP and dexamethasone 
seems to achieve optimal control in delayed nausea and 
vomiting. An effective pharmacological treatment for anti-
cipatory nausea and vomiting is also not available. 
Despite the improved results over the last decade 
research should continue in order to optimize anti-emetic 
control. The development of 5-HT3 receptor antagonists 
opens new perspectives for further progress and will hopely 
provide a better insight in the etiology of chemotherapy-
induced emesis, which may be even more important in the 
long run. 
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Abstract 
Ondansetron, granisetron and tropisetron are highly 
selective and competitive serotonin 5-HT3 receptor 
antagonists that probably act at peripheral as well as 
central 5-HT3 receptors. The drugs interfere with the von 
Bezold-Jarisch reflex, the provocation of pain from a 
blister base and intradermal flare response, with gastro-
intestinal motility and nausea/vomiting, and with some 
psychological functions. A review is given of the pharma-
cological and toxicological data of these compounds, as 
well as their metabolism. Pilot studies confirmed anti-
emetic efficacy in the prophylaxis of chemotherapy-induced 
emesis, whereas potential clinical use in psychiatric 
disorders also has been suggested. 
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The vasoactive alkylamine neurotransmitter serotonin (5-
hydroxytryptamine, 5-HT) (Fig.1) was first described by 
Rapport and Page in 1948 [1]. It is mainly present in 
neurones in the central and peripheral nervous system, in 
platelets, and in enterochromaff in cells of the intestinal 
mucosa [2]. Already 30 years ago evidence was obtained for 
the existence of two types of serotonin receptors [3]. A 
major step forward was the recent development of selective 
agonists and antagonists, enabling for these receptors the 
investigation of the interaction between 5-HT and its 
different membrane receptors. At present it is recognized 
that there are 4 main types of 5-HT receptors. Furthermore 
the existence of subtypes or interspecies differences of 
the 5-HT., and 5-HT3 receptors has been suggested [2,4,5]. 
Moreover some 5-HT receptors can not be classified in one 
of these groups [6], and the classification will therefore 
certainly undergo further adaptation in the near future. 
The 5-HT3 receptors are neuronal receptors coupled to 
cation channels, involved in the mediation of the von 
Bezold-Jarisch reflex (see further) [7]; in the provocation 
of pain from the blister base and intradermal flare 
response [7]; in nausea/vomiting and gastro-intestinal 
motility [2,8,9]; and in anxiety, drug dependency, and 
schizophrenia [10,11]. These receptors have first been 
identified on peripheral neurones such as in the 
sympathetic nerves innervating the heart, postganglionic 
neurones in the superior cervical ganglion, enteric 
neurones in the ileum and vagal afferent terminals [12]. 
Recently 5-HT3 receptors have been found widespread through 
the central nervous system, with a high density in the 
(human) area postrema [13,14]. 
Ondansetron (Zofran ), granisetron (KytrilR), and tropi-
setron (ICS 205-930) are the first representatives of a 
group of highly selective and competitive 5-HT3 antagonists 
[7,15,16]. 
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CHEMISTRY 
Ondansetron ( 1,2,3,9,-tetrahydro-9-methyl 3-[(2-methyl-
imidazole-lyl) methyl] carbazol-4-one hydrochloride di-
hydrate) (GR38032F), has been developed from methyl-
carbazolone, which in turn originally descended from a 
modification of the serotonin molecule. The pure drug is a 
white, crystalline powder with a molecular weight of 365.8 
daltons, and is stable over a wide range of relative 
humidities (e.g. 22-96%) at 300C. At 200C the solubility in 
water is 3.2% w/v, and 0.8% w/v in 0.9% saline [15]. 
Tropisetron [(3a-tropanyl)-lH-indole-3-carboxylic acid 
ester] (ICS 205-930), was derived from structural 
modification of 5-HT, using the indole moiety as the 
nucleus [7]. Granisetron (endo-N-(9-methyl-9-azabicyclo 
[3.3.1] nonan-3-yl)-1-methyl-1H-indazole-3-carboxamide) 
(BRL46394), however, was developed using metoclopramide as 
the chemical starting point. First the (diethylamino)-ethyl 
side chain underwent a restriction in the form of the 
azabicyclic tropane, and subsequently the aromatic nucleus 
was modified. The drug has a molecular weight of 348.9 
daltons and a solubility of >40ng/ml in 0.9% saline at 20 С 
[16] (Fig. 1). 
The common structural feature of these agents is a 6,5 
aromatic nucleus connected, via a carbonyl group and a 4-
atom unit, to a basic nitrogen atom. It may be that this 
part adopts a similar configuration which is active at 5-
HT, receptors. 
MECHANISM AND SITE OF ACTION 
In vitro specificity of 5-НТд receptor antagonist activity 
The potency of compounds in blocking the 5-HT3 receptors 
located on peripheral neurones can be assessed in 3 
different bioassay systems: the rat or rabbit vagus nerve, 
the rabbit heart and the guinea-pig ileum [2]. The affinity 
of the different 5-HT3 receptor antagonists for central 5-
HT3 recognition sites is determined by radioligand binding 
techniques, using autoradiographic analysis [13,14]. As 
shown in Table 1, all 3 antagonists cause a blockade of the 
5-HT3 receptors at each of the 3 peripheral functional 
models as well as at central recognition sites. The dose of 
metoclopramide required for 5-HT3 receptor antagonism was 
at least 100- to 1000-fold greater. Although it has been 
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suggested that the different affinities for the various 
peripheral 5-HT3 responses reflect the existence of 5-HT3 
receptor subtypes [2,7,18], species differences and/or 
artefacts associated with drug penetration might account 
for some of the differences [23]. 
The selectivity of the activity at 5-HT3 receptors was 
demonstrated by a lacking antagonistic effect at 5-HT^like 
and 5-HT2 receptors. Additionally the 3 agents were either 
inactive or only weakly active at a variety of non-5-HT3 
receptors such as alpha.,, alpha2, and beta-, adrenoceptors, 
muscarinic and nicotinic cholinergic receptors, gamma amino 
butyric acid, histamine H1 and H2 receptors, dopamine D2 
receptors, benzodiazepine and neurokinin receptors [5,7,18, 
20]. Weak activity was observed at the 5-HT1A receptor 
subtype for gramsetron [20], and at the 5-HT4 receptor for 
tropisetron [6]. Ondansetron binds to a second, lower-
affinity site which is not related to 5-HT3 receptors [5]. 
Overall this makes the 3 agents selective, competitive 
antagonists at 5-HT3 receptor sites. 
Table 1. Activity of different agents at 5-HT3 receptor 
sites in various isolated tissues and the Bezold-
Jarish reflex. 
5-HT3 receptor 5-HT MCP Ond Gran Trop Ref 
site 
Peripheral (PA2)° 
Rabbit vagus 7.5,7.7 9.4 - 10.2 17,18 
Rabbit heart 7.2,6.8 10.5* 10.7 10.6 2,7,18, 
20 
Guinea-pig ileum 5.5 7.3,7 8.1 7.9,8.1 7,18-20 
Rat brain membranes 
Radioligand (Κ , 
[ H]quipazine 
[3H]GR65630 
[ H]zacopride 
Bezold-Jarish 
effect in rats 
(ID50, ng/kg) 
nM) 
-
128 
642 
IV 
po 
IV 
po 
IV 
120 
360 
326 
24* 
5.3 
530 
-
2.9 
4.8 
0.4* 
8.0 
2.5 
275.0 
3.6 
0.3 
0.6 
2.7 
0.7 
-
-
0.7 
0.4 
3.1 
2.0 
0.4 
2.7 
142.0 
1.4 
21 
13 
22 
17,19 
17 
18 
18 
23 
: Рдр= - log KB; : tested against 2-methy1-5HT; Ond, ondansetron; Gran, 
gramsetron; Trop, tropisetron; MCP, metocl oprami de; iv: intravenous; po: per os. 
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Action on the cardiovascular system 
The von Bezold-Jarisch reflex is a transient, dose-related 
and vagally mediated bradycardia and consequent hypo-
tension, following depolarization by various compounds of 
sensory nerve endings in the wall of the right ventricle. 
An intravenous (i.v.) injection of 5-HT [24] or 2-methyl-
5HT [18] in anaesthethized rats is able to elicit this 
reflex, known to occur via 5-HT3 receptors. This reflex is 
inhibited dose-dependently by ondansetron in anaesthetized 
rats and cats [18,19]. This inhibitory activity was also 
observed in rats after granisetron [20], and after 
tropisetron [7,19] (Table 1). No other cardiovascular 
effects have been observed after therapeutic doses of 
ondansetron and granisetron in several animals [18,25]. 
Actions on the gastro-intestinal system 
Anti-emetic properties in animals 
Table 2 lists the anti-emetic activity of ondansetron, 
granisetron, tropisetron, and metoclopramide investigated 
in ferrets and dogs after various emetic stimuli. Compared 
with the three 5-HT3 receptor antagonists, the dose of 
metoclopramide required to prevent chemo- and radiotherapy-
induced emesis was 50- to 500-fold. On the contrary, unlike 
metoclopramide, the serotonin antagonists do not protect 
against apo- and morphine-induced emesis, and motion 
sickness [31]. Ondansetron was able to re-establish anti-
emetic control once radiation-induced emesis already had 
began [27], and granisetron could terminate chemotherapy-
induced emesis within 5-30 sec [28]. 
When comparing the potency and the anti-emetic efficacy 
of the different 5-HT3 antagonists some considerations 
should be made. No randomized studies have been performed 
with 5-HT3 receptor antagonists. Moreover, studies from 
different laboratories are mostly not done under completely 
identical conditions. The importance of identical study 
designs and techniques may appear from the observation that 
the emetic potential of an agent varies with dose and route 
of administration [31], and that the sensitivity of a 
certain species differs for various emetic stimuli [31]. 
Additionally, the study observation time should be long 
enough in view of the latency time between the 
administration of some cytotoxic drugs and the onset of 
emesis [23]. The available data do not allow a careful 
comparison between those agents. 
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Table 2. Activity of 5-HT3 antagonists against emetic 
agents in animals. 
Emetic agent 
Cisplatin 
Cyclophosph 
Doxorubicin 
Radiation 
Apomorphine 
Morphine 
Motion sickness 
Species 
ferret 
dog 
ferret 
ferret 
ferret 
dog 
ferret 
dog 
ferret 
human 
Route 
admin. 
IV 
po 
in AP 
4 І К 
iv 
sc 
IV 
iv 
sc 
po 
iv 
sc 
IV 
IV 
sc 
Ond 
4-
+ 
+ 
+ 
+ 
-
-
Gran 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
-
Trop 
+ 
+ 
MCP 
± 
± 
± 
± 
± 
+ 
Ref 
26,17,28 
23 
27 
19,30 
23 
8,28 
26.31 
8,28 
8,28 
26,31 
28 
23 
31 
23 
28,30 
23 
32 
Abbreviations: Ond, ondansetron; Gran, gramsetron; Trop, tropisetron; MCP, 
metoclopramide; AP, area postrema; 4 V, ventricle; 
Effect on gastro-intestinal motility 
In the guinea-pig ondansetron, tropisetron and meto-
clopramide increased the gastric emptying rate (X-ray 
location of barium sulphate speroids) in a dose-dependent 
manner. Both 5-HT3 antagonists (0.001-1 mg/kg) were more 
potent than metoclopramide (2-5 mg/kg) [33,34]. The small 
bowel transit time (breath hydrogen analysis) was not 
altered by ondansetron in the guinea-pig and rat [33]. 
In 10 healthy volunteers there was no change in gastric 
emptying rate (radioisotope labelling method), small bowel 
transit time (breath hydrogen analysis) and mouth-to-coecum 
transit time after ondansetron, 16 mg tds, as compared to 
placebo. In contrast the whole gut transit time (radio-
opaque markers) was significantly prolonged to 55 hours 
compared with 32 hours in the control population (P=0.001) 
[9]. The latter observation was confirmed in 39 healthy man 
(39 versus 28 hrs). The most marked prolongation occurred 
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in the left colon [35]. In healthy subjects, tropisetron 
was found to shorten mouth-to-coecum time (breath hydrogen 
analysis), to enhance gastric emptying of a solid, but not 
of a semi-solid meal [36]. After the administration of 
tropisetron the secretory diarrhea in 3 patients with a 
carcinoid syndrome was reduced, but no effect was observed 
in 2 patients having VIP tumours [37]. Although further 
information is required these data indicate that the 5-HT3 
receptor is involved in the regulation of gastro-intestinal 
motility. 
Effect on the central nervous system 
The development of selective 5-HT3 receptors was warmly 
wellcomed by investigators in psychiatry, enabling the 
study of serotonin and its potential central effects. 
In four of the five tested animal models predictive of 
anxiolytic activity (social interaction of rats in high-
light conditions, aversion of mice for the light section of 
a light/dark box, anxiety-related behaviour in marmoset and 
monkey) ondansetron showed a more potent activity than 
diazepam, and no sedation [10]. Similar anxiolytic activity 
was also demonstrated with tropisetron and granisetron in 
the same and another laboratory [10,38]. However, Johnston 
and File found in their studies only a weak anxiolytic 
effect for tropisetron and granisetron, and not for 
ondansetron [39]. 
The potential anti-psychotic activity of the 3 agents was 
suggested by the inhition of the hyperactivity caused by an 
infusion of dopamine into the nucleus accumbens of rat or 
marmoset. The locomotor activity was not depressed and 
rebound hyperactivity after cessation of treatment did not 
occur. There was no explanation for the observation that 
the efficacy of the 3 compounds, particularly of gra-
nisetron and tropisetron, diminished at high doses [40]. In 
various animals ondansetron prevented some of the 
behavioural consequences of withdrawal from subchronic 
treatment with diazepam, alcohol, nicotine and cocaine. 
Chronic ondansetron use reduced alcohol consumption in 
alcohol-preferring rats and marmosets [11]. 
Site of action 
The major detectors of emetic stimuli are located in the 
gut and the area postrema, in which regions a high density 
of 5-HT, receptors has been observed [12,14]. A low dose of 
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ondansetron, 0.01-1цд, injected directly into the -area 
postrema inhibited cisplatin-induced retching and emesis in 
ferrets, compared to control animals [41]. These ob­
servations were confirmed for other 5-HT3 receptor anta­
gonists and indicate that at least one functional site for 
5-HT3 receptors in modulating the emetic response is the 
area postrema. 
In ferrets it was shown that abdominal vagotomy as well 
as the three 5-HT3 receptor antagonists markedly reduced or 
abolished emesis, evoked by total body irradiation and 
several cytotoxic drugs [19,26,31]. Serotonin and 5-hydro-
xyindole acetic acid are increased in the ileal mucosa 
after cisplatin [26,42], while activation of vagal mechano-
and chemoreceptor afférents by 5-HT is mediated by the 5-
HT3 receptor. These data indicate that 5-HT3 receptor 
blockade may occur at abdominal visceral afférents to exert 
its anti-emetic action. However, as yet, insufficient data 
are available to determine which (if either) of these sites 
of action is the clinically relevant one [31]. Although it 
may be clear that it is difficult to compare the different 
5-HT3 antagonists, a clear difference between the 3 agents 
does not appear from these data. 
PHARMACOLOGY 
Pharmacokinetics 
Volunteer data 
Determination of ondansetron base and granisetron level in 
plasma is carried out using a high pressure liquid chroma-
tography (HPLC) procedure. Ondansetron is detected by UV 
absorption at 305 nm (detection limit Ing/ml, working range 
1-20 ng/ml) [43], whereas for granisetron a fluorimetrie 
detection is used (lower limit of determination 0,1 ng/ml) 
[25]. Most data on tropisetron have not yet been published. 
The pharmacokinetic parameters, established in healthy 
subjects, after i.v. doses of granisetron ranging from 30-
300 цд/кд [44], and various oral and i.v. regimens of 
ondansetron [45] are summarized in Table 3. Generally 
plasma levels were related to dose. However, atypical 
plasma concentration-time profiles (e.g. delayed peak 
concentration, concentration plateau before the elimination 
phase) were observed in 30% of the subjects after 
ondansetron, and could not always be reproduced in the same 
person [45]. Evenso wide interpatient differences were seen 
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after granisetron [46]. After oral administration of 
ondansetron absorption began after approximately 30 min., 
reaching peak levels at ca. 1.5 hours; the bioavailability 
was ±60%. At steady state there was no evidence of undue 
accumulation. In elderly volunteers (>65 years) pharmaco­
kinetic parameters were mostly similar, although there is a 
tendency for a reduced plasma clearance (421 ml/min) and a 
prolonged half-life (5 hrs) [43,45]. Except for plasma 
levels and AUC values, there were no apparent dose-related 
changes in the pharmacokinetic parameters over the 
different dose schedules investigated for both agents, 
indicating linear pharmacokinetics. 
Table З.Меап values for pharmacokinetic parameters after 
different i.v. and oral doses of ondansetron and 
granisetron in healthy subjects. 
Dose l e v e l 
G r a n i s e t r o n ( u q / k q ) 
40 (n=4) 
50-130 (n=8) 
270,300 (n=8) 
Ondansetron (mq) 
8 (n=16) 
8+1/h (n=15) 
8 ( e l d e r l y = 1 6 ) 
p . o . 
8 (n=16) 
8 t d s / (n=16) 
5days 
For r e f e r e n c e s see: 
Cmax 
ng/ml 
33.8 
0 . 7 + 
0 . 7 + 
95.6 
125.2 
114 
31.2 
38.9 
43-45. * : n= 
AUC 
h.ng/ml 
106.0 
3 . 3 + 
3 . 3 + 
229.4 
885.1 
317 
133.0 
=14¡ ° : n=9; 
t l / 2 
h 
4 . 0 
5.5 
5.9 
3.5 
3 .7 
5.0 
3 . 2 * 
3 .3° 
i . v . : 
Vd 
1 
174 
210 
244 
163 
-
i n t ravenous 
CLp 
m l / m m 
556.7 
778.3 
781.7 
578.1 
601.8 
421.0 
-
;; p . o . : 
ml / rmn 
60 
67 
67 
10.0 
16.9 
17.5 
15.6 
per os ; + : 
dose normalised mean values. 
Clinical data 
Pharmacokinetic data were obtained in a small number of 
patients receiving emetogenic chemotherapy and i.v. either 
granisetron or ondansetron (Table 4). Plasma levels showed 
a similar wide inter-patient variability [25,47-52], and 
appeared to be somewhat higher with ondansetron compared to 
those of healthy subjects [45]. Most of the pharmacokinetic 
data were not clearly different to those observed in 
healthy subjects, but plasma half-life of granisetron was 
prolonged (9-11.6 hrs)[25,52,53]. Peak plasma concen-
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trations, AUG and plasma half-life time of ondansetron were 
increased in elderly patients (>65 years) compared to 
younger and elderly healthy subjects (<40 years). There was 
however no major accumulation indicating that dose 
adjustment is not necessary [54]. For both agents, although 
more pronounced for ondansetron, there was a trend toward a 
better anti-emetic control or better protection against 
failure with higher AUG or plasma concentration [47,48,50, 
53]. Pharmacokinetic data on tropisetron are not yet 
published. 
Table 4. Mean values for pharmacokinetic parameters of 
ondansetron and granisetron in patients, receiving 
emetogenic chemotherapy. 
Dose l e v e l Cmax AUC tl/2 Vd CL Ref 
ng/ml h.ng/ml h 1 1/h/kg 
Granisetron (мд/кд) 
i .v . 
40 (n=18) 37.5 
range 11-124 
80 (n=12) 67.7 
Ondansetron (mg) 
i.v. 
0.15/kgx3/day 119 
5days (n=12) 
8+ 1/h (n=15) 109 
10+ 2/h (n=19) 173 
12+ 4/h (n= 9) 276 
p.p. elderly 
8 tds/4 days 118.0 
range (n=10) 92-151 
*: 1/h, + : AUC (0-8hrs). 
Metabolism 
Ondansetron is widely distributed and metabolized, 
primarily by hydroxylation followed by glucuronide and 
sulphate conjugation. The major proportion of the drug 
(60%) is rapidly excreted in man via the urine with less 
than 10% of the parent drug recovered unchanged in the 
urine [55]. Granisetron is also extensively distributed and 
rapidly cleared, primarily by hepatic metabolism, as less 
than 15% of the parent compound was identified in the urine 
[25]. 
350 
66-1127 
10.6 
3-21 
2.2 
1-4 
0.21 
0.04-0.6 
25 
52 
359 9.7 3.3 0.48 25 
1,590 
1,415 
2,500 
4,517 
3.9 1.68 23.9 
* 
19.6 
17.3 
18.4 
48 
49,50 
50 
50 
500+ 8.2 
275-998 5.6-9.4 
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TOXICOLOGY 
Animal studies 
An extensive series of toxicological tests were carried out 
in rodents and dogs, using dose levels of ondansetron from 
30- to 100-fold higher than human doses, and being at least 
1000 times the dose required for 5-HT3 receptor blockade in 
vivo, for as long as 18 months. Toxic effects, consisting 
of a decreased blood pressure and heart rate, were observed 
at doses of 10 mg/kg i.v., whereas behavioural changes 
(ataxia, convulsions) occurred only at near lethal doses 
(rats > 30 mg/kg, dogs > 12,5 mg/kg). At the higher dose 
levels transient increases of serum transaminases (max.50%) 
were observed, which were not accompanied by macro- and/or 
microscopic changes of the liverstructure. A further, wide 
variety of toxicology studies did not show any indication 
for reproductive, genetic, teratogenic or oncogenic effects 
[56]. In rats the non-toxic effect level of granisetron was 
3 mg/kg/day, the dose-limiting toxicity consisted of 
seizures and ECG changes at doses of 10 mg/kg, in dogs the 
maximum tolerated i.v. dose was 3 mg/kg [25]. 
Human studies 
No major adverse events were reported after the 
administration of ondansetron to 223 volunteers and 438 
patients with psychiatric disorders, postoperative emesis 
and pain in more than 2000 occasions. Mainly 2 categories 
of symptoms appeared related to ondansetron, occurring more 
frequently in repeat (R) compared to single (S) dose 
studies. These were: headache (3:17%, R:31%), and consti­
pation/abdominal discomfort (3:1%, R:16%). Headache, 
however, was also often reported after repeat doses of 
placebo (3:5%, R:28%) [56]. Similarly minor adverse effects 
were noticed after granisetron. Constipation was first 
encountered at a dose of 80 цд/кд, occurring in 4 out of 8 
volunteers at 160 цд/кд. Although headache was observed 
quite often after a placebo administration (9%), the 
incidence was higher with granisetron (15%) [46]. Transient 
mild elevations of transaminases were reported occasionally 
with both drugs (ondansetron 5%), but also after placebo 
(12%) [46,56]. 
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PILOT STUDIES 
In a few pilot studies the anti-emetic efficacy and safety 
of ondansetron, given as repeated intravenous and oral 
doses, were studied in patients receiving cisplatin and 
non-cisplatin chemotherapy. Complete and major control (0-2 
emetic episodes) was obtained in 45% of the cisplatin-
treated patients, whereas refractory nausea and vomiting 
were abolished in 93% of patients receiving different 
chemotherapy regimens [57,58]. 
CONCLUSION 
Extensive preclinical research has demonstrated that 5-HT3 
antagonists selectively interact at both the peripheral and 
central 5-HT3 receptor sites. Potential clinical use in 
psychiatric disorders and in the prevention of chemo-
therapy-induced emesis has been suggested. The latter was 
confirmed in pilot studies and therefore further anti-
emetic studies were designed. Results of our own experience 
with ondansetron are described in following chapters. 
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Chapter 4 
ONDANSETRON IN THE PROPHYLAXIS OF NAUSEA AND VOMITING 
INDUCED BY CISPLATIN 
Seynaeve1, P.A. Van Liessum , P.H.M. de Mulder , S. Kaasa , 
E. Lane-Allman4, J. Verweij 
Department of Medical Oncology, 
Rotterdam Cancer Institute/Dr. Daniel den Hoed Kliniek, 
the Netherlands. 
Department of Medical Oncology, Radboud University 
Hospital, Nijmegen, the Netherlands. 
Norwegian Radium Hospital, Oslo, Norway. 
4
 Glaxo Group Research Ltd, Greenford, Middlesex, United 
Kingdom. 
Part of this has been published in Eur J Cancer 1990, 26: 
769-770. 
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Abstract 
In a multicentre, open, dose finding study forty-five 
patients were treated with the selective 5-HT3 antagonist 
ondansetron in the prophylaxis of acute and delayed nausea 
and vomiting induced by cisplatin (70-120 mg/m ) containing 
chemotherapy. Ondansetron was given at 3 different dose 
levels starting with a 15 minute loading infusion (8,10,12 
mg), followed by a 24-h infusion (1,2,4 mg/h). Twenty-eight 
patients who were successfully treated within the first 24 
hours (0-2 emetic episodes) continued with oral ondansetron 
(4,8,12 mg qds) for 5 days. Acute emesis was completely 
controlled (CR) in 17 patients (40%), 10 patients (23%) had 
1-2 emetic episodes (MR) and 6 (14%) experienced 3-5 emetic 
events (mR) . Absent or mild nausea on day 1 was recorded in 
21 patients (49%). Delayed emesis was completely or majorly 
controlled both in 9 patients (32%), 10 patients (36%) had 
more than 2 emetic episodes. Mild headache (22%) and 
constipation (16%) were the main drug-related adverse 
events. Major sedation and extrapyramidal reactions were 
not observed. In conclusion, ondansetron is a well 
tolerated and effective anti-emetic agent against acute 
cisplatin-induced emesis. There is no clear difference in 
anti-emetic efficacy at the 3 dose levels (P=0.09). Its 
efficacy in the prevention of delayed emesis warrants 
further investigation. 
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INTRODUCTION 
Cisplatin containing chemotherapy induces acute nausea and 
vomiting in nearly 100% of the patients if anti-emetics are 
not given prophylactically [1]. Concern about delayed 
nausea and vomiting has been expressed [2,3], but only a 
few studies have been performed trying to control the 
phenomenon [4]. Although the anti-emetic effectiveness of 
high-dose metoclopramide may be improved by changing from a 
multiple bolus dose regimen to a continuous infusion 
schedule [5], none of the currently used anti-emetics or 
combination regimens is entirely effective in preventing 
cisplatin-induced emesis [6,7]. A major drawback of the 
present standard use of high-dose metoclopramide in anti-
emetic combinations is the occurrence of extrapyramidal 
symptoms and drowsiness [8,9]. 
Ondansetron (GR38032F) is a highly selective, competitive 
5-HT3 antagonist with probable activity at peripheral and 
central sites, but without dopamine receptor antagonism. It 
is therefore unlikely to cause extrapyramidal reactions and 
major sedation. Ondansetron, when given as a single agent, 
has been shown to be well tolerated and effective in 
controlling emesis in patients receiving cisplatin [10,11] 
and non-cisplatin containing chemotherapy [12]. 
The aims of this study were to evaluate the safety and 
the anti-emetic efficacy of ondansetron, given at different 
dose levels as a continuous infusion, in acute and delayed 
nausea and vomiting induced by cisplatin chemotherapy. The 
continuous infusion was chosen in order to achieve a 
constant plasma level of ± 30 ng/ml, that was considered to 
give an optimal blockade at 5-HT3 receptors and a maximal 
anti-emetic effect [5]. The half-life time of elimination 
of ondansetron of 3.5 hours emphasized the probable benefit 
of this method of administration. 
PATIENTS AND METHODS 
In this open, dose finding study eligible patients were 
aged between 18-70 years receiving their first or 
subsequent course of anticancer chemotherapy including 
cisplatin (70-120 mg/m ). The cisplatin was administered 
over a period of less than 4 hours. Exclusion criteria 
were: severe concurrent illness other than neoplasia; 
elevated bilirubin; pretreatment serum alanine amino-
transferase >25 U/l or more than twice the upper limit of 
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normal unless caused by liver metastases; nausea and 
vomiting and/or anti-emetic therapy in the 24 hours prior 
to therapy with ondansetron. All patients gave oral 
informed consent. 
Blood samples for routine hematology, electrolytes, renal 
and liver function tests were taken before treatment, at 24 
hours, 7-10 days and 2-4 weeks after treatment with 
ondansetron. Any abnormal parameter was followed up until a 
return to normal values, unless the disturbance was known 
to be related to other causes than ondansetron. 
Nausea and vomiting were analyzed separately for the 
acute (first 24 hrs) and delayed part (days 2-6). The 
severity of nausea was assessed using 100 mm visual 
analogue (VAS) and graded (none, mild, moderate, severe) 
scales. Response criteria for control of emesis were: 
complete response (CR): 0 emetic episodes; major response 
(MR): 1-2; minor response (mR): 3-5 and failure (F): >5 
emetic episodes or rescued. One emetic episode was defined 
as any vomit productive of liquid or 1-5 retches within a 5 
minute period. 
Patients were monitored in hospital for the first 24 
hours following the start of the anti-emetic infusion. The 
timing and number of retching and vomiting episodes were 
recorded. The intensity of nausea (VAS scale) was assessed 
at the start and at the end of the ondansetron infusion. 
Further information was recorded on any adverse events. 
During days 2-6 patients completed diary cards daily 
recording the number of vomits and retches, the severity of 
nausea using VAS and graded scales, and any upsetting 
symptoms. Seven to 14 days after the cytotoxic treatment 
patients attended the outpatient clinic and diary cards 
were checked for completeness. Patients also indicated 
their satisfaction for the treatment using the question "If 
you receive chemotherapy again would you want the same 
treatment to prevent nausea and vomiting?" 
Anti-emetic treatment 
Ondansetron, diluted in a 100 ml of saline, was given as a 
loading 15 min infusion, beginning 30 min prior to the 
start of the cisplatin infusion. This was followed 
immediately by a 24-hour continuous infusion given via a 
syringe pump. Regimen A consisted of a loading dose of 10 
mg of ondansetron, followed by 2 mg/h over 24 hours. The 
loading dose in regimen B1 was θ mg, the hourly infusion 
dose 1 mg, and in regimen B2 the bolus dose was 12 mg, 
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followed by 4 mg/h/24 hours. 
Schedule A was used initially in the first 8 patients in 
each centre. The dose level was increased or decreased 
depending on the anti-emetic response in each center: if 
7/8 patients experienced less than 3 emetic episodes 
(CR+MR) in the first 24 hours, the dose was decreased (Bl) 
for the next 8 patients. If more than 1 patient at level A 
had more than 2 emetic events (mR+F) the next 8 patients 
received a higher dose of ondansetron (B2). 
Table 1. Demographic results 
Acute 
group 
Delayed 
group 
Number of patients 45 2Θ 
Age: median 
range 
Gender: M / F 
55 
31-71 
16/29 
56 
31-71 
13/15 
Pr ior chemotherapy 
none 
d s p l a t i n 
non-cisplat in 
27 
9 
9 
22 
1 
5 
Primary tumour site 
Ovary 
Melanoma 
Bladder 
Head and neck 
Miscellaneous 
17 
9 
7 
б 
6 
Concomitant chemotherapy 
None 
Cyclophosphamide 
Ifosfarmde 
Epi-/Doxorubicin 
5-FU 
Miscellaneous 
9 
17 
7 
3 
6 
3 
7 
10 
4 
6 
1 
Those patients having a successful anti-emetic response 
(CR + MR) within the first 24 hours continued with oral 
ondansetron for the following 5 days. Again the oral dose 
depended on the anti-emetic response in each centre. The 
starting dose was 8 mg qds. If only 1/8 patients 
experienced a mR or F throughout days 2-6, the next group 
of patients received 4 mg qds. If >1 patient experienced a 
mR of F the next patients received oral ondansetron 12 mg 
qds. 
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Statistical analysis 
Anti-emetic response (emesis versus no emesis) was analyzed 
in relation to dose level, gender, and prior treatment 
using the chi-square test (2x3- and 2x2-tables). 
RESULTS 
Forty-five patients (27 naive, 1Θ previously treated) were 
enrolled in the acute part of the study, 28 patients 
continued with oral ondansetron in the delayed part. 
Patient characteristics are given in Table 1 . Twenty-one 
patients were treated using schedule A, 15 schedule B1 and 
9 patients schedule B2. The main variables such as age and 
gender were proportionally distributed among the different 
dosage groups. The proportion of naive/previously chemo-
therapeutic treated patients was similar at the different 
dose levels, but not in the different centres. 
Two patients were excluded from the analysis of acute 
emesis. One patient received only 47 mg/m of cisplatin, 
and the other used concurrent dexamethasone in a non-
physiological dose. The 2 patients of 71 years and 5 others 
receiving cisplatin doses between 67-69 mg/m2, which is 
within 10% of the dose specified in the selection criteria, 
were included in the analysis of efficacy. All patients 
enrolled in the delayed study part were évaluable. 
Anti-emetic efficacy 
Acute nausea and emesis 
The results of the anti-emetic control at the different 
dose levels respectively are shown in Figure 1. The overall 
efficacy for the whole group and stratified for previous 
cytotoxic therapy, gender and cisplatin dose is shown in 
Table 2. In 90% of the patients that had an emetic episode, 
the onset of emesis occurred within the first 10 hours 
after start of the cisplatin infusion. Female patients were 
poorly controlled in comparison with men (P=0.04). All the 
failing patients were female, and 80% of them had 
previously received chemotherapy. The difference of anti-
emetic control was not statistically significant different 
(P=0.09). 
The assessment of the intensity of nausea on the VAS was: 
15 patients (35%) scored <10mm, 6 (14%) <26mm, 9 (21%) 
between 26-60mm and 13 (30%) >60mm. 
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Table 2. Response in acute emesis stratified for prior 
treatment, gender and cisplatin dose. 
η (%) 
Entire group 
Dose level 
B1 
A 
B2 
Prior treatment 
none 
yes 
Gender 
Male 
Female 
Male 
Tot 
Female 
Male 
Tot 
Female 
Cisplatin (tose 
<95mg/nC 
>95mg/m¿ 
Total 
43 
14 
20 
9 
11 
26 
15 
4 
17 
13 
15 
28 
33 
10 
CR 
17 
6 
5 
6 
6 
12 
6 
4 
5 
1 
10 
7 
12 
4 
(40) 
( 43) 
( 25) 
( 67) 
( 55) 
( 46) 
( 40) 
(100) 
( 30) 
( 8) 
( 67) 
( 25) 
( 36) 
( 40) 
MR 
10 
3 
6 
1 
3 
10 
7 
0 
0 
0 
3 
7 
7 
3 
(23) 
(21) 
(30) 
(11) 
(27) 
(38) 
(47) 
( 0) 
(20) 
(25) 
(22) 
(30) 
mR 
6 
0 
5 
1 
2 
2 
0 
0 
4 
4 
2 
4 
2 
3 
(14) 
( 0) 
(25) 
(11) 
(18) 
( 8) 
(23) 
(31) 
(13) 
(14) 
( 6) 
(30) 
F 
10 (23) 
5 (36) 
4 (20) 
1 (11) 
0 
2 ( 8) 
2 (13) 
0 
8 (47) 
8 (61) 
0 ( 0) 
10 (36) 
12 (36) 
0 ( 0) 
Abbreviations: n: number of patients, CR: complete response, MR: major, mR: minor, 
F: failure, M: male, F: female. 
Delayed nausea and emesis 
Patient characteristics of the 2Θ évaluable patients are 
shown in Table 1. Eighteen patients received 8 mg 
ondansetron qds, 5 patients were treated at each of the 
other dose levels (4 or 12 mg qds). The results of the 
control of delayed emesis at the different levels are given 
in Figure 2. Overall, delayed vomiting was absent in 9 
patients (32%), MR was achieved in 9 patients (32%), mR and 
F were recorded in 5 patients each (18%). Separate data on 
the emetic episodes for each of 5 consecutive days from 24-
144 hours after cisplatin administration are given in 
Figure 3. 
The assessment of the severity of nausea (graded) on days 
2-6 is shown in Figure 4. Because of missing VAS data in 9 
patients this method was not used for the analysis. In the 
delayed study period 2 patients stopped oral medication 
because of lack of efficacy. 
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η·14 η·20 η-β 
8mg * Img/h 10mg • 2mg/h 12mg * 4mg/h 
•iCR ^ЗМЯ ПЗтП Ше 
Figure 1. 
Control of acute emesis by ondansetron, at the different dose regimens, in 
cisplatin containing chemotherapy. 
When patients were asked whether they wanted to receive 
the same anti-emetic medication with following chemotherapy 
courses, the answer after 24 hrs was "yes" in 29 patients 
(67%), "no" in 6 (14%) and "uncertain" in 8 patients (19%). 
At the end of the delayed phase 22 patients (78%) were in 
favour of ondansetron, and 3 (11%) were uncertain. 
4mg qda Bmg qde 12mg qds 
I H CR Εδ3 MR CUmR B F 
Figure 2. 
Control of delayed emesis by different doses of oral ondansetron. 
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n-26 n-24 n-24 n-23 Γ-21 
2 3 4 5 6 "W 
mm CR ^ M R cDmn ra F 
F i g u r e 3. 
The incidence of delayed emesis for each consecutive day from 24-144 hours after 
cisplatin administration. 
η·24 η·24 П"2* П"24 п-24 
none NWWN mild 1 I moderate Ш^ severe 
Рідгіге 4. 
The incidence of the intensity of delayed nausea (graded) 
for each treatment day with ondansetron. 
Adverse events 
Two patients died during the study period (disease 
progression, pulmonary oedema). Both events were considered 
unrelated to ondansetron. Twenty-one patients reported a 
total of 30 minor adverse events which were thought to be 
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related to ondansetron (Table 3). Headache (22%) and 
constipation (16%) were the commonest reported events, and 
were generally mild. No major sedation of extrapyramidal 
side effects were observed. Minor elevations of liver 
function tests, possibly linked to ondansetron treatment, 
were noticed in 4 patients, but without any clinical 
relevance. 
DISCUSSION 
The results from this study indicate that ondansetron, in 
these schedules, is an effective drug in preventing acute 
cisplatin-induced nausea and vomiting. There was no clear 
dose-response relationship although a better response 
occurred at the higher dose level. The number of patients 
however was small. The overall efficacy rate in 63% of the 
patients is comparable with the results reported for single 
agent "high-dose" metoclopramide [9]. 
Table 3. Observed adverse events related to ondansetron 
B1 
Dose level 
A B2 
Total 
(%)* 
Headache 
Light headed 
Dizziness 
Sleepiness 
Sedation 
Xerostomia 
Flushing 
Cold sensation/shivering 
Constipation 
Frequent bowel movement 
7 
1 
1 
-
4 
-
1 
1 
1 
1 
10 
1 
1 
1 
4 
1 
1 
1 
7 
3 
(22) 
( 9) 
(16) 
( 7) 
Total 17 30 
* expressed as percentage of total study population 
Refractory and anticipatory symptoms are often related to 
poor control of emesis during previous chemotherapy. The 
results in our study also show poor anti-emetic control in 
previously treated patients, as was observed by other 
investigators [10]. A retrospective stratification for 
prior/no prior treatment did not show a clearly different 
anti-emetic result (Table 2). In contrast, in previously 
treated female patients emesis was clearly more difficult 
to control, with a 61% failure rate. The role of the 
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concomitant chemotherapy, in this group mostly consisting 
of cyclophosphamide, remains to be clarified. Since 90% of 
the failing female patients started to vomit <10 hours 
after the beginning of the cisplatin infusion, there is no 
indication that this is caused by cyclophosphamide, as this 
drug is known to have a long time to onset of emesis (12-
18h) . 
During days 2-6 after cisplatin containing chemotherapy 
77-100% of the patients experience some degree of nausea 
and vomiting, with the greatest incidence from 4Θ-72 hours 
[2,4]. Although delayed emesis appears to be better 
controlled on the highest ondansetron dose the patient 
number is too low to make a valid conclusion. Complete 
protection of nausea and emesis was poor on the second day 
after the cisplatin administration, and improved from the 
third day on. This may suggest that ondansetron indeed 
interferes with the natural course of delayed symptoms [2]. 
After day 3 the anti-emetic results were comparable with 
those seen after a combination of dexamethasone and meto-
clopramide [4]. Further studies are required to confirm the 
role of ondansetron in delayed nausea and vomiting. 
Ondansetron was well tolerated, no extrapyramidal 
reactions nor major sedation were observed. Only minor 
adverse events were thought to be related to the 
medication. 
In conclusion, ondansetron is effective and well 
tolerated over a broad dose range in the prevention of 
acute cisplatin-induced emesis. Double-blind, controlled 
studies are in progress to compare its efficacy with metoc-
lopramide. The role of ondansetron in delayed emesis is 
less clear, and requires further investigation. 
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Abstract 
Forty-three cancer patients receiving cisplatin-based 
chemotherapy (70-120 mg/m ) were treated with ondansetron 
(Zofran ) for the prophylaxis of acute nausea and vomiting. 
Ondansetron, at 3 escalating dose levels, was given as a 15 
min. loading infusion (8,10,12 mg) followed by a 24h 
infusion (1,2,4 mg/h). There was no significant difference 
in the complete control of acute emesis with the 3 dose 
levels. Pharmacokinetic parameters were analyzed at the 3 
dose levels in 9, 19 and 9 patients respectively. The 
relationship between plasma levels (measured by HPLC) and 
anti-emetic response was assessed. At each dose level the 
plasma concentrations showed wide interpatient variation, 
independent of several patient variables. No dose-response 
relationship or threshold plasma concentration above which 
complete protection occurred was found. However, the 
control of acute emesis was significantly better if plasma 
ondansetron concentration was greater than 105 ng/ml at 3h 
(P=0.015) and/or more than 100 ng/ml at 6h (P=0.012). 
Plasma levels of ondansetron above 100 ng/ml between 3 and 
6 hours after start of the anti-emetic infusion were 
associated with complete control in 67% of the patients, 
compared to 21% with values below this level (P=0.005). 
These data suggest a positive relationship between 
ondansetron plasma concentration and the control of acute 
cisplatin-induced emesis may exist in the period between 3-
6 hrs from start of anti-emetic treatment (2.5-5.5 hrs 
after the start of cisplatin). Further studies are 
indicated to confirm this observation. In the meanwhile, 
patients with poor anti-emetic control may benefit by an 
increased ondansetron dose over the first 6-8 hours with 
their next chemotherapy course. 
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INTRODUCTION 
Acute and delayed nausea and vomiting are frequent and 
distressing side effects of cisplatin containing chemo-
therapy [1,2]. Currently available anti-emetics give 
insufficient control of acute emesis in 20-30% and in 50% 
of the patients in the delayed phase. Improved anti-emetic 
protection can be achieved by an increased dose of anti-
emetic drug, by combinations of agents with different sites 
of action and by new anti-emetic agents (e.g. 5-HT3 anta-
gonists). Over the last decade high-dose metoclopramide, 
the most effective single agent anti-emetic, has been 
studied in different schedules [3-5] and combinations 
[3,6,7]. Attempts to correlate plasma concentrations of 
metoclopramide with anti-emetic control have shown no 
conclusive proof that specific plasma levels are predictive 
of better control [8-10]. 
D 
Ondansetron (Zofran ) is a highly selective, competitive 
5-HT3 antagonist, which has shown significant anti-emetic 
activity in patients receiving cisplatin and non-cisplatin 
containing chemotherapy [11-13]. Unlike metoclopramide, the 
drug lacks dopamine antagonism, and neither extrapyramidal 
reactions or major sedation have been reported. 
This report correlates ondansetron plasma levels with 
clinical efficacy in patients receiving cisplatin-based 
chemotherapy. 
PATIENTS AND METHODS 
Clinical protocol 
Eligible patients were those, aged between 18-70 years, 
receiving combination chemotherapy with cisplatin (70-120 
mg/m ) which was administered over less than 4 hours. 
Exclusion criteria were: severe concurrent illness other 
than neoplasia; elevated bilirubin; serum alanine amino-
transferase >25 U/l or more than twice the upper limit of 
normal if liver metastases were present; nausea and 
vomiting and/or anti-emetic therapy in the 24 hours prior 
to therapy with ondansetron. All patients gave informed 
consent. 
The pretreatment evaluation included a history and 
physical examination, a full blood cell count, and routine 
biochemistry (electrolytes, total protein, bilirubin, renal 
and liver function tests). The same analyses were carried 
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out at the completion of the ondansetron infusion (24 hrs) 
and repeated after 7-10 days and 2-4 weeks. 
Patients were monitored by trained staff nurses in 
hospital for the first 24 hours following the start of 
cisplatin infusion. The timing and number of retching and 
vomiting episodes were recorded and cross-checked with the 
patient. Further information was recorded on appetite and 
adverse events. The severity of nausea was assessed using a 
graded (none, mild, moderate and severe) and a 100 mm 
visual analogue scale (VAS; 0 mm no nausea, 100 mm nausea 
as bad as it can be). The response criteria for emesis 
were: Complete response (CR):0 emetic episodes, Major 
response (MR) :1-2 emetic episodes, Minor response (mR):3-5 
emetic events and Failure (F):>5 emetic events. One emetic 
episode was defined as any vomit productive of liquid or 1-
5 retches within a 5 minute period. 
Anti-emetic treatment 
Ondansetron, diluted in a 100 ml of saline, was given as a 
loading infusion over 15 minutes, beginning 30 minutes 
prior to the start of the cisplatin infusion. Thereafter a 
24-hour continuous infusion was administered via a syringe 
pump. The doses used were: 
dose schedule initial dose 24-h infusion dose total dose 
(1) 8 mg 1 mg/h 32 mg 
(2) 10 mg 2 mg/h 58 mg 
(3) 12 mg 4 mg/h 108 mg 
Pharmacokinet ics 
A 10-ml venous blood sample for assay of ondansetron was 
obtained from the arm opposite to the infusion site before 
treatment and at 0.25, 1, 3, 6, 12 and 24 hours after the 
start of the anti-emetic infusion (time 0). The blood 
samples were placed into heparinized tubes and centrifuged. 
The separated plasma fraction was frozen and stored below 
-20 С until assayed. 
Plasma concentrations of ondansetron were measured by 
high-performance liquid chromatography (HPLC) after solid 
phase extraction on Bondelut CN extraction cartridges. The 
extracts were dried to a residue in a Savant Speed Vac 
Concentrator and then dissolved in mobile phase (60% of 
0.025 M sodium acetate, pH 4.2, and 40% acetonitrile) . One 
hundred μΐε of the solution was introduced into a 3 μιη 
70 
hundred μΐε of the solution was introduced into a 3 μιη 
Spherisorb Silica S3W HPLC column (100 χ 4.6 mm, t 350C) 
using an autosampler. The ondansetron base was detected by 
UV absorption at 305 nm, after a run time of 8 min. Data 
collection and integration was done by a Trilab 2000 or 
Trilab 3000 chromatograpy data system. The working range of 
the measurement method is 1 to 20 ng ondansetron per ml 
plasma. Samples containing >20 ng/ml ondansetron were 
diluted with control plasma before analysis. Within this 
concentration range the mean coefficient of variation is 
<7.5% [14]. 
The area under the plasma-time concentration curve (AUG) 
was determined using the trapezoidal method between time 0 
and the last data point. The steady state plasma con­
centration was defined as that measured at the last 
quantifyable time point (24 hrs). The total plasma 
clearance was calculated as infusion rate/steady state 
plasma concentration. 
Statistical analysis 
Anti-emetic response (emesis versus no emesis) was analyzed 
in relation to dose level and several patient variables 
(age, gender, cisplatin dose, concomitant chemotherapy and 
liver dysfunction) using the chi-square test (2x3- and 2x2-
tables). The relationship between dichotomized plasma 
levels and anti-emetic response was also analyzed by the 
chi-square test. In addition, a logistic model was used to 
explore the relationship between plasma levels, dose, anti­
emetic response and the patient variables mentioned above. 
RESULTS 
Patient characteristics 
Forty-three évaluable patients (26 naive, 17 previously 
treated) were enrolled into this study. Sufficient blood 
samples were obtained from 37 patients, although 17 of 
these did not have a 12-h sample. Patient characteristics 
are given in Table 1. The 3 treatment groups were well 
balanced, except for primary tumor sites and concomitant 
chemotherapy (Ρ < 0.0 5) . 
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Table 1. Patient Characteristics 
Number o f p a t i e n t s 
Age ( y e a r s ) : median 
range 
Gender: M / F 
P r i o r chemotherapy 
none 
c i s p l a t i n 
n o n - c i s p i a t i η 
Primary tumour s i t e 
Ovary 
Melanoma 
B l a d d e r 
Head and neck 
M i s c e l l a n e o u s 
Concomittant chemotherapy 
None 
Cyc1ophosphamide 
I f o s f a i m d e 
E p i - / D o x o r u b i c i n 
5-FU 
M i s c e l l a n e o u s 
Anti-emetic e f f i c a c y 
1 
9 
57 
41-71 
5/4 
6 
2 
1 
4 
3 
2 
3 
4 
2 
Dose l e v e l 
2 
19 
56 
31-71 
6/13 
12 
4 
3 
5 
5 
1 
4 
4 
3 
4 
4 
2 
4 
2 
3 
9 
62 
42-68 
3/6 
6 
1 
2 
5 
2 
1 
1 
1 
6 
2 
T o t a l 
group 
37 
55 
31-71 
14/23 
24 
7 
6 
14 
7 
5 
6 
5 
7 
14 
6 
2 
6 
2 
Table 2 shows the control of emesis overall for each dose 
level, gender, cisplatin dose and whether patients had 
prior treatment or not. There was no significant difference 
in the complete control of emesis between the 3 dose levels 
(P=0.09), and in patients who had received previous chemo­
therapy, 31% versus 50% (P=0.26). In contrast, the 
difference in complete control in males compared to 
females, 64% versus 30% (P=0.04), was significantly in 
favour of male patients. 
Plasma ondansetron level and pharmacokinetic data (Table 3) 
There was wide interpatient variation, with the maximal 
concentration (Cmax) ranging from 62-267 ng/ml, 79-359 
ng/ml and 163-467 ng/ml within patients on the 3 dosage 
regimens. Plasma concentrations were not influenced by age, 
gender, cisplatin dose, concomitant chemotherapy or liver 
function disturbance. Likewise there was no relation be-
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Table 2. Anti-emetic response 
π (%) 
Entire group 
Dose level 
1 
2 
3 
Prior treatment 
none 
yes 
Gender 
male 
female 
Cispiatiα dose 
<95тд/гт£ 
>95mg/m 
Total 
37 
9 
19 
9 
24 
13 
14 
23 
28 
9 
CR 
16 
5 
5 
6 
12 
4 
9 
7 
12 
4 
(43) 
(56) 
(26) 
(67) 
(50) 
(31) 
(64) 
(30) 
(«) 
(45) 
MR 
θ 
1 
6 
1 
8 
0 
3 
5 
5 
3 
(22) 
(И) 
(32) 
(11) 
(34) 
( 0) 
(22) 
(22) 
(18) 
(33) 
mR 
5 
0 
4 
1 
2 
3 
2 
3 
3 
2 
(13) 
( 0) 
(21) 
(Π) 
(β) 
(23) 
(14) 
(13) 
(Π) 
(22) 
F 
8 (22) 
3 (33) 
4 (21) 
1 (Π) 
2 ( 8) 
6 (46) 
0 ( 0) 
8 (35) 
8 (28) 
0 ( 0) 
Abbreviations: η: number of patients, CR: complete response, MR: major, 
mR: minor, F: failure, 
tween the concentration of ondansetron and body weight or 
body surface area. Increasing the ondansetron dose was 
paralleled by a general increase of the plasma con­
centration. The mean steady state concentration (C
ss
) value 
also increased in an approximately linear fashion with 
infusion rate. Hence the mean estimated plasma clearance 
values do not show any particular trend. However, as the 
achievement of steady state could not be demonstrated in 
all cases, the estimated clearance values should be viewed 
with caution. The AUC values show a large degree of overlap 
between dosage groups, but the mean values do not indicate 
any gross non-linearity in the disposition kinetics of 
ondansetron with increased dose. 
Plasma levels of ondansetron versus clinical response 
No dose-response relationship or threshold plasma con­
centration above which complete anti-emetic control 
occurred was found. The anti-emetic response in all 
patients was examined in relation to ondansetron plasma 
concentrations. Figure 1 shows the percentage of patients 
achieving complete control of acute emesis versus those 
experiencing acute emesis, in relation to the median plasma 
concentrations at the different time points. The 
ondansetron levels at 15 minutes and one hour showed no 
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Table 3. Pharmacokinetic data 
η 
1 
2 
3 
4 
5 
6 
7 
8 
9 
Dose 
l e v e l 
Median 
Range 
Mean 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
Geom. 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
Median 
Range 
Mean 
29 
30 
31 
32 
33 
34 
35 
36 
37 
Geom. 
3 
3 
3 
3 
3 
3 
3 
3 
3 
Median 
Range 
Mean Geom. 
Cmax 
( n g / m l ) 
96.6 
117 
138 
90 
267 
60.6 
95.9 
107 
60.6 
96.6 
Time t o 
peak ( h ) 
24 
24 
0.25 
0.25 
0.25 
0.25 
6 
0.25 
0.25 
60.6-267 
100.9 
231 
359 
259 
172 
180 
104 
153 
184 
190 
224 
214 
79.1 
114 
259 
140 
170 
177 
110 
130 
177 
79.1-359 
172.7 
301 
196 
467 
251 
163 
427 
376 
213 
238 
251 
163-467 
275.6 
24 
0.25 
24 
0.25 
0.25 
0.25 
0.25 
0.25 
24 
0.25 
0.25 
24 
0.25 
0.25 
6 
24 
0.25 
0.25 
12 
0.25 
6 
6 
0.25 
24 
0.25 
24 
24 
0.25 
C
S s (ng?ml) 
96.6 
117 
3 1 . 4 
56.1 
78.7 
28.3 
31.6 
24.8 
20 
31.6 
20.0-117 
44.9 
231 
354 
259 
143 
149 
59.5 
152 
91.2 
190 
149 
133 
79.1 
85.8 
50 
124 
170 
44.3 
17.4 
104 
133 
17.4-354 
115.5 
222 
235 
420 
160 
163 
183 
376 
213 
235 
213 
128-420 
217 
AUC 
( n g . h / m l ) 
1786.9 
2216.9 
1057.7 
1497.9 
3102.4 
707 
1401.3 
869.1 
793.3 
1401.3 
707.0-3102 
1233.8 
4140.3 
5470.4 
3638.0 
3045.9 
1224.8 
1300.2 
2705.2 
1884.1 
3546.4 
3715.6 
2650.7 
1501.1 
2107 
1534.2 
3015.9 
2817 
1161.9 
906.2 
2623.9 
2650.7 
906.2-5470. 
2499.7 
5015.8 
3751.9 
9565.5 
4325.5 
3243.7 
4029.9 
6770.4 
2453 
4632.8 
4325.5 
2453-9565 
4517.2 
Clearance 
ml/min 
172.5 
142.5 
530.8 
297.1 
211.8 
588.9 
527.4 
672 
833.3 
527.4 
142.5-833 
371.2 
144.3 
9 4 . 2 
128.7 
233.1 
223.7 
560.2 
219.3 
365.5 
175.4 
223.7 
250.6 
421.4 
388.5 
666.7 
268.8 
196.1 
752.4 
1915.7 
320.5 
250.6 
4 94.2-1915 
288.5 
300.3 
520.8 
158.7 
416.7 
409 
364.3 
177.3 
313 
283.7 
313 
158-520 
307.1 
Resp 
CR 
CR 
CR 
CR 
MR 
MR 
F 
F 
F 
CR 
CR 
CR 
CR 
CR 
MR 
MR 
MR 
MR 
MR 
MR 
mR 
mR 
mR 
mR 
F 
F 
F 
F 
CR 
CR 
CR 
CR 
CR 
CR 
MR 
mR 
F 
Abbreviation: Cmax: maximum concentration, Css: steady state concentration, AUC: 
area under the plasma-time concentration curve, resp: response. 
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significant predictive value for complete protection (chi-
sguare=3.41 with 1 df, P=0.06 each time). At 12 hours no 
conclusion can be drawn because of insufficient sampling 
data (P=1.0). Median plasma levels at 24 hours were also 
not predictive for significantly better complete control 
(chi-square= 2.16 with Idf, P=0.14). 
Control of acute emesis 
related to plaama concentration at varloua tlmepointa 
П· IB 19 1B 19 20 17 18 IS 19 18 
16 min 1h 3h eh 24 h 
^Ш Complete control K\\\\4 Emesia 
Figure 1. 
Percentage of anti-emetic control (no emesis versus emesis) at the different 
timepoints in relation to the median ondansetron plasma concentration fat that 
timepoint. (for P-values see text) 
in contrast, in patients with an ondansetron plasma 
concentration above 105 ng/ml at 3 hours, the complete 
response rate was 65% (11/16), compared to 25% (5/15) in 
those patients having a plasma level below this value (chi-
square= 5.90 with Idf, P=0.015). If the ondansetron plasma 
concentration was greater than 100 ng/ml at 6 hours, 
complete anti-emetic control was seen in 12/19 patients 
(63%), compared to a complete response in 4/18 patients 
(22%) with ondansetron concentrations below this value 
(chi-square=6.31 with Idf, P=0.012). These differences were 
independent of cisplatin dose, gender, age, pretreatment 
and concomitant chemotherapy. 
If the plasma concentration of ondansetron was greater 
than 100 ng/ml between 3 and 6 hours (=2.5 and 5.5 hours 
after start of cisplatin), complete control of acute emesis 
occurred in 12 out of 18 patients (67%), compared with 4 
out of 19 patients (21%) with values below this level (chi-
square=7.83 with Idf, P=0.005) (Fig.2). 
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100 l i 
«100 ng/ml >100 ne/mi Рімт« ββ"» 
• ondansetron 
• i Complete control Ш З Emesis ρ • o oos 
Figure 2. 
Percentage of control of acute emesis (no emesis versus emesis) related to 
ondansetron plasma concentration being lower or greater than 100 ng/ml over 3-6 
hours after start of treatment with ondansetron. 
DISCUSSION 
The results from this study indicate that ondansetron is an 
effective drug in the prevention of acute cisplatin-induced 
emesis. The overall efficacy rate (CR+MR) of 65% compares 
favourably with the results reported for "high-dose" meto-
clopramide. In agreement with observations of other 
investigators, anti-emetic control was clearly less in 
female patients and was also poor in patients who had 
received previous chemotherapy [13,15]. 
The wide interpatient variation of ondansetron plasma 
levels is consistent with previous reports for meto-
clopramide [9,10], and the S-HTj antagonists granisetron 
[16,17] and ondansetron [18]. The plasma concentrations 
were unrelated to any of the patient variables examined. 
There is no clear explanation for this variability, 
indicating that it is difficult to predict the plasma 
concentration of a fixed drug dose using pharmacokinetic 
models. It suggests that drug dosing on a weight or surface 
area basis may also not achieve optimal plasma concentra­
tions. Furthermore, it is not surprising that a dose-
response relationship was not found. 
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in this study a positive correlation was found however 
between ondansetron plasma concentrations, greater than 100 
ng/ml over 3-6 hours after starting anti-emetic therapy 
(2.5-5.5 hrs after start of cisplatin), and improved 
complete anti-emetic protection. This may indicate that it 
is important for effective anti-emetic control to maintain 
sufficient 5-HT3 receptor blockade during this time period. 
Unfortunately, because of insufficient sampling data at 12 
hours, we could not evaluate the correlation of plasma 
concentration and efficacy at this time point. It was 
recently demonstrated that the excretion of 5-hydroxyindole 
acetic acid was increased in the same time period [19], it 
is possible that the first 6-8 hours is the most critical 
period in the acute phase emesis. Indeed, good anti-emetic 
results were also shown when anti-emetics were given during 
the first 8 hours only [6,7,19-21]. Moreover, a single dose 
of ondansetron (32 mg) has recently been shown to be as 
effective as a continuous infusion schedule [22]. Other 
effective single dose regimens have been reported with 
metoclopramide [23] and granisetron [24]. It would be of 
interest therefore to investigate if a positive con-
centration-response relationship also holds true for these 
dosing schedules, over the first 8 hours following 
cisplatin administration. Likewise, it would be of interest 
to see whether an additional dose of ondansetron can re-
establish control of breakthrough symptoms. 
Comparisons between this analysis and previous studies 
are difficult because of the sometimes limited sampling 
techniques used (single serum level [8,10], small sample 
size [8]), because of the different anti-emetic drugs 
[10,17,18] and the differences in response assessment. 
Obviously, further studies are required using larger 
patient samples, sufficiently sampling timepoints, 
specified drugs, and clearly defined response assessments 
to confirm these data or determine further a plasma con-
centration-response relationship. More information on this 
question may make it possible to rationally improve anti-
emetic control. 
Patients experiencing poor anti-emetic control after 
cisplatin chemotherapy may have low ondansetron plasma 
levels. Increasing the dose of ondansetron, over the first 
6-8 hours, in the following chemotherapy cycle may help to 
improve the individuals' anti-emetic control. 
In conclusion, ondansetron is an effective anti-emetic in 
acute cisplatin-induced emesis. Complete control is 
significantly better if the ondansetron plasma level is 
77 
maintained above 100 ng/ml between 3 and 6 hours after the 
start of anti-emetic treatment (2.5-5.5 hrs after 
cisplatin) . Further studies are required to confirm these 
findings. Patients experiencing emesis despite treatment 
with ondansetron may benefit by receiving a higher dose 
with subsequent courses, in order to improve anti-emetic 
control. 
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Abstract 
The efficacy and safety of 2 dose schedules of the 5-HT3 
antagonist ondansetron (Zofran ) were studied in 35 
patients (group A: 19 patients, group B: 16 patients) 
previously refractory to standard anti-emetics after non-
cisplatin based chemotherapy (>5 emetic episodes). The 
maintenance of the anti-emetic efficacy of ondansetron was 
further studied in 28 patients (13 A, 15 B) in respectively 
36 and 48 retreatment courses. Ondansetron was administered 
as an 8 mg loading dose (A: 4 mg i.v.+ 4 mg orally; B: 8 mg 
i.V.), followed by oral treatment for 5 days (A: 4 mg 6-
hourly; B: 8 mg 8-hourly). In the first treatment cycle 
acute emesis was completely controlled in 53% of the 
patients in group A and in 50% of the patients in group B. 
Delayed emesis was absent in 75% and 38% of the patients in 
group A and В respectively. In a second treatment cycle 
acute anti-emetic control was achieved in 54% and 53% of 
the patients in group A and В respectively. Over the third 
and fourth subsequent treatment, complete control occurred 
in 56% and 38% of the patients in group A, and in 46% and 
56% of the patients in group В respectively. Delayed emesis 
did not occur over the following courses in 62%, 89% and 
75% of the patients on regimen A, in 57%, 60% and 63% of 
the patients on regimen B. The observed adverse effects 
were headache (37%) and constipation (42%). No extrapyram­
idal reactions were seen. Ondansetron is able to re­
establish an acceptable anti-emetic control in previously 
refractory patients on non-cisplatin based chemotherapy, 
without major toxicity. This efficacy is maintained over 
the 3 following retreatment courses. 
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INTRODUCTION 
With the increased use of chemotherapy frequently resulting 
in nausea and vomiting, the need for improved control of 
this side effect has become an important goal in the 
management of cancer patients. With combinations of the 
effective anti-emetics 20-30% of the patients cannot satis-
factorily be protected, resulting in refractory and anti-
cipatory symptoms. Furthermore many drugs are associated 
with distressing side effects as the extrapyramidal reacti-
ons associated with some dopamine antagonists, such as 
metoclopramide [1]. Intensified research over the last 
decade has led to a better understanding of the causative 
mechanisms of chemotherapy-induced nausea and vomiting and 
indicated that the 5-hydroxytryptamine3 receptor (5-HT3) 
plays a major role in this phenomenon [2-4]. This hypo-
thesis is supported by the observation that the urinary 
exretion rate of 5-hydroxyindole acetic acid increases 
following chemotherapy and that this rise parallels the 
onset of emesis [5]. These 5-HT3 receptors have been 
demonstrated on vagal afférents in the gastrointestinal 
tract [6] and in the area postrema [7]. 
Ondansetron (Zofran ) binds selectively and competitively 
at 5-HT3 receptor sites [8], probably both centrally [7,9] 
and peripherally [8,10]. The drug has no dopamine anta-
gonizing properties, therefore lacking extrapyramidal 
reactions. Ondansetron is effective in the prevention of 
acute emesis associated with cancer chemotherapy [5,11,12]. 
Data from these studies have shown that 4 and 8 mg are safe 
and effective dose schedules. 
Based on these data we initiated a phase II study to 
investigate 1 ) the efficacy and safety of 2 consecutive 
dose regimens (A,B) of ondansetron in the prophylaxis of 
previously refractory nausea and vomiting induced by a 
variety of non-cisplatin chemotherapeutic regimens and 2) 
the maintenance of this anti-emetic effect with subsequent 
chemotherapy courses. 
PATIENTS AND METHODS 
Adult patients who were receiving emetogenic non-cisplatin 
containing chemotherapy and failed (>5 emetic episodes) 
previous effective standard anti-emetics (alizapride or 
metoclopramide) were eligible to enter into this study. All 
emetogenic chemotherapy was given intravenously (i.V.). 
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Informed consent was obtained from all patients. Exclusion 
criteria were: elevated bilirubin; serum alanine amino­
transferase >30 U/L or more than twice the upper limit of 
normal if liver metastases were present; modification of 
the previous chemotherapy dose; nausea and vomiting and/or 
anti-emetic therapy in the 24 hours prior to therapy with 
ondansetron; use of benzodiazepines in the 24 hours 
preceding start of the therapy and severe concurrent 
illness other than neoplasia. 
Regimen A consisted of a loading dose of 8 mg of 
ondansetron (4 mg i.v. and 4 mg orally) followed by 4 mg 
orally being repeated б-hourly. The loading dose of 8 mg of 
ondansetron in regimen В was administered intravenously, 
followed by an oral dose of 8 mg 8-hourly. The patients who 
were successfully treated during the first 24 hours (s 2 
emetic episodes) continued the same oral ondansetron 
treatment for a further 4 days (days 2-5). Rescue 
medication could be given to patients with unsatisfactory 
anti-emetic control (s 3 emetic episodes) at any time 
during the study period. With following treatment courses 
the patients received the same anti-emetic regimen and an 
identical dose of chemotherapy. 
Efficacy was assessed at 24 hours following chemotherapy 
(acute) and daily by the patients on diary cards for days 
2-5 (delayed). In-patients were monitored regularly by 
trained staff nurses. For out-patients information on the 
outcome of treatment with ondansetron after 24 hours was 
obtained by telephone. At the same time patients were asked 
if they wanted to continue with the anti-emetic medication. 
The following information was recorded on the diary 
cards: the severity of nausea (visual analogue (VAS) 0-100 
mm and graded scales: none, mild, moderate and severe), the 
number of vomiting and retching episodes in each 24 hour 
period, an assessment of appetite and any adverse events. 
The response criteria for emesis were : complete response 
(CR): 0 emetic episode; major response (MR): 1-2 emetic 
episodes; minor response (mR): 3-5 emetic episodes and 
failure (F): more than 5 emetic episodes. One vomit or one 
to five retches within any 5-minute period was counted as 
an emetic event. Appetite was graded. 
Patients were assessed at the out-patient clinic after 1 
week, where the diary cards were cross-checked and the 
acceptability of ondansetron as an anti-emetic was judged. 
The investigators assessed the adverse events as not 
related, unlikely, possibly, probably or almost certainly 
related to ondansetron treatment. 
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A blood sample for routine laboratory analysis was taken 
before treatment, after 7 days and at 2-4 weeks. This 
included full blood cell count, urea, creatinine, sodium, 
potassium, total protein, bilirubin, ASAT, ALAT, alkaline 
phosphatase and yGT. 
RESULTS 
Thirty-five refractory patients were enrolled in this 
study, 19 patients received regimen A and 16 regimen B. 
Thirteen (A) and 15 (B) patients received ondansetron again 
over 36 and 48 subsequent chemotherapy cycles respectively. 
Patient characteristics and details of the chemotherapy 
regimens are given in Table 1, and are equally distributed 
among the 2 groups. The results of anti-emetic control in 
subsequent courses were studied for each identical numbered 
course, adverse events were considered overall. 
Table 1. 
Variable 
Patient character i s t ic s and chemotherapy regimens 
Regimen A Regimen В 
Number of patients 19 16 
Male / Penale 6/13 5/11 
Age (years) median 45 3 
range 20-66 37-72 
Primary tumour site 
Lymphoma 5 
Lung (SCLC) - 3 
Breast 7 6 
Ovary 2 4 
Sarcoma 1 2 
Miscellaneous 4 1 
Chemotherapy 
CDE 1 3 
Doxo/± ifosf 1/1 2/0 
MOPP 4 
CMF/CAF 4/3 4/2 
Ipro-/Carboplatin 3 5 
Other 2 
CDE: CTX 1000mg/m + Doxo 45mg/m + VP16 100mg/m2 day!,3,5; Doxo SOmg/m ; ifosfamide 
5g/m ; MOPP: M 6mg/m2 + VCR 2rog + PRC 100mg/mZ + PRD 40mg/m . Of: CTX 14xl00mg/m2 
+ MTX 40mg/m2 + 5-FU 600mg/m ; CAF: CTX 500mg/m2 + ADR 50mg/m2 + 5-FU 600mg/m2; 
I prop!atiη 300mg/m , Carboplatin 400mg/m . 
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Anti-emetic efficacy, first cycle 
All patients were évaluable for assessment of acute nausea 
and vomiting and 32 patients were évaluable for assessment 
of delayed emesis. Two patients of group A being unsuccess-
fully controlled during the first 24 hours received rescue 
medication, and one patient failed to complete the diary 
card. The failing patient in group В continued oral 
treatment on his own request. 
The results of the control of nausea on the 5 consecutive 
study days are shown in Figure 1 . The data scored on the 
VAS for the same period showed comparable results. Delayed 
nausea ("worst day" analysis) was absent in θ patients 
(50%) of group A and in 5 patients (31%) of group B. 
Several data on the VAS were missing over days 2-5 and 
could therefore not be used for evaluation. 
CONTROL OF NAUSEA 
REGIMEN A 
i r « η·1β іиіб η·« mie 
ACUTE OCLAYED 
REGIMEN В 
1 2 3 4 6 DAYS 
ACUTE DELAYED 
M NONE E S MILD E D MODERATE WÍ SEVERE 
Figure 1. 
Intensity of nausea on the 5 consecutive study days of the first treatment course 
with ondansetron, in patients receiving treatment A and В respectively. 
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The anti-emetic control is shown in Figure 2. The 
percentages of complete control were not statistically 
different between the 2 schedules (P=0.61). 
On the first day, appetite was normal in 8 (42%) A and in 
8 (50%) В patients. In the delayed study part 14 patients 
(87.5%) of group A reported a normal appetite, and 5 
patients on regimen B. 
CONTROL OF EMESIS 
ACUTE 
PATIENTS 
HEFFUCTOBY 
DELAYED 
REFHACTOflY 
ШЙСЯ ЕЯ MR CDmR Шг 
Figure 2. 
Control of acute and delayed emesis τη the first treatment course with 
ondansetron, for patients on regimen A and В respectively. 
Assessment of preference after 24 hours was in favour of 
ondansetron in 11 patients (58%) of group A and in 14 (87%) 
of group B. After 7 days 75% of the patients on regimen A 
and 87% on schedule В found ondansetron superior to their 
previous anti-emetic treatment. 
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Anti-emetic efficacy, subsequent cycles. 
The anti-emetic response in subsequent cycles for both 
regimens is shown in Table 2. The number of treated 
patients diminishes with each following cycle, mainly due 
to discontinuation of the chemotherapy. One patient of 
group В did not complete the diary card. 
The anti-emetic results did not differ significantly in 
the 2 treatment schedules, but the sample size was small in 
the fifth and sixth retreatment cycle. Overall complete 
control in each second, thirth, fourth, fifth and sixth 
retreatment cycle occurred in 15 (54%), 10 (50%), 8 (47%), 
6 (55%), and 3 patients (50%) respectively. Delayed emesis 
in the same subsequent courses was absent in 16 (59%), 14 
(74%), 11 (69%), θ (80%) and 4 patients (75%) respectively. 
Table 2. Anti-emetic control in subsequent cycles. 
Subsequent 
cycle 
second 
third 
fourth 
fifth 
sixth 
Regimen 
CR 
MR 
mR 
F 
CR 
MR 
mR 
F 
CR 
MR 
mR 
F 
CR 
MR 
mR 
F 
CR 
MR 
mR 
F 
ACUTE (n 
A 
7 
3 
3 
-
5 
2 
1 
1 
3 
3 
2 
1 
3 
-
1 
-
-
1 
(54) 
(23) 
(23) 
(56) 
(22) 
(11) 
(11) 
(38) 
(38) 
(25) 
(25) 
(75) 
(50) 
(50) 
(%)) 
В 
8 
5 
1 
1 
5 
4 
2 
-
5 
1 
3 
5 
2 
_ 
2 
-
2 
-
(53) 
(33) 
(12) 
(12) 
(46) 
(36) 
(18) 
(56) 
(11) 
(33) 
(72) 
(28) 
(50) 
(50) 
DELAYED (n 
A 
β 
2 
1 
2 
8 
1 
-
-
6 
1 
1 
2 
1 
1 
2 
-
-
-
(62) 
(15) 
( 8) 
(15) 
(89) 
(11) 
(75) 
(12.5) 
(12.5) 
(50) 
(25) 
(25) 
(100) 
(%)) 
В 
8 (57) 
2 (15) 
3 (21) 
1 ( 7) 
6 (60) 
1 (Ю) 
3 (30) 
-
5 (63) 
2 (25) 
1 (12) 
6 (100) 
-
_ 
2 (50) 
2 (50) 
-
-
Abbreviations: CR: complete response, MR: major response, mR: minor response, F: 
fai lure. 
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Adverse events 
Seventeen patients (49%) were free of side effects, a total 
of 43 minor adverse events were reported in 18 patients. 
Mild sedation, flushing and dizziness were each reported 
once (2.5%). Ten patients experienced 16 episodes of head-
ache (37%) requiring acetaminophen treatment on 2 oc-
casions. Two patients had 3 episodes of abdominal cramps 
(7%). Eleven patients reported 18 episodes of constipation 
(42%), 9 events were moderate, requiring lactulose on 3 
occasions. In 2 patients slight elevations of transaminases 
were observed which, according to the investigators were 
not caused by ondansetron. In patients with préexistent 
elevation of liver function tests there was no worsening of 
the disturbance. 
DISCUSSION 
In our study, ondansetron was able to re-establish satis-
factory control (0-2 emetic events) of acute chemotherapy 
induced emesis in 80-90% of the previously refractory 
patients. This is an improvement for all these patients and 
is the more significant as this type of emesis is generally 
considered therapy resistent. It is also emphasized by the 
preference for ondansetron in 75-80% of the patients. There 
was no significant difference m the 2 treatment schedules. 
Assessment of nausea and vomiting are discongruent, 
consistent with the idea that nausea and vomiting may be 
separate entities with a different pathophysiological 
mechanism [2]. It confirms that it is important to assess 
both parameters separately in an anti-emetic study. 
Unlike for cisplatin containing chemotherapy, no 
prospective studies have systematically assessed the 
incidence and duration of delayed nausea and vomiting in 
non-cisplatin containing regimens. In a randomized study, 
published in 1979, Morran reported an incidence of delayed 
emesis in 78% of patients on day 2 (placebo treated). Over 
the next days the frequency of emesis decreased rapidly, 
while nausea persisted for several days despite the use of 
metoclopramide [13]. In another study Strum mentioned 
delayed emesis to occur m 22%, but this report gives no 
information on the methodology of assessment [14]. In a 
recent study delayed emesis was observed in 30% of the 
patients receiving different chemotherapy regimens on an 
out-patient basis [15]. Our data on delayed emesis in the 
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first treatment cycle are certainly influenced by the 
previously refractory symptoms. However, we did not notice 
an increased frequency of delayed symptoms with subsequent 
treatment cycles. Obviously, further studies are required 
to define the importance of the problem and to prove if the 
absence of delayed emesis we observed in 50-85% of our 
patients is due to ondansetron treatment or merely is a 
reflection of the natural course of delayed emesis. 
Available data from studies on original naive patients 
mostly show a decrease in anti-emetic efficacy with 
following courses [16,17]. Research, however, is obviously 
hampered by the absence of an universally accepted 
methology. Nevertheless, an improved control of postchemo-
therapy emesis postpones the development of anticipatory 
symptoms [18], underscoring the need for an initial and 
persistent good anti-emetic protection. The maintenance of 
an overall complete control of acute emesis in 44-55% of 
the refractory patients for 3 following retreatment courses 
in our study is wellcome and expands the experience with 
ondansetron, confirming its anti-emetic potential. Results 
from randomized studies and larger sample size are awaited. 
The observed adverse events were minor, headache and 
constipation being the most common, rarely requiring 
treatment and never necessitating discontinuation of 
ondansetron therapy. 
Ondansetron is an effective anti-emetic, which is able to 
restore control of previously refractory emesis induced by 
non-cisplatin chemotherapy. The anti-emetic efficacy is 
maintained over the next 3 retreatment cycles. Randomized 
studies should be performed to confirm this finding. The 
lack of major adverse events and extrapyramidal reactions 
in particular, makes ondansetron suitable for use in an 
outpatient setting. 
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Abstract 
Objective: To compare the efficacy and side effects of 
ondansetron with those of high-dose metoclopramide in 
treating acute and delayed cisplatin-induced nausea and 
vomiting. 
Design: Randomized, double-blind, crossover trial. 
Setting: Conducted at two university hospitals, a cancer 
institute, and six community hospitals. 
Patients: Of 125 patients, 95 were évaluable for the 
acute phase and 79 for the delayed phase. Major reasons for 
not being évaluable were no second course (14 patients), 
protocol violation (5 patients), and change in cisplatin 
dose (3 patients) for the acute phase; and rescue 
medication on day 1 (7 patients), protocol violation (3 
patients), and inadequate data (4 patients) for the delayed 
phase. 
Interventions: All patients received cisplatin, 50 to 100 
mg/m body surface area (median, 75 mg/m ); none had 
previously received chemotherapy. Thirty minutes before the 
cisplatin administration, ondansetron was given intra-
venously over 15 minutes, at a loading dose of 8 mg 
followed by a continuous infusion of 1 mg/h for 24 hours. 
Metoclopramide was given at a loading dose of 3 mg/kg body 
weight, followed by a continuous infusion for 8 hours (4 
mg/kg). For the delayed phase (days 2 - 6 ) , the first oral 
dose was given as soon as the infusion was completed; the 
oral dose consisted of either metoclopramide, 20 mg three 
times daily, or ondansetron, 8 mg three times daily for 
another 5 days. 
Measurements and Main results: In the acute phase, a 
major or complete response was seen in 72% of the 
ondansetron-treated and 41% of the metoclopramide-treated 
patients (P<0.001). Nausea was significantly better con-
trolled among the ondansetron-treated patients (P=0.04). In 
the delayed phase, no statistically significant difference 
was seen between ondansetron- and metoclopramide-treated 
patients. Nausea was significantly better controlled with 
metoclopramide (P=0.016). 
Conclusions: Ondansetron is significantly more effective 
than metoclopramide in preventing acute nausea and 
vomiting. In the delayed phase, the results of both drugs 
were disappointing, although metoclopramide's effect on 
delayed nausea was superior. Patients preferred 
ondansetron. 
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Chemotherapy-induced nausea and vomiting is an important 
clinical problem. Progress has been made in preventing 
acute nausea and vomiting (occurring within 24 hours of 
chemotherapy) (1-7); however, managing delayed and anti-
cipatory nausea and vomiting is still a significant problem 
(8-10). Metoclopramide has been proved efficacious and is 
considered the drug of choice in treating cisplatin-induced 
emesis (1-7). Metoclopramide is usually given by repeated 
intravenous bolus injections (1). It is more efficacious 
when it is continuously infused after a loading dose than 
when it is intermittently infused (4,11,12). The inter-
action between metoclopramide and the 5HT3 receptor has 
stimulated interest in the anti-emetic properties of the 
recently developed, specific 5HT3 receptor antagonists (13-
17). 
Ondansetron (GR38032F) is a highly selective 5HT3 
receptor site antagonist that does not affect dopamine 
receptors (18). In open studies, over a wide dosage range 
and using different schedules, anti-emetic efficacy was 
achieved using both cisplatin (19-22) and non-cisplatin-
containing regimens (17,23). The side effects seen, in-
cluding constipation, headache, and, rarely, a slight, 
transient elevation of liver enzyme levels, were mild. In a 
recently reported randomized study, ondansetron provided 
complete and major control of acute cisplatin-induced 
emesis in 75% of patients compared with 42% with meto-
clopramide (P<0.001). 
In our randomized, double-blind, crossover study, the 
same regimen was used. The primary objective was to compare 
the efficacy and safety of continuously infused ondansetron 
with high-dose, continuously infused metoclopramide in the 
prophylaxis of acute nausea and vomiting induced by 
cisplatin-containing chemotherapy regimens. In addition, 
the management of delayed nausea and vomiting (occurring 
from day 2 to day 6) was investigated by comparing 
ondansetron with metoclopramide, both given orally for 5 
days. Further, risk factors such as gender and alcohol 
intake were considered. 
PATIENTS AND METHODS 
Patients 
From May 1988 to February 1989, 121 patients with patho-
logically confirmed cancer entered the study. Seventy-five 
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percent of these patients were recruited by three centres. 
Eligible patients were 18 years of age or older, had not 
previously received chemotherapy, and were inpatients 
receiving cisplatin, from 50 to 100 mg/m body surface 
area. The patients were intended to receive at least two 
cycles of cisplatin, at the same dose. Exclusion criteria 
were vomiting or the use of anti-emetic drugs within the 24 
hours before the start of chemotherapy; clinical evidence 
of hepatic dysfunction in the absence of liver metastases; 
use of corticosteroids, unless as physiologic sup­
plementation or as part of the chemotherapy regimen; and 
use of benzodiazepines, except as night sedation. 
The pretreatment evaluation included a complete history 
and physical examination. A complete blood count and a 
biochemical profile (urea, creatinine, electrolyte, bili­
rubin, alkaline, phosphatase, aspartate aminotransferase, 
alanine aminotransferase, and γ-glutamyltransferase levels) 
were done before patients received the study treatment and 
were repeated after 24 hours, 7 days, and 2 to 4 weeks. 
Brief demographic details and history of alcohol con­
sumption (either nonuser, less than 7 units/wk, 1 to 4 
units/d, or more than 4 units/d) were recorded. Written or 
verbal informed consent was obtained from all patients, and 
the study was conducted according to the guidelines of the 
Helsinki declaration for human experimentation. The study 
was approved by the institutional ethical committees of 
each participating centre. 
Chemotherapy treatment 
Patients received various cisplatin-containing chemotherapy 
regimens. Cisplatin was given in 1 L of normal saline 
before and in 4 L of normal saline after hydration over 3 
to 4 hours at a dose of 50 to 100 mg/m , once every 3 to 4 
weeks. 
Materials 
Ondansetron was supplied by Glaxo Group Research Limited 
(Greenford, Great Britain) in 10-mL ampoules containing the 
equivalent of 2 mg of ondansetron base/mL and as white 
film-coated tablets containing the equivalent of 4 mg of 
ondansetron base. All doses referred to in this study are 
expressed in terms of the base. Commercially available 
metoclopramide (20-mL ampoules containing metoclopramide 
hydrochloride equivalent to 100 mg of the anhydrous 
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substance and tablets containing 10 mg of metoclopramide) 
was used. All tablets were prepacked, of the same form and 
color, and provided in boxes with two containers, each 
labeled with the randomization number and treatment period. 
Anti-emetic treatment 
The randomization sequence was computer-generated, with 
treatment assigned to blocks of ten patients. Patients 
received either ondansetron or metoclopramide with their 
first course of chemotherapy, crossing over the the other 
treatment with their second course at least 3 weeks later. 
Table 1. Patient Characteristics 
Characteristics 
Patients, η 
Median age, y (range) 
Men : Women 
Tumour site 
Head or neck 
Lung 
Gastrointestinal 
Gem to-uri nary 
Gynecologic 
Other 
Alcohol consumption* 
None 
< 7/wk 
1-4/d 
г 4/d 
Unknown 
Ondansetron, 
then 
Metoclopramide 
63 
58 (33-74) 
24:39 
6 
7 
1 
15 
31 
3 
26 
29 
6 
1 
1 
Metoclopramide, 
then 
Ondansetron 
58 
57 (27-74) 
29:29 
8 
9 
5 
9 
21 
6 
23 
19 
13 
1 
1 
* Number of drinks. 
Acute phase 
The infusions were centrally prepared and labeled with 
randomization number and treatment period. Thirty minutes 
before the cisplatin infusion, ondansetron was given intra­
venously over 15 minutes, at a loading dose of 8 mg diluted 
in 100 mL of normal saline. This dose was followed 
immediately by a coninuous infusion at a rate of 1 mg/h for 
24 hours, divided into an 8-hour period and a 16-hour 
period because of the blinded nature of the study. Meto­
clopramide was given similarly, at a dose of 3 mg/kg body 
weight, diluted in 100 mL of normal saline, followed by 4 
mg/kg, continuously infused for 8 hours. Normal saline was 
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given thereafter for 16 hours. 
Table 2. Type of cancer chemotherapy administered 
Chemotherapy Number of 
Patients 
Cisplatin Π 
Cisplatin and cyclophosphamide 33 
Cnsplatm and methotrexate with or without 
vinblastine 16 
Cisplatin and podophyllotoxin derivatives 14 
Cisplatin/5 and fluorouracil 15 
Cisplatin and vindesine with or without bleomycin 10 
Cisplatin, epi/doxo-rubicin, and cyclophosphamide 16 
Cisplatin, epirubicin, cyclophosphamide, and 
prednisolone 4 
Other 2 
Total 121 
Delayed phase 
The first oral dose was given as soon as the infusion was 
completed. Patients received either metoclopramide, 20 mg, 
or ondansetron, 8 mg, three times a day and were instructed 
to coninue to take this amount for 5 days. 
Patient evaluation 
All patients were carefully instructed by a research nurse 
of physician about methods of efficacy assessment. Patients 
were observed in the hospital for the first 24 hours after 
cisplatin administration. Baseline nausea was assessed 
using a graded scale (none, mild, moderate, or severe) 
immediately before treatment and after 24 hours. The timing 
and number of episodes of vomiting and dry retching were 
recorded by an observer, cross-checked with the patients, 
and entered in the clincial record form. A single emetic 
episode was defined as any vomiting that produced liquid or 
1 to 5 retches within a 5-minute period. Control of emesis 
was graded as complete response (no emetic episodes), major 
response (1-2 episodes), minor response (3-5 episodes), and 
failure (> 5 episodes or when rescue medication was given) 
(3). Overall appetite was assessed as better than usual; 
usual; decreased, but consuming some solids; or consuming 
liquids only. 
Patients entered the delayed phase of the study unless 
the investigators considered it inappropriate. The patients 
completed diary cards daily on days 2 through 6. The 
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following information was recorded: number of episodes of 
vomiting or retching, nausea, appetite, number of tablets 
taken each day, and any upsetting symptoms. These diary 
cards were collected after 7 to 10 days and checked for 
completeness. Patients returned the treatment container, 
and the number of tablets was counted and recorded. In this 
phase, an emetic episode was defined as one retch or one 
episode of vomiting because of the inaccuracy of assessing 
the timing of retches on diary cards. After the second 
course of treatment, patients were asked to indicate which 
treatment course they preferred. 
Table 3. Reasons that patients were not évaluable 
Reason Number of 
Patients 
Acute phase 
No second course because of patient refusal 
No second course because of progressive disease 
No second course because of adverse events 
Change in ci spiati η dose 
Study drug not given according to the protocol 
Concomitant administration of benzodiazepines 
Vomiting before the second course 
Insufficient data 
Code broken 
Not évaluable 
Evaluable 
Delayed phase 
Not évaluable for the acute phase 
Received rescue medication on day 1 
Not entered 1n the delayed phase (physician's 
decision) 
Inadequate tablet intake 
Insufficient data 
Not évaluable 
Evaluable 
3 
3 
θ 
3 
5 
1 
1 
1 
1 
26 
95 
26 
7 
2 
3 
4 
42 
79 
Statistical consideration 
For each course of treatment, efficacy was assessed 
separately for the acute and delayed phases. Patients were 
included in a crossover analysis of a responsible variable 
if data were available for them on both courses of 
treatment for that variable. In the analyses of emetic 
response (episodes of vomiting or of vomiting and 
retching), a patient's response was graded for each course 
as either a success (complete or major response) or a 
failure (any other response). These data were analyzed 
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using log-linear models for binary crossover data. The 
models included the Hills-Armitage test for interaction 
between treatment and course number and the Prescott test 
for treatment differences (25). Estimates of the 
probability of a success for each treatment were derived 
with 95% confidence intervals (CIs). 
The number of emetic episodes (episodes of vomiting or of 
vomiting and retching) and the time between cisplatin 
therapy and the first emetic episode were analyzed using 
nonparametric methods for the crossover design (26). The 
methods are based on Wilcoxon rank sums. For patients who 
had more than five episodes and those who received rescue 
medication, the number of emetic episodes was arbitrarily 
scored as six. For patients who did not have an emetic 
episode within the first 24 hours after the start of 
cisplatin therapy, the time between cisplatin therapy and 
the first emetic episode was arbitrarily set as 25 hours 
before the analysis. The analysis included a test for 
interaction between treatment and course number. A separate 
analysis, stratified by centre, was also done using the Van 
Eiteren method for combining Wilcoxon statistics over 
strata (27). In the analysis of nausea grades, only the 
post-treatment grades were considered. The course with the 
lowest grade, if any, was recorded, and these preference 
data were analyzed using log-linear models. The Prescott 
test for treatment differences was used. 
The analyses done for the delayed phase were similar to 
those done for the acute phase of each treatment period. 
The response used for these analyses, however, was based on 
the "worst day" data for the two courses of treatment. 
Table 4. Distribution of complete or major response on day 
1 by sequence Group* 
Sequence Group 
Ondansetron, then 
metoclopramide 
Metoclopramide, then 
ondansetron 
F-F 
12 
10 
F-S 
1 
12 
S-F 
22 
4 
S-S 
16 
18 
total 
51 
44 
Total 22 13 26 34 95 
* F = failure; S = success (complete or major response) 
Patients' overall preferences were registered, and the 
data were analyzed using log-linear models. The Prescott 
test for treatment differences was used. The Ρ values refer 
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to two-sided tests; values of less than 0.05 were 
considered to be significant. 
RESULTS 
Acute phase 
The characteristics of the 121 study patients are shown in 
Table 1. The types of chemotherapy given are summarized in 
Table 2. The median cisplatin dose was 75 mg/m (range, 50 
to 100 mg/m ). No statistically significant differences 
were found in age, sex, alcohol consumption, or primary 
site of cancer between the group that first received meo-
clopramide and the group that first received ondansetron. 
Twenty-six patients were not évaluable for both courses of 
treatment (Table 3). 
Adverse events included myocardial infarction (2 cases), 
intercurrent death (1 case), cisplatin-related ototoxicity 
(1 case), stridor (2 cases), restlessness (1 case), and 
hallucination (1 case). These events (except for the last 
one) were not considered to be related to the anti-emetic 
treatment and were equally distributed over both treatment 
arms. Fifty-one patients first received ondansetron; 44 
first received metoclopramide. 
diy 1 diy 2-β 
CR ESSiMR CUmH Ш Р 
Figure 1. 
Control of emesis dunng the acute (day 1) and delayed (days 2 through 6) phases 
for patients receiving ondansetron (0ND) and metoclopramide (MCP). On day 1, η = 
95 and PiO.001. On days 2 - 6, η = 79 and P=0.212. 
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Vomiting and retching 
The overall response to treatment, as indicated by the 
number of emetic episodes, is shown in Figure 1 and Table 
4. The estimated probabilities of a success were 0.77 (95% 
CI, 0.66 to 0.85) for ondansetron and 0.32 (CI, 0.21 to 
0.45) for metoclopramide. This difference was statistically 
significant in favour of ondansetron (P<0.001). There was 
no interaction between treatment and courses or between 
treatment and centres. When the response of all 121 
patients during the first treatment period was analyzed, 
56% of those receiving ondansetron and 26% of those 
receiving metoclopramide showed a complete response 
(P<0.001). 
The overall median time between cisplatin therapy and the 
first emetic episode was 21 hours with ondansetron and 4.5 
hours with metoclopramide (Figure 2). This difference was 
statistically significant (P<0.001). The median time 
between the first and last emetic episodes was 9 hours 
(range, 1 to 22 hours) with ondansetron; and 4 hours 
(range, 0.3 to 21 hours) with metoclopramide; this 
difference was also significant (P<0.05). 
Metoclopramide infusion 
Ondansetron infusion 
θ 10 12 U 16 1Θ 20 22 2¿ 
Hours after Cisplatin 
Figure 2 . 
The timing of first emetic episodes in the 24 hours after treatment with 
cisplatin. Closed circles indicate ondansetron; open circles indicate meto-
clopramide. 
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Nausea 
Among the 51 patients who received ondansetron first, 27 
had lower nausea grades while they received ondansetron, 16 
had the same nausea grade while receiving ondansetron as 
while receiving metoclopramide, and 8 had higher nausea 
grades while receiving ondansetron. Of 44 patients who 
first received metoclopramide, 12 had lower nausea grades 
while receiving metoclopramide, 23 had the same nausea 
grade while receiving metoclopramide as while receiving 
ondansetron, and 9 had higher nausea grades while receiving 
metoclopramide (Figure 3). No nausea was seen in 37.9% of 
the ondansetron-treated patients compared with 21.1% of the 
metoclopramide-treated patients. Nausea grades during 
ondansetron therapy were significantly lower (P = 0.04). 
Diy 1 Diy 2-β 
Ond MCP Ond MCP 
H None ШЭ Mild • Moderate В Severe 
Figure 3. 
Control of nausea during the acute (day 1) and delayed (days 2 through 6) phases 
in patients receiving ondansetron (OND) and metoclopramide (MCP) respectively. On 
day 1, η = 95 and P=0.042. On days 2-6, η = 79 and P=0.012. 
Delayed phase 
Seventy-nine patients were évaluable for the delayed phase 
(days 2-6) of the study (Table 3). Of these patients, 41 
received ondansetron and 3Θ received metoclopramide first. 
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Vomiting and retching 
During ondansetron therapy, 56% of patients had a complete 
or major response compared with 63% during metoclopramide 
therapy. This difference was not statistically significant 
(P=0.212) (Figure 1). When only episodes of vomiting were 
used in the response analysis, there was a statistically 
significant difference in favour of metoclopramide 
(P=0.004). There was no evidence of interaction between 
either treatment and courses or between treatment and 
centres. The "worst" day was most often day 2, with a rapid 
improvement of symptoms thereafter. 
Nausea 
Of the 41 patients first given ondansetron, 8 had a lower 
nausea grade while receiving ondansetron, 11 had a lower 
grade while receiving metoclopramide, and 22 had the same 
grade while receiving ondansetron as while receiving meto-
clopramide. Of the patients who received metoclopramide 
first, 18 had a lower nausea grade while receiving meto-
clopramide, 6 while receiving ondansetron, and 14 had 
similar grades (Figure 3). The response to metoclopramide 
therapy was significantly better (P=0.016). 
Patients' overall preference 
This information was not available for 5 of the 95 
patients. Of the 48 patients given ondansetron first, 29 
(60%) preferred ondansetron, 15 (31%) preferred meto-
clopramide, and 4 (8%) expressed no preference. Of the 42 
patients given metoclopramide first, 20 (48%) preferred 
ondansetron, 12 (29%) preferred metoclopramide, and 10 
(24%) expressed no preference. The overall preference was 
54% for ondansetron and 30% for metoclopramide (P=0.012). 
Influence of sex 
In our study, an additional analysis was done to 
investigate the influence of sex on the final outcome. The 
average success rate (complete and major response) when 
treated with ondansetron was 65% for women and 95% for men. 
For metoclopramide treatment, these values were 31% and 
65%, respectively. Irrespective of treatment, men responded 
markedly better than women to anti-emetic treatment. 
Further analysis showed no relation between sex and the 
type of chemotherapy given (such as cisplatin and cyclo-
phosphamide to treat ovarian cancer). 
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Side effects 
The most common side effects related to ondansetron were 
headache (20%); constipation (10%); fatigue, sedation, 
lethargy, and drowsiness (10%); dry mouth (10%); and 
diarrhea (8%) (Table 5). The side effects were generally 
mild to moderate in severity. Hospitalization was required 
for fecal impaction that resulted in signs of gastro­
intestinal obstruction in one patient. This patient was 
also receiving opioids. Total recovery occurred with con­
servative treatment. The most commonly reported side 
effects of metoclopramide included fatigue, sedation, 
lethargy, and drowsiness (17%); diarrhea (16%); headache 
(10%); and dry mouth (8%). Side effects related to the 
dopamine antagonistic activity of metoclopramide were 
extrapyramidal reactions (6%); anxiety, restlessness, and 
hyperactivity (8%); and tremors (2%). Three patients were 
withdrawn from the study because they developed extra­
pyramidal symptoms. There were no major changes in clinical 
biochemistry levels. In seven patients, elevated liver 
enzyme levels were recorded (in 2 patients only during 
therapy with ondansetron, in 2 patients only during therapy 
with metoclopramide, and in 3 patients during both courses 
of therapy). 
Table 5. Main adverse events associated with ondansetron 
and metoclopramide therapies 
Event Ondansetron Metoclopramide Ρ Value* 
(n = 114) (n = 113) 
η (%) 
23 (20) 11 (10) 0.028 
11 (10) 9 ( θ) NS 
Π (10) 5(4) NS 
Π (10) 19 (17) NS 
9(8) 18 (16) NS 
0 9 ( 8 ) 0.002 
0 7 ( 6 ) 0.007 
0 2 ( 2 ) 
* NS = not significant 
Headache 
Dry mouth 
Constipation 
Fatigue, sedation, 
lethargy, or 
drowsiness 
Diarrhea 
Anxiety, restlessness, 
or hyperactivity 
Extrapyramidal 
effects 
remors 
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DISCUSSION 
In this randomized, double-blind, crossover study, we 
compared ondansetron, a representative of a new class of 
anti-emetic drugs, with metoclopramide. It proved to be 
superior in controlling the acute onset of nausea and 
vomiting induced by cisplatin-containing chemotherapy. 
Ondansetron's value in treating delayed nausea and vomiting 
at the dosage and regimen used in this study is unclear; it 
was inferior to metoclopramide for treating such nausea. 
Based on animal data, 5-HT3 antagonists were promising 
candidates for preventing the nausea and vomiting induced 
by cytotoxic agents (28-30). In open studies, this efficacy 
was clearly shown (19-24,31-33). No clear dose-response 
relation was discovered. 
On the basis of these results, we initiated a double-
blind trial, using the lowest tested dose. We used a cross-
over design to avoid interpatient variability in type of 
chemotherapy, age, sex, or alcohol intake. Further, 
patients' treatment preference could thus be recorded. In 
crossover studies, a carry-over effect may interfere 
(6,34); however, such an effect was not seen in our study. 
In our study, complete and major response to therapy, as 
indicated by fewer episodes of vomiting and retching, was 
achieved in only 41% of patients treated with meto-
clopramide and was significantly less than the response 
obtained with ondansetron (71%). These results were very 
similar to those obtained by Marty and colleagues (24). In 
general, the reported efficacy of metoclopramide in 
treating cisplatin-induced vomiting varies from 30% to 100% 
(1-7,35-37). These studies, however, should be compared 
with caution, because they differ in factors possibly 
influencing the occurrence of nausea and vomiting, such as 
cisplatin dose, concurrent emetogenic medication, duration 
of cisplatin infusion, alcohol consumption, sex, and metho-
dology of reporting results. 
A remarkable finding in our study was the pattern of 
failure seen for the two regimens. In metoclopramide-
treated patients, 87% had their first emetic episode within 
the first 6 hours after cisplatin therapy (during the 
metoclopramide infusion). The ondansetron-treated patients' 
first emetic episodes occurred over the whole 24-hour 
period, with a slight peak between 6 and 12 hours. This 
finding indicates a major difference in action between 
these two drugs. The relatively early onset of vomiting 
with continuously infused metoclopramide suggests that an 
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adequate dose given early in the process of vomiting rather 
than a certain dose over a prolonged (8-hour) period is 
important. Of interest in this respect is the observation 
that a single large dose of metoclopramide, 4 to 6 mg/kg 
given in combination with lorazepam and dexamethasone, 
prevented emesis in 55% to 64% of the patients treated with 
high-dose cisplatin (37). If the 5HT3 receptor is the main 
receptor acted on by metoclopramide and ondansetron, the 
observed difference is difficult to explain and suggests 
that other, unknown factors are relevant. 
Also striking in our study was the overall poorer 
response of women in comparison with men, irrespective of 
the type or anti-emetic treatment. This phenomenon is 
described in the literature and is a factor to be 
considered when reporting or comparing the results of anti-
emetic studies (38,39). 
Delayed nausea and emesis are considered to constitute a 
distinct syndrome that occurs more than 24 hours after the 
administration of chemotherapy. This syndrome is pre-
dominantly linked to the use of cisplatin; the incidence of 
vomiting and nausea associated with cisplatin use in a 
prospective study were 74% and 87%, respectively (8). In 
retrospective studies, 20% to 35% of patients were found to 
have some nausea and vomiting 2 to 7 days after cisplatin 
administration (35,36). The highest incidence is seen from 
48 to 72 hours after cisplatin administration (8,40). In a 
randomized, placebo-controlled trial, dexamethasone 
combined with oral metoclopramide, 0.5 mg/kg four times 
daily for 4 days, prevented vomiting and retching in 52% of 
patients compared with 11% of patients receiving placebo 
and 35% in patients treated with only dexamethasone (P = 
0.006) (40). For nausea, a similar pattern was seen. In our 
study, ondansetron, 24 mg/d, and metoclopramide, 60 mg/d, 
completely prevented delayed vomiting and retching in 24% 
and 27% of patients, respectively. Metoclopramide's effect 
on delayed nausea was significantly better than that of 
ondansetron. As documented in the literature, nausea was 
the most severe between 24 and 72 hours after cisplatin 
administration. 
Side effects that were specifically related to 
ondansetron were easily controlled headache and con-
stipation. Extrapyramidal effects, diarrhea, fatigue, 
sedation, lethargy, and drowsiness were specifically 
related to metoclopramide. In this study, no elevation of 
liver enzyme levels could be related with certainty to 
ondansetron use; this side effect has been described in 
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earlier studies and may also be induced by chemotherapy 
(41). 
In conclusion, ondansetron, first given as a loading 
dose, then continuously infused, was significantly more 
effective than high-dose, continuously infused meto-
clopramide in preventing acute nausea and vomiting, in 
treating delayed nausea and vomiting, the results of both 
drugs were disappointing, although metoclopramide's effect 
on delayed nausea was superior. However, patients preferred 
ondansetron. The observed side effects of ondansetron were 
minimal. These results prove the value of this new class of 
anti-emetic drugs. Further studies, with special emphasis 
on dose, infusion time, and their role in treating delayed 
nausea and vomiting, however, are needed. 
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Chapter 8 
COMPARISON OF THE ANTI-EMETIC EFFICACY OF 
DIFFERENT DOSES OF ONDANSETRON, GIVEN AS EITHER A 
CONTINUOUS INFUSION OR A SINGLE INTRAVENOUS DOSE, 
IN ACUTE CISPLATIN-INDUCED EMESIS. 
A multicentre, double-blind, randomized, parallel group 
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Abstract 
A total of 535 patients (263 male/272 female) scheduled to 
receive cisplatin (50-120 mg/m ) containing regimens par-
ticipated in a randomized, double-blind, parallel group 
study to evaluate the efficacy and safety of three intra-
venous dose schedules of ondansetron in the prophylaxis of 
acute nausea and emesis. One hundred and eighty-two 
patients received a loading dose of 8 mg of ondansetron 
followed by a 24-hour infusion of 1 mg/h (group I), 180 and 
173 patients received a single dose of 32 mg (group II) or 
8 mg (group III) respectively, followed by a 24-hour 
placebo infusion. Complete and major control (s 2 emetic 
episodes) of acute emesis were achieved in 74% of patients 
in group I, 78% in group II and 74% in group III. Seventy 
seven per cent of the patients in group I, and 75% in 
groups II and III respectively experienced none or mild 
nausea during the 24-hour study period. The response rate 
in females was significantly lower when compared to males 
(43% versus 67%). Ondansetron was well tolerated; mild 
headache (11%) was the most commonly reported adverse event 
with a similar incidence in the 3 groups of patients. 
Extrapyramidal reactions were not observed. 
In conclusion, a single intravenous dose of 8 mg of 
ondansetron is as effective as a 32 mg daily dose in the 
prophylaxis of acute cisplatin-induced emesis. 
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INTRODUCTION 
A considerable advance was made in alleviating one of the 
most distressing side effects of cytotoxic anticancer 
treatment when it was demonstrated that high-dose meto­
clopramide considerably improved the control of cisplatin-
induced emesis [1,2]. Since then high-dose metoclopramide 
has been the cornerstone of effective anti-emetic com­
binations [3,4]. However, it can induce extrapyramidal 
reactions especially in adolescents, and this remains a 
major drawback. The recent development of 5-HT3 receptor 
antagonists showing anti-emetic efficacy against chemo­
therapy- and radiotherapy-induced emesis without extra­
pyramidal symtoms is another major step forward [5]. 
The 5-HT3 receptor antagonist ondansetron (Zofran
R) has 
been shown to be superior to high-dose metoclopramide in 
the control of acute cisplatin-induced emesis when given 
intermittently as short infusions (0.15 mg/kg χ 3, 4-
hourly) or by a constant infusion (Θ mg + 1 mg/h/24 hrs) 
[6-8]. The pattern of emesis observed in the latter 2 
studies indicated that for patients who received 
ondansetron and experienced emesis then this occurred in 
the 16-24 hour period after cisplatin. Emesis observed for 
patients who received metoclopramide occurred most 
frequently in the first 6-12 hours following cisplatin 
[7,8]. A similar pattern of emesis with metoclopramide was 
also seen in previous studies, and suggests that the first 
8-12 hour period after cisplatin might be critical [9]. The 
urinary excretion of 5-hydroxyindole acetic acid (5-HIAA), 
a metabolite of serotonin (5-HT) also has been shown to 
increase in the 4- to 6-hour period after the cisplatin 
infusion parallelling the onset of emesis [10]. These 
observations suggested that shorter treatment regimens of 
ondansetron may be as effective as the continuous infusion 
of multiple dose schedules employed in the initial com­
parative studies with ondansetron. Moreover, results from 
studies with high-dose metoclopramide [11] and other 5-HT3 
receptor antagonists, granisetron and tropisetron [12,13] 
have shown that single doses of these agents, given prior 
to chemotherapy, are effective in controlling acute 
symptoms. 
This study was therefore designed to determine whether 
the recommended daily dose of 32 mg of ondansetron, when 
given as a single intravenous dose prior to chemotherapy, 
is as safe and effective as the established 24-hour 
continuous infusion schedule in the prevention of acute 
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cisplatin-induced emesis. It further investigated the 
contribution made by the continuous infusion of 1 mg/h to 
efficacy by the addition of a third dosing arm, a single 8 
mg dose. If effective, a single intravenous dose would be 
advantageous in terms of convenience and ease of 
administration benefitting both patients and nursing staff. 
PATIENTS AND METHODS 
Patients 
Male or female patients, aged at least 18 years, who were 
scheduled to receive their first course of chemotherapy 
with cisplatin at a dose of 50-120 mg/m2 given over a 
period up to 4 hours, either alone or in combination with 
other cytotoxic drugs, were eligible for the study. 
Patients were excluded if they experienced nausea or 
vomiting and/or received anti-emetic therapy in the 24 hour 
period prior to the start of the treatment, had a serious 
concurrent illness other than cancer or another aetiology 
for emesis, and concurrently used corticosteroids (except 
for physiological supplementation) or benzodiazepines 
(unless given for night sedation). 
A complete history and physical examination were carried 
out prior to treatment. Blood samples were taken for full 
blood cell count, electrolytes, liver and renal functions 
prior to starting the study, and repeated after 24 hours 
and 1-4 weeks later. Oral or written informed consent was 
obtained from all the patients. The study protocol was 
approved by the health authorities where required, and by 
local Hospital Ethics Committees. The study was conducted 
according to the principles of the Declaration of Helsinki. 
Study design and treatment 
The required number of patients was calculated under the 
assumption that complete and major anti-emetic control (0-2 
emetic episodes) would be achieved in ±75% of the patients 
with the continuous infusion schedule. Using two-sided 
tests at an overall 5% significance level and a power of 
0.8, 170 patients (of whom 150 could be expected to be 
évaluable) would be required in each group to detect a 
difference of at least 15% between the continuous infusion 
regimen and either of the 2 single dose regimens. The trial 
design allowed for an interim analysis when approximately 
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50 évaluable patients in each treatment group were 
recruited. If the analysis provided clear evidence of a 
treatment difference, then the study would be terminated or 
recruitment would be halted into the inferior study arm. 
Eligible patients were randomly allocated to one of the 3 
ondansetron schedules as detailed in Table 1 . The 
randomization sequence was computer-generated and balanced 
the treatment in blocks of 9 patients. The ondansetron and 
placebo infusions were prepared by a dedicated nurse, 
physician or pharmacist not involved with the care or the 
evaluation of the patient to ensure blindness. 
Table 1. Treatment schedules 
Ondansetron 
Study Loading dose Continuous infusion Total dose 
group (15 mms) (24 hours) (24 hours) 
Ι θ mg Img/hour 32 mg 
II 32 mg placebo 32 mg 
III 8 mg placebo 8 mg 
The loading dose of either 8 mg (group I and III) or 32 
mg (group II) of ondansetron was diluted to a 100 ml of 
saline, and administered over 15 minutes starting 30 
minutes prior to the initiation of the cisplatin infusion. 
This was followed by a 24-hour continuous infusion, either 
with 1 mg/h of ondansetron (group I) or the same volume of 
saline solution (group II and III). The cisplatin infusion 
was set up 15 minutes after the start of the continuous 
infusion and run over 1-4 hours. 
Assessment of efficacy and side effects 
All patients were monitored in hospital for the 24 hours 
after the cisplatin infusion. Nausea was assessed by the 
patient before treatment, and at 8 and 24 hours after 
treatment, using a four-point graded scale (none, mild -did 
not interfere with normal daily life, moderate - interfered 
with daily life, severe - bedridden due to nausea). 
The timing and number of emetic episodes were recorded 
and cross-checked with the patient. A single emetic episode 
was defined as a single vomit or retch (vomit not 
productive of liquid), or any number of continuous vomits 
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or retches. Each episode was separated by the absence of 
symptoms for at least one minute. The overall response 
criteria for emesis were: complete response (CR): 0 emetic 
episodes, major response (MR): 1-2, minor response (mR): 3-
5, and failure (F): > 5 emetic episodes or rescued. 
Any adverse medical events that occurred during the study 
(or the follow-up period) were recorded and their severity 
and relationship to ondansetron assessed. 
Statistical analysis 
All analyses were performed on the total population 
(intention to treat analysis) providing efficacy data were 
available, as well as the évaluable population (with satis-
factory protocol compliance). The proportions of patients 
showing a complete or a complete plus major response were 
compared between treatments using a two-sided Mantel-
Haenszel chi-square test stratified by centre. 
The time to first emetic episode was compared for all 
pairs of treatment using Wilcoxon rank sum analysis. A 
separate analysis was also carried out after stratification 
by country, using the Van Eiteren method for combining 
Wilcoxon statistics over strata [14]. 
The grades of nausea for the θ and 24 hours after chemo­
therapy were analysed using the stratified, extended 
Mantel-Haenszel method. 
Subset analysis for the difference in gender, cisplatin 
dose and concurrent chemotherapy was carried out using the 
chi-square test for 2x2-, 2x3-, and 2x4-tables. 
RESULTS 
The interim analysis of data on the first 149 patients on 
an intention to treat basis indicated that complete or 
major control of emesis was achieved in 36/46 (78%) 
patients of group I, 42/50 (84%) of group II and 40/53 
(76%) patients of group III. As there appeared to be no 
differences between the treatment groups, a statistical 
analysis was not carried out and the study was progressed 
to completion. 
Between September 1989, and June 1990, 535 patients with 
pathologically confirmed cancer were enrolled in the study. 
Demographic characteristics of the 535 patients entered 
into the trial are shown in Table 2. The median cisplatin 
dose was 72 mg/m , the type of concurrent chemotherapy is 
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presented in Table 3. There were no significant differences 
in age, gender, average alcohol intake, primary tumour 
site, cisplatin dose and concomitant chemotherapy among the 
3 treatment groups. There were 42 patients who did not 
fully comply with the protocol. The reasons for this are 
shown in Table 4. Although the distribution of the un-
evaluable patients over the 3 groups was significantly 
different (P=0.016), the analysis of the efficacy results 
of the total and the évaluable population showed no 
differences between them. Therefore the efficacy results 
presented here are for the "intention to treat population" 
since this more closely reflects clinical practice. 
Table 2. Patient demography 
Patients randomized 
Sex 
male 
female 
Age (years) 
19-29 
30-65 
> 65 
median 
range 
Primary tumour site 
Head and neck 
Lung 
Gastrointestinal 
Genitourinary 
gynaecological 
bone/soft tissue 
miscellaneous 
Alcohol intake 
none or 
< 7/week 
1-4 U/day 
> 4 U/day 
8mg+lmg/h 
182 
Θ2 (45) 
100 (55) 
10 (5) 
136 (75) 
36 (20) 
57.5 
19-84 
31 (17) 
30 (16) 
15 (8) 
28 (15) 
67 (38) 
3 (2) 
Π (4) 
143 (79) 
25 (14) 
14 (8) 
Nuntoer of pat 
32mg 
180 
95 (53) 
85 (47) 
12 (7) 
117 (65) 
51 (28) 
60 
19-77 
30 (17) 
41 (23) 
10 (6) 
22 (12) 
66 (37) 
3 (2) 
13 (3) 
140 (7B) 
25 (14) 
14 (8) 
ierrts (%) 
8mg 
173 
86 (50) 
87 (50) 
5 (3) 
120 (69) 
48 (28) 
60 
25-82 
27 (16) 
39 (23) 
9 (5) 
25 (15) 
65 (38) 
4 (2) 
11 (1) 
132 (76) 
27 (16) 
13 (8) 
Total 
535 
263 (49) 
272 (51) 
27 (5) 
373 (70) 
135 (25) 
59 
19-84 
88 (16) 
110 (21) 
34 (6) 
75 (14) 
200 (37) 
10 (2) 
35 (4) 
415 (78) 
77 (14) 
41 (8) 
1 unit of alcohol = 1 measure of spirit, 1 glass of wine or 250 ml of beer 
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Table 3. Concurrent chemotherapy and cisplatin dose. 
Number 
Concurrent chemotherapy 
None 
Cyclo/ifosfamide 
Epi/doxorubicin 
Cyclophosphamide + 
epi/doxorubicin 
Eto/teni poside 
5-fluorouracil 
Miscellaneous * 
Cisplatin <tose 
< 50 mg/m 
8mg+1mg/h 
1Θ2 
58 
32 
17 
13 
18 
16 
28 
Π ( 6) 
Nimber of patients (Ζ) 
32mg 
180 
57 
37 
14 
8 
21 
17 
26 
6 ( 3) 
8mg 
173 
63 
36 
11 
Π 
19 
14 
19 
10 ( 6) 
Total 
535 
178 
105 
42 
32 
58 
47 
73 
27 ( 5) 
50-69.9 mg/ili 
70-99.9 тд/іт£ 
г. 100 mg/m 
ρ 
Median dose (mg/m ) 
Range 
79 (43) 66 (37) 
58 (32) 62 (34) 
34 (19) 46 (26) 
70 
30-125 
76 
31-124 
70 (40) 
66 (38) 
27 (16) 
71 
37-153 
215 (40) 
186 (35) 
107 (20) 
72 
30-153 
•miscellaneous: Bleomycin, Vincristine, Vinblastine, Vindesine, 
Methotrexate, Mitoxantrone, Mitomycin, Dacarbazine. 
Table 4. Reasons for unevaluability 
Concurrent 
anti-emetics 
corticosteroids 
benzodiazepines 
Patients not naive 
Cisplatin dose 
wrong dose 
wrong time 
Concurrent illness 
Others 
Total 
8mg+1n>g/h 
2 
1 
-
3 
2 
4 
1 
1 
14 
Number of 
32mg 
-
1 
-
-
2 
4 
_ 
-
7 
patients 
8mg 
2 
4 
2 
4 
2 
4 
3 
-
21 
Total 
4 
6 
2 
7 
6 
12 
4 
1 
42 
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Acute Nausea 
Pretreatment nausea was absent in 94% of the patients, 5% 
of the patients had mild nausea. After 8 hours of study 
treatment 88% (I), 87% (II), and 85% (III) of the patients 
had none or mild nausea. The percentages of patients 
experiencing none or mild nausea after 24 hours were 77% in 
group I, 75% in both groups II and III (P>0.5). The results 
are shown in Fig. 1. 
n-182 n-179 n-171 
β hr 24 hr β hr 24 hr θ hr 24 hr 
24 hr infuilon 32 mg 8 mg 
Η none И mild ( Z U moderate Е Ш severe 
Figure 1. 
Control of acute nausea with the continuous infusion (n=182), 32 mg single dose 
(n=179) and θ mg single dose (n=171) schedules. 
Acute Emesis 
Results for the control of acute emesis are shown in Fig. 
2. Complete and major responses were achieved in 74% of 
patients (I), 78% (II) and 74% (III). In the pairwise 
treatment comparison, no significant differences were found 
between the 3 dose regimens. 
The pattern of emesis, expressed as the total number of 
emetic episodes at hourly intervals over 24 hours, was 
similar in the 3 groups (Fig.3). There was an initial small 
peak in the first 8 hours which was repeated at 18 hours. 
The time to the first emetic episode was similar for the 3 
dosage schedules, and was not dependent on the cisplatin 
dose, sex, or concomitant chemotherapy. 
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n-182 η·1βΟ n-ІГЭ 
7 S * 
25% 
24 hr ΙηΙυβιοη 32mg 8mg 
¡ H CR Е Й MR E H m R ^ F 
Figure 2. 
Control of acute emesis with the continuous infusion (n=182), 32 mg single dose 
(n=180) and 8 mg single dose (n=173) schedules. 
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Figure 3. 
Episodes of emesis during the 24 hours after cisplatin administration with the 
continuous infusion, 32 mg single dose and 8 mg single dose schedules. 
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Control of Acute Nausea and Emesis 
Fifty-two percent of patients in group I, 53% in group II 
and 51% in group III had no emesis and reported none or 
mild nausea over the 24 hour period. Obviously these 
results were not significantly different. 
Influence of cisplatin dose and concomitant chemotherapy 
A retrospective stratification of efficacy data (emesis) on 
the basis of cisplatin doses and concurrent cytotoxic 
agents revealed that there were no statistically sig-
nificant differences between the treatment groups for these 
prognostic factors (Table 5). Overall, complete control of 
emesis was achieved in a significantly greater proportion 
of patients (157/242 (65%)) who received cisplatin at doses 
<70 mg/m2 compared with 137 of 293 (48%) patients who 
received higher doses of cisplatin (> 70 mg/m ) (P<0.001). 
Of the 107 patients who received cisplatin at doses > 100 
mg/m , complete control was achieved in 16 of 34 (47%), 21 
of 46 (46%) and 11 of 27 (41%) of patients in groups I, II, 
and III respectively. The concurrent use of other 
moderately emetogenic agents also significantly affected 
the degree of control of emesis; complete control was 
achieved in 114 of 167 (68%) patients who received 
cisplatin alone, compared with 84 of 190 (44%) patients who 
received other emetogenic cytotoxic agents concurrently 
(P<0.001). 
Influence of patient gender 
A retrospective stratification of efficacy data on the 
basis of patient gender revealed that there were no statis-
tically significant differences between the treatment 
groups for this factor. However, stratification of the 
pooled efficacy data as shown in Tables 5 and 6 indicated 
that overall, complete control of emesis was achieved in a 
significantly higher proportion of male patients (67% 
versus 43%, P<0.001). The observed difference was not 
influenced by the doses of cisplatin or concurrent cyto-
toxic agents administered to the patients. 
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Table 5. Number (percentage) of complete responses in the 
different treatment groups s t r a t i f i e d for sex, 
c i sp la t in dose and chemotherapy. 
Total 
population 
Number of patients (Z) 
II III Pooled 
data CR 
Sex 
male 
female 
263 
272 
55 (67) 
44 (42) 
65 (68) 
37 (44) 
57 (66) 
36 (41) 
177 (67) 
117 (43) 
Cisplatin dose 
< 70 mg/mZ 
70-99 mg/nu 
ï 100 mg/m 
240 
187 
108 
51 (57) 
32 (54) 
16 (47) 
50 (69) 
31 (50) 
21 (46) 
56 (71) 
27 (41) 
11 (39) 
157 (66) 
90 (48) 
48 (44) 
Concomitant Chemotherapy 
none 167 32 (58) 38 (76) 44 (71) 114 (68) 
high 190 31 (48) 29 (43) 24 (41) 84 (44) 
low 178 36 (58) 35 (56) 25 (47) 96 (54) 
Concomitant chemotherapy: High emetoqenic: cyclophosphamide, ifosfamide, epi/doxo-
rubicin, dacarbazme; Low emetoqenic: 5-f luorouracil, mitoxantrone, mitomycin, 
bleomycin, etoposide, vmblastin, vincristine; Alone: cisplatin. 
CR: complete response. 
Table 6. Number (percentage) of complete responses in male 
and female patients, stratified for cisplatin 
dose or concurrent chemotherapy. 
(%) Male Female 
Cisplatin dose 
о 
< 70 mg/m 
70-99 mg/nC 
i 100 mg/m2 
89 (78) 
53 (62) 
36 (56) 
68 (53) 
37 (36) 
12 (27) 
Concomitant chemotherapy 
alone 
high 
low 
84 (77) 
22 (71) 
71 (58) 
30 (52) 
62 (40) 
25 (45) 
Concomitant chemotherapy: High emetoqenic: cyclophosphamide, ifosfamide, epi/doxo-
rubicin, dacarbazme; Low emetoqenic: 5-fluorouracil, mitoxantrone, mitomycin, 
bleomycin, etoposide, vmblastin, vincristine; Alone: cisplatin. 
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Tolerabilitv 
All 3 dosage schedules were well tolerated, in particular 
the 32 mg single dose was not associated with an increase 
in the incidence of adverse events. The most commonly 
reported side effects considered by the investigator 
possibly, probably or almost certainly related to 
ondansetron are listed in Table 7. Headache was the most 
commonly reported side effect (11% of patients). None of 
these patients were withdrawn from the study and the 
symptoms resolved spontaneously or were treated with mild 
analgesics. Two major adverse events were considered 
related to ondansetron treatment: one case of severe con­
stipation and one case of pseudomembranous colitis, which 
resolved spontaneously. Transient changes in ALT/AST, which 
were considered to be related to ondansetron, occurred in 4 
patients of group I, in 7 patients of group II and in 1 
patient of group III. All changes resolved at follow-up, 
and none were associated with any clinical signs or 
symptoms. 
Table 7. Adverse Events (assessed related to ondansetron) 
Headache 
Diarrhea 
Constipation 
flushing 
Xerostomia 
Laboratory changes 
Mnscellaneous 
Number of 
8fng+1mg/h 
16 (9) 
3 (2) 
3 (2) 
2 (1) 
1 (0.5) 
4 (2) 
η (6) 
patients r 
32mg 
25 (14) 
5 (3) 
3 (2) 
2 (1) 
3 (2) 
5 (3) 
14 (8) 
ι (%*) 
8mg 
20 (12) 
5 (3) 
-
-
-
2 (D 
10 (6) 
Total 
61 (П) 
13 (2.5) 
6 (1) 
4 (0.8) 
4 (0.8) 
13 (2.5) 
35 (7) 
* = percentage of total study population 
DISCUSSION 
Several studies have shown ondansetron to be a safe and 
efficacious anti-emetic in the prevention of cisplatin-
induced emesis. Pharmacokinetic modelling suggested that 
ondansetron given as an θ mg intrvenous loading dose 
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followed by 1 mg/h for 24 hours would give consistent 
plasma levels of 30 ng/ml. These levels were considered to 
be optimal for blocking 5-HT3 receptors and maximizing 
anti-emetic efficacy. Two comparative trials which in-
vestigated the efficacy of this selected dosing schedule 
[7,8] showed ondansetron to be superior to high-dose meto-
clopramide in the prophylaxis of acute cisplatin-induced 
emesis. This trial has investigated whether single pro-
phylactic doses of ondansetron are as effective as the 
constant infusion schedule and the contribution of the 24 
hour continuous infusion to overall efficacy. Single dose 
prophylaxis would have obvious benefits to patients and 
hospital staff alike. 
The most striking observation in this study is the 
similarity in anti-emetic control achieved with the 3 
treatment schedules, either for complete and/or major 
response, as well as for the control of emesis and nausea 
considered together. These results are consistent with 2 
other comparative trials that investigated the efficacy of 
the continuous infusion regimen of ondansetron, and a 
recent trial where complete control of emesis was reported 
in 58% of patients with a single intravenous dose of 32 mg 
and in 57% with the continuous infusion schedule [7,8,15]. 
The pattern of emesis provide further evidence that the 3 
dose schedules are equally efficacious. 
The half-life time of elimination of ondansetron is 
approximately 4 hours in healthy volunteers and young 
patients [16,17] but may be upto 7 hours in elderly 
patients (>65 years) [18]. Following a single bolus dose of 
8 mg of ondansetron plasma levels fall to below 5 ng/ml at 
12 hours, compared to consistent levels of 30-50 ng/ml with 
the continuous infusion schedule used in this study 
[19,20]. The similar degree of anti-emetic control and 
pattern of emesis experienced by patients in the 3 
treatment groups indicate that these low consistent plasma 
levels afforded by the continuous infusion regimen confer 
no additional benefit during the acute phase of emesis. 
This emphasizes that the period up to 8-12 hours following 
the cisplatin infusion may be the critical period for acute 
anti-emetic control. 
Several prognostic factors such as previous exposure to 
chemotherapy, patient age, gender, chronic alcohol use, and 
dose of cisplatin administered are known to affect the 
control of chemotherapy-induced nausea and vomiting [21]. 
This large parallel group study excludes that the results 
are influenced by a carry-over effect [22]. Moreover, this 
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comparative trial was designed to include chemotherapy-
naive patients only and all the important prognostic 
factors were well balanced within the 3 groups. The com­
parable efficacy observed with the θ mg single dose, in 
particular, cannot therefore be attributed to a chance 
selection of patients who were likely to have a more 
favourable response in this treatment group. Some 
interesting points emerged from the retrospective stratifi­
cations of response based on gender and the concurrent use 
of cytotoxic agents. It is known that emesis in women is 
less easy to control than in men [21], but it is not clear 
whether this is due to an underlying mechanism(s) or the 
more frequent use of moderately emetogenic agents such as 
cyclophosphamide or doxorubicin with cisplatin. In this 
study the degree of complete control was significantly 
lower in female patients. This difference was consistently 
observed in further retrospective stratifications to 
determine the effect of cisplatin dose or concurrent chemo­
therapy on treatment outcome in men and women. The results 
suggest that although the use of concurrent cytotoxics 
affect treatment outcome in women, they are not found to be 
an influencing factor on their own. Other factor(s) 
therefore may be involved. Further studies should 
investigate the impact of several prognostic factors in 
order to optimize the most suitable prophylactic anti­
emetic regimen for patients. 
In the population studied, the majority of patients 
(>80%) received cisplatin at doses < 100 mg/m2 and the 
continous infusion of 1 mg/h or a higher single dose of 32 
mg conferred no additional benefits over a single 8 mg 
dose. The degree of complete control was significantly 
lower in the 107 patients receiving a cisplatin dose > 100 
mg/m , consistent with literature data [21]. Within this 
group patients (20% of patients) there were no statisti­
cally significant differences in response rates between the 
3 treatment schedules. However, the power of the com­
parisons was lower than that carried out for the response 
rates between treatment groups for patients who received 
cisplatin at doses < 70 mg/m . 
Although serotonin is a significant mediator of acute 
emesis [10], failure to completely protect all patients 
indicates that other mechanism(s) may also be involved. The 
addition of dexamethasone to ondansetron has been shown to 
significantly improve anti-emetic control [23]. As the 
mechanism and site of action of dexamethasone are not yet 
known, it is possible that dexamethasone contributes to 
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overall efficacy by suppressing these additional mecha-
nism(s). 
The side effects considered to be related to ondansetron 
were generally mild in nature, and the incidences were 
similar between the treatment schedules. As previously 
observed, headache was the most common event. 
In conlusion, this study shows that a single intravenous 
dose of θ mg of ondansetron is as efficacious as a 32 mg 
dose in the prophylaxis of acute cisplatin-induced emesis. 
A continuous infusion regimen of 1 mg/hour for 24 hours 
conferred no additional benefit in anti-emetic protection. 
The efficacy of single dose prophylaxis is likely to 
improve patient and nursing staff acceptance of 
ondansetron, and can suitably be given in an out-patient 
setting. 
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In previous chapters the anti-emetic efficacy and safety 
results of ondansetron obtained in our own studies in 
cisplatin and non-cisplatin chemotherapy have been 
described. Meanwhile anti-emetic trials with granisetron 
and tropisetron were also untertaken and evenso showed a 
good anti-emetic efficacy in chemotherapy-induced emesis. 
To date, studies have not yet been performed comparing the 
efficacy of the different compounds. 
This chapter reviews the data obtained in clinical 
studies with the three 5-HT3 receptor antagonists, 
ondansetron, granisetron and tropisetron. 
PHASE I/ DOSE ESCALATING PHASE II STUDIES 
In cisplatin containing regimens dose-ranging anti-emetic 
studies with ondansetron have been performed using con-
tinuous infusion schedules or intermittent bolus doses 
(Table 5). Pharmacokinetic modelling indicated that a 
consistent concentration above 30 ng/ml, thought to block 
all 5-HT3 receptors, could be achieved with a bolus dose of 
8 mg i.v. followed by an hourly infusion of 1 mg for 24 
hours, which was therefore used as basis in European 
studies. The anti-emetic efficacy of this and higher dose 
schedules showed a complete anti-emetic control in 20-40% 
of the chemotherapy-naive and pretreated patients. A dose-
response relationship was not established [49,57]. In dose-
ranging trials in the Unites States the anti-emetic 
efficacy of either 3 or 6 bolus doses of ondansetron (range 
0.01-0.48 mg/kg) at 2-8 hour intervals was evaluated [60-
65]. Anti-emetic response was poor with bolus doses below 
0.1 mg/kg. The highest anti-emetic response rate was 
obtained with bolus doses of 0.12-0.18 mg/kg. At higher 
doses, used in later trials, no improvement of results were 
seen. So far no schedule dependent efficacy has been found. 
In multiple-day cisplatin regimens a dose of 0.15 mg/kg of 
ondansetron given 3 times at 2- or 6-hour intervals, showed 
complete control in 36-82% of the chemotherapy-naive 
patients and in 33-75% of the pretreated patients. An 
increased bolus dose of ondansetron (0.3 mg/kg) did not 
result in an improved control [48]. There was a trend 
toward decreased activity on the third and fourth day of 
treatment, which is in contrast with other non-5-HT3 anta-
gonistic anti-emetics [62,66]. 
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Table 5. Anti-emetic results of 5-HT3 antagonists in emeto-
genic chemotherapy, open phase I and early phase 
II studies. 
Num 
ber 
Prior 
treatm 
no/yes 
ONDANSETRON 
42 
6 
10 
7 
23 
38 
10 
10 
39 
36 
17 
* 
79 
Anti-emetic 
dqse 
(mg/mZ) 
Continuous infusion 
n/y 
n/y 
n/y 
η 
8 + 1/h/24h 
10 + 2/h/24h 
12 + 4/h/24h 
12 + 3/h/18h 
Cisplatm 
dose 
CR 
(mg) 
70-120 
100-120 
100-120 
> 99 
Intermittent bolus doses (mg/kci) 
n/y 
n/y 
η 
η 
n/y 
η 
η 
GRANISETRON 
22 
13 
9 
20 
32 
149 
147 
n/y 
η 
η 
n/y 
У 
η 
η 
TROPISETRON 
22 
22 
25 
(56 ι 
100 
n/y 
У 
n/y 
:ourses 
η 
0.04-0.35 χ 3 
2-hourly 
0.01-0.48 χ 3 
4-hourly 
0.18 χ 3 
2-hourly 
4-hourly 
6-hourly 
8-hourly 
0.18 χ 6 
4-hourly 
0.15,0.3 χ 3 
4-hourly 
(w/kg) 
10-40 
40,80 
40,80 
40-100 
100 
40 
160 
(mg) -
12-48/m¿ 
5-20/m2 
10-40 
) 
5-40 
60-120 
> 59 
> 99 
> 99 
> 59 
> 99 
> 99 
> 99 
20-100 
25-120 
Doxo/CTX 
13 pts >50 
various CT 
66-120 
> 49 
> 49 
lOpts >99 
various CT 
75-100 
60-100 
> 50 
Anti-emetic 
MR 
16 
2 
2 
(38) 
(33) 
(20) 
2 (28) 
8 
17 
3 
4 
22 
18 
7 
41 
12 
7 
5 
9 
12 
92 
93 
8 
7 
33 
54 
(35) 
(45) 
(30) 
(40) 
(57) 
(50) 
(41) 
(52) 
(54) 
(54) 
(55) 
(45) 
(38) 
(62) 
(63) 
(36) 
(31) 
(59) 
(54) 
response 
F 
8 (19) 
1 (17) 
1 (10) 
2 (28) 
14 (61) 
13 (34) 
2 (20) 
2 (20) 
11 (28) 
8 (22) 
4 (24) 
12 (15) 
4 (18) 
5 (38) 
4 (45) 
4 (20) 
9 (28) 
24 (16) 
20 (14) 
5 (22) 
5 (23) 
17 (30) 
23 (23) 
18 
3 
7 
3 
1 
8 
5 
4 
6 
10 
6 
26 
6 
1 
0 
7 
11 
33 
34 
9 
6 
23 
n(%) 
(43) 
(50) 
(70) 
(44) 
( 4) 
(21) 
(50) 
(40) 
(15) 
(28) 
(36) 
(33) 
(28) 
(8) 
(35) 
(34) 
(22) 
(23) 
(42) 
OD 
(23) 
Ref 
59,49 
49 
49 
59 
60 
61 
62 
62 
61,63 
63 
64 
65 
67 
25 
25 
68 
69 
70 
70 
72 
73 
74 
75 
Abbreviations: CR: complete response; MR: major response; mR: minor response; F: 
failure, >3 emetic episodes; doxo: doxorubicin; CTX: cyclophosphamide; CT: 
chemotherapy. results of the 0.015 mg/kg dose not included (CR:15%). 
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In phase l/ll studies 10 цд/кд of granisetron showed no 
anti-emetic efficacy. At a dose of 40 цд/кд a complete 
control was obtained in 38-55% of the patients, both in 
cisplatin and non-cisplatin-based chemotherapy. A dose 
escalation up to 160 цд/кд did not increase the anti-emetic 
response [25,67-70]. Obviously postponement of the gra­
nisetron infusion for 2, 4, 6 hours had no impact on its 
efficacy [52]. Preliminary results with oral granisetron, 
at doses of 1 and 2.5 mg bd, indicate that it is also 
effective [71]. Up to now, only few data on tropisetron 
have been published. Doses of 5-40 mg and 5-48 mg/m have 
been tested, and again there was no dose-response relation­
ship. Five or 10 mg of tropisetron seemed to be as 
effective as the higher doses [72-75] (Table 5). 
In a further 5 open trials ondansetron was administered 
to 107 évaluable patients (65 chemotherapy-naive, 42 with 
refractory emesis), receiving non-cisplatin chemotherapy 
(e.g. cyclophosphamide >500 mg/m , doxorubicin >50 mg/m , 
ifosfamide 5 g/m2). A loading dose of 8 mg (oral, i.v. or 
partly i.v./ oral) was given before chemotherapy, and 
followed by 4 mg 6-hourly or 8 mg 8-hourly for 2-4 days. 
The combined results showed a complete protection in 69% of 
the chemotherapy-naive patients and in 67% of the patients 
with previously refractory emesis [76]. There was no clear 
difference between the various treatment schedules. 
Different doses of oral ondansetron (2 mg qds, 4 mg 
tds/qds, 8 mg tds) were administered to 54 évaluable 
patients receiving radiotherapy to the upper abdomen (field 
>100 cm2). The 2 mg dose was not effective in single 
exposure irradiation, higher ondansetron doses (4, 8 mg) 
completely controlled emesis in 59% and 62% of patients. 
With fractionated irradiation complete anti-emetic control 
occurred in 33% of the patients receiving 2 mg qds and in 
83% with a dose of 4 mg qds [77]. 
COMPARATIVE STUDIES 
Highly emetogenic chemotherapy (cisplatin >50 mg/m ) 
The comparison of the efficacy of three i.v. doses of 
ondansetron (0.15 mg/kg) given at 4-hour intervals with 
metoclopramide (2 mg/kg) given 3 times 2-hourly showed a 
complete control of 40% with ondansetron and of 30% with 
metoclopramide (P=0.07) [78]. The results of 2 double-
blind, crossover studies comparing the anti-emetic efficacy 
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of a continuous infusion of ondansetron (8 mg + 1 mg/h/ 
24hrs) with metoclopramide (3 mg + 4 mg/kg/8hrs) in 171 
naive patients demonstrated similar results which were sig-
nificantly in favour of ondansetron with regard to nausea 
and control of acute emesis (P<0.02) [79,80] (Table 6). 
Recent data indicate that a single bolus dose of 8mg of 
ondansetron is as effective as a dose of 32 mg, either 
given as a single bolus or a continuous infusion (CR: 
55%,58%,57% respectively) [81, this thesis]. Three 
different trials investigated the anti-emetic efficacy of a 
single dose of either granisetron or tropisetron in 
comparison with a combination of dexamethasone and meto-
clopramide, the latter was given as either a continuous 
infusion or a bolus dose regimen (Table 6). In these 
studies the single dose of each 5-HT3 antagonist was as 
effective as the combination regimen, an additional dose of 
granisetron was able to relieve breakthrough symptoms in 
most of the patients [82-84]. The addition of dexamethasone 
to ondansetron significantly increased anti-emetic control 
(CR:91% versus 64%, P<0.05) [85]. 
The incidence of delayed emesis was less after 
ondansetron (16 mg tds) compared to placebo [78]. Compared 
to metoclopramide, the control of delayed emesis was not 
different either with ondansetron or tropisetron [80,84]. 
In fact metoclopramide showed a better control of delayed 
nausea than ondansetron [80]. 
Moderately emetogenic chemotherapy (non-cisplatin or 
cisplatin 20-50 mg/mz) 
In 3 different double-blind studies the anti-emetic 
efficacy of ondansetron and metoclopramide has been com-
pared in mainly female patients receiving non-cisplatin 
chemotherapy. Acute nausea was better controlled with 
ondansetron. Complete control of acute emesis varied 
between 60-66% with ondansetron versus 27-49% with meto-
clopra-mide (P<0.001). Delayed emesis occurred less after 
ondansetron compared to metoclopramide, but this difference 
was not always statistically significant [86]. The combined 
data showed a superiority of ondansetron above meto-
clopramide on days 2 and 4 (P=0.001, P=0.013). Recently it 
has been shown that a twice daily oral administration of 8 
mg of ondansetron is as effective as a three times a day 
dose, for the first 24 hours as well as for the following 2 
days [87]. Compared with a combination regimen of chlor-
promazine and dexamethasone granisetron significantly 
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showed a better control of acute nausea and emesis in 
patients receiving moderately emetogenic chemotherapy (CR: 
70% versus 49%, P=0.001) [88] (Table 7). 
Table 6. Results of 5-HT3 antagonists in highly emetogenic 
chemotherapy (phase II/III trials). 
Num Male Platin Anti-Gtnetic Dose Anti-emetic response η (%) Ref 
ber Fem dose 5- н тз anta- Comparative CR MR CR MR 
(mg/m2) gomst (1) drug (2) (1) 
ACUTE Cisplatin emesis 
Ondans (mg) MCP (mg) 
274 209 > 99 0.15/kgx3 2x3/2-h 58 (40) 37 (30) 41 (30) 30 (22) 78 
98 2x3/3-h 
76 41 80-100 8+l/h/24h 3+4/kg/8h 35 (46) 22 (29) 12 (16) 20 (26) 79 
56 
95 53 50-100 8+l/h/24h 3+4/kg/8h 41 (44) 27 (28) 21 (22) 18 (19) 80 
68 
305 165 50-100 8+1/h/24h (58) (18) 81 
140 32 (57) (15) 81 
Gran (цд/кд) 
234 63 > 49 40 МСРЗ+4/кд/ 80 (70) 17 (15) 83 (69) 10 (8) 82 
37 8h+Dex 12mg 
149 > 49 80 MÇP2/kgx5 34 (46) 33 (44) 83 
Dex 20nig 
Diphenh 
Trop (mg) MÇP (mg) 
253 > 49 5 iv 3/kgx2 80 (63) 30 (24) 79 (63) 29 (23) 84 
Dex гОтд 
DELAYED Cisplatin emesis 
45 Ond 16 tds placebo significant difference on day 4 78 
79 Ond 8 tds MÇP 20 tds 28 (36) 16 (21) 29 (37) 24(30) 80 
216 Trop 5 od MCP 10 tds (61-91) (76-90) 84 
Abbreviations: CR, complete response; MR, major response; Ond, ondansetron; Gran, 
gramsetron; Trop, tropisetron; MCP, metocl oprami de; Dex, dexamethasone; 
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Table 7. Anti-emetic results of 5-HT3 receptor antagonists 
in moderately emetogenic chemotherapy (phase 
II/III trials). 
Num Plat in АгтЫ-emetic Dose Anti-emetic response η (%) 
ber dose 
(mg/m ) 5-HT, anta- Comparât CR MR CR MR 
gom st (1) drug (2) (1) (2) 
Chemo Ond (mg) MCP (mg) 
68 FAC/FEC Ac:4iv/4po 6(W20po 23 (66) 7 (20) 9 (27) 5 (15) 
Del: 8 tds 20 tds 33 (58) 13 (23) 28 (49) 9 (16) 
82 EC/AC Ac: 8 iv 60 iv 26 (65) 6 (15) 17 (41) 9 (21) 
± F Del: 8 tds 20 tds 29 (76) 25 (68) 
109 EC Ac: 8 po 60 iv 30 (60) 6 (12) 28 (47) 8 (14) 
Del: 8 tds 20 tds (69) (65) 
225 carbopl Gran 40мд/ Chi or prom 80 (70) 55 (49) 
CTX kg Dex 12mg 
piati η <50 
Abbreviations: CR, complete response; MR, major response; Ond, ondansetron; Gran, 
gramsetron; Trop, tropisetron, MCP, metoclopramide; Dex, dexamethasone; FAC, 5-
fluorouracil, doxorubicin, cyclophosphamide; E, epirubicin; CTX, cyclophosphamide; 
Ac, acute; Del, delayed. For references see 86, 88 
Radiotherapy 
Ondansetron, at a dose of θ mg tds, provided superior 
control in the prevention of acute nausea and emesis 
following radiotherapy compared to 10 mg of metoclopramide 
tds. Because the latter dose is not optimal, further 
studies are warranted [Θ9]. 
ADVERSE EFFECTS 
Clinical symptoms 
The assessment of a causal relation of a side effect with 
an anti-emetic drug in chemotherapy trials may be difficult 
because of the underlying disease and the use of cytotoxic 
drugs with intrinsic toxicities. It is therefore more 
realistic to consider the side effect profile in com­
parative trials. The reported side effects for 5-HT3 anta­
gonists were generally minor and transient (Table 8). 
Furthermore they were similar irrespective of the type of 
chemotherapy, but the frequency was lower in less emeto­
genic chemotherapy. Consistent adverse events in com-
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parative trials were headache and constipation; no extra-
pyramidal reactions were seen whilst on treatment with a 5-
HT3 antagonist [48,90,91]. In multiple-day trials with 
ondansetron the incidence of adverse events was increased, 
with diarrhea occurring less (6% versus 23%) and con-
stipation more frequently (11% versus 0%) [90]. 
Table 8. Percentage of adverse effects in comparative 
trials. 
headache 
diarrhea 
constipation 
sedation 
abd. discomfort 
extrapyramidal 
reactions 
akathisia 
Ondansetron 
n=338 
17 
15 
3.5 
3 
25 
0 
0 
Metoclopramide 
n=156 
8.5 
22.5 
1 
4 
2 
5 
3 
Granisetron 
n=982 
14 
1 
4 
2 
0 
0 
Comparative 
anti-emetic 
n=233 
5 
6 
1 
10 
for references see 56,90,91. 
Laboratory findings 
Occasional minor changes in liver function tests have been 
noted (ALT, AST) with ondansetron which were not dependent 
of dose, treatment duration, or route of administration. At 
the moment this is rather thought to be associated with the 
cisplatin dose [90]. Similarly, no major abnormalities have 
been reported with granisetron and tropisetron [91]. 
CONCLUSION 
Serotonin 5-HT3 receptor antagonists are a new class of 
drugs with an established anti-emetic efficacy in the 
prevention of radiotherapy- and acute chemotherapy-induced 
emesis. They protect against delayed emesis induced by 
moderately emetogenic chemotherapy, but their role in 
delayed cisplatin-induced nausea and vomiting requires 
further investigation. A major advantage of the compounds 
is their ease of administration and the absence of extra-
pyramidal reactions. Their interference with gastro-
intestinal motility which appears from the recorded con-
stipation needs attention. Besides headache, no other 
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causally related adverse effects or laboratory changes have 
been observed. Finally, the 3 discussed compounds appear 
not essentially different, neither in anti-emetic activity 
nor in safety profile. 
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SUMMARY 
The studies in this thesis report on the efficacy and 
safety profile of ondansetron (Zofran ), a selective and 
potent 5-HT3 receptor antagonist, in chemotherapy-induced 
nausea and vomiting. The recent discovery that serotonin3 
(5-HT3) receptor antagonists can markedly reduce chemo-
therapy- and radiotherapy-induced emesis activated further 
research and resulted in a re-evaluation of the neuro-
pharmacology and the sequence of events in the vomiting 
reflex arch. 
A survey of the current insights into chemotherapy-in-
duced emesis with serotonin (5-HT) and the 5-HT3 receptor 
as a potentially common thread is given in chapter 1 . The 
proposed key anatomical components of the vomiting reflex 
arch, consisting of afferent and efferent pathways and a 
central vomiting centre, provided some 30 years ago as a 
model is still a valuable framework. Rather than being a 
single anatomical entity, the vomiting centre is currently 
thought to be represented by complex interactions between 
adjacent areas in the brainstem. To date, the main emetic 
detectors are thought to be the chemoreceptor trigger zone 
and the abdominal visceral afférents. The chemoreceptor 
trigger zone receives information via peripheral neural 
afférents, and may be activated directly by blood borne 
agents or indirectly via numerous neurotransmitters. 
Changes in the intestinal morphology and motility, induced 
by chemotherapy, activate the vagal and splanchnic nerves 
which convey their signals to the chemoreceptor trigger 
zone and vomiting centre. Several indications support the 
idea that the transmission of this information, at least 
partly, occurs via 5-HT and its type 3 receptor. However, 
interactions with and involvement of other neurotrans-
mitters or mechanisms have to be clarified. 
Chapter 2 reviews the efficacy and toxicity data of the 
available anti-emetics in chemotherapy-induced emesis, and 
illustrates some pitfalls in the methodology of anti-emetic 
trials as well as factors known to affect the individual 
sensitivity of patients for the emetic challenge. So far 
high-dose metoclopramide (MCP)(3-6 mg/kg/day) has been the 
most effective single agent in the control of acute emesis. 
The dose to administer depends on the nature of the chemo-
therapeutic regimen (cisplatin/non-cisplatin, dose). 
However, high-dose MCP as well as other dopamine anta-
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gonists can induce extrapyramidal reactions, especially in 
young patients, and these remain a major drawback. The 
addition of dexamethasone and/or lorazepam not only de-
creases the incidence of extrapyramidal reactions, but 
further improves anti-emetic control, protecting ap-
proximately 60-70% of the patients. At present, the most 
effective regimen in the prevention of delayed nausea and 
emesis is a combination of MCP and dexamethasone, offering 
protection in 50% of the patients on cisplatin chemo-
therapy. Anticipatory nausea and emesis remain major 
problems because an effective treatment is lacking. 
Attempts to control this type of emesis focus on drugs with 
amnesic properties and behaviour therapy. 
Chapter 3 summarizes the available literature data (pre-
clinical/pilot studies) on three selective, competitive 5-
HT3 receptor antagonists: ondansetron, granisetron, and 
tropisetron. Their site of action is probably at both 
peripheral and central 5-HT3 receptor sites. Plasma con-
centrations of ondansetron and granisetron were generally 
dose-related, but showed a wide interpatient-variation. 
Pharmacokinetic data seem to be linear. The half-life time 
of elimination of granisetron is prolonged in patients 
compared to volunteers. Peak plasma concentrations, AUG and 
plasma half-life time of ondansetron were 2 to 3-fold 
greater in elderly patients, but there was no major ac-
cumulation. The 3 compounds are mainly excreted via the 
urine after extensive metabolism. Potential clinical use of 
these compounds in some psychiatric disorders has been 
suggested from animal studies, but clinical data are still 
awaited. The role of the 5-HT3 receptor antagonists in 
controlling gastro-intestinal contractility is well es-
tablished, although the results of in vivo studies con-
cerned with intestinal transit times are not always con-
sistent. The observed anti-emetic efficacy of the 3 agents 
against chemotherapy- and radiotherapy-induced emesis in 
animals, has been confirmed in the clinic. As far as has 
been described, major toxicity in animals only occurs at 
extremely high doses. In human studies headache and con-
stipation/abdominal discomfort seemed related to both 
ondansetron and granisetron, extrapyramidal reactions were 
never observed. Laboratory changes related to 5-HT3 anta-
gonists were occasionally reported and consisted of tran-
sient mild elevations of transaminases without any clinical 
impact. 
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The following chapters (4-8) describe the results of our 
studies that were mainly carried out in Dutch centers, and 
investigated the anti-emetic efficacy and safety of dif-
ferent ondansetron schedules in cytotoxic chemotherapy. 
Response criteria for emesis were: complete response (CR): 
0 emetic episodes; major response (MR): 1-2 emetic epi-
sodes; minor response (mR): 3-5 and failure (F) : >5 emetic 
episodes or rescued. An emetic episode is one vomit or 1-5 
retches within any 5-minute period. The intensity of nausea 
was assessed using a 100 mm visual analogue scale (VAS), 0 
mm representing "feeling not sick at all, 100 mm "worst 
ever feeling of sickness, and/or a graded scale (none, 
mild, moderate, severe). 
In chapter 4 and 5 we report on the results of 3 dif-
ferent dosage schedules of ondansetron in the prophylaxis 
of acute (first 24 hours) and delayed nausea and vomiting 
(days 2-6) induced by a first or subsequent course of 
cisplatin-based chemotherapy (>70 mg/m2) . On day 1 the 
forty three évaluable patients received the assigned dose 
of ondansetron as a continuous infusion (loading dose + 
infusion/24 hours). This regimen was chosen to achieve a 
constant plasma level of ondansetron following the obser-
vation that MCP was more effective when given as an in-
fusion. After 24 hours ondansetron was given orally to 28 
patients for a further 5 days. Complete and major control 
of acute emesis was achieved in 40% and 23% of patients 
respectively, and in delayed emesis 32% in both. Headache 
and constipation were the most commonly reported adverse 
events related to ondansetron, neither sedation nor extra-
pyramidal reactions were seen. 
In the same population, blood samples for assay of 
ondansetron concentration (HPLC) were obtained from 37 
patients on several time points over the first 24 hours. 
Plasma levels of ondansetron showed a wide interpatient 
variation independent of several patient variables. Neither 
a dose-response relationship, nor a threshold plasma level 
above which complete anti-emetic control occurred was 
found. However, the percentage of complete control was 
higher if patients had an ondansetron plasma level above 
the median plasma value for that timepoint (>±100 ng/ml), 
reaching a statistically significant difference at 3 and 6 
hours after the start of the ondansetron treatment. These 
data suggest that a plasma-response relationship may exist. 
We concluded that ondansetron is a safe and effective anti-
emetic agent in the prophylaxis of acute cisplatin-induced 
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emesis. The lowest dose schedule (θ mg + 1 mg/h/24hrs) was 
chosen for further comparative studies. Patients who were 
not controlled might benefit by an increased dose of 
ondansetron over the first 6-Θ hours after the ad­
ministration of cisplatin. 
Thirty-five patients refractory to standard anti-emetics 
after non-cisplatin chemotherapy received one of the 2 oral 
ondansetron treatment schedules (loading dose 8 mg, 
followed by 4 mg qds or θ mg tds) on first and subsequent 
chemotherapy courses (chapter 6). Complete and major con­
trol of acute emesis were obtained in 89% and 81% of 
patients, and in delayed emesis in 94% and 76% of patients 
respectively. The anti-emetic efficacy was maintained over 
the 3 following retreatment courses. Again headache and 
constipation were the main adverse events related to 
ondansetron. Therefore, oral ondansetron (daily dose 16-24 
mg) is a valuable anti-emetic drug in non-cisplatin based 
chemotherapy. 
In a randomized, double-blind crossover study a com­
parison was made between the anti-emetic efficacy and 
safety of ondansetron with high-dose MCP in the prophylaxis 
of acute and delayed cisplatin-induced (50-120 mg/m ) 
nausea and vomiting in 125 chemotherapy naive patients 
(chapter 7). On day 1, ondansetron was given as a con­
tinuous infusion (8 mg + 1 mg/h/24hrs), MCP as an 8-hour 
infusion (3 mg/kg + 4 mg/kg). On the following days, oral 
treatment consisted of either ondansetron 8 mg tds or MCP 
20 mg tds. In the acute phase a major or complete response 
was seen in 72% of the ondansetron-treated patients and in 
41% of the MCP-treated patients. Acute nausea was also 
significantly better controlled among the patients on 
ondansetron. Control of delayed emesis was similar and 
disappointing with both agents, whereas the control of 
delayed nausea was superior with MCP compared to 
ondansetron. Comparison of the side effect profile of both 
agents revealed that headache occurred more often during 
ondansetron treatment; whereas extrapyramidal reactions, 
tremors and anxiety/restlessness were only seen with MCP. 
The incidence of diarrhea was higher during MCP treatment, 
and constipation more frequent with ondansetron. Mild and 
transient increases of transaminases were equally seen on 
both treatments. In conclusion: this schedule of 
ondansetron is superior to high-dose MCP in the prophylaxis 
of acute cisplatin-induced nausea and vomiting, whereas the 
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effect of this MCP regimen on delayed nausea was superior. 
Chapter θ reports on the anti-emetic and safety results 
of 3 different doses of ondansetron, given as either the 
continuous infusion (I) or a single intravenous dose of 32 
mg (II) or 8 mg (III) respectively in 535 patients 
receiving cisplatin-based (50-120 mg/m ) chemotherapy for 
the first time (multicentre, randomized, double-blind, 
parallel study). The results in the 3 treatment arms were 
remarkably similar. Complete anti-emetic control was 
achieved in 54%, 57% and 54% of patients respectively, and 
nausea was absent in 53%, 51% and 48% of patients 
respectively. The lower response rate in female patients 
when compared to males (CR 43% versus 67%) was independent 
of any particular variable. Overall complete control was 
less at a cisplatin dose above 70 mg/m and when concurrent 
chemotherapy is given. Obviously, further research is 
required into the impact of several prognostic factors in 
order to optimize the anti-emetic regimen for the 
individual patient. Adverse events were not different among 
the 3 treatment groups, and similar to previous obser­
vations. We conclude that a single intravenous dose of 8 mg 
of ondansetron is as effective as a daily dose of 32 mg, 
given either as a single dose or a continuous infusion 
schedule, in the prophylaxis of acute cisplatin-induced 
nausea and vomiting. 
A survey of the anti-emetic results obtained with the 5-
HT3 receptor antagonists ondansetron, granisetron and 
tropisetron in clinical studies are given in chapter 9. 
Although the anti-emetic regimens in the control group were 
not always optimal, it becomes clear that a single dose of 
the three 5-HT3 receptor antagonists is superior in the 
prevention of acute nausea and vomiting induced by cis­
platin and non-cisplatin chemotherapy. The agents are 
effective in the control of delayed emesis induced by 
moderately emetogenic chemotherapy, whereas their role in 
the delayed symptoms after cisplatin needs further in­
vestigation. A major advantage is the absence of extra­
pyramidal reactions. If headache and constipation occur, 
they rarely require treatment. The transient increases of 
transaminases seen are probably related to the chemotherapy 
rather than the 5-HT3 receptor antagonists. 
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In conclusion: the 5-HT3 receptor antagonist ondansetron 
is an effective anti-emetic agent in the prophylaxis of 
acute cisplatin- and non-cisplatin-induced emesis. A single 
intravenous dose of θ mg of ondansetron is as effective as 
a higher daily dose in cisplatin chemotherapy. Patients 
with uncontrolled emesis may benefit by a higher dose of 
ondansetron, given over the first 6-Θ hours. Its efficacy 
and optimal dose in the prevention of delayed emesis in­
duced by cisplatin needs further investigation. A major 
advantage, next to the ease of administration, is the 
absence of extrapyramidal reactions. 
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SAMENVATTING 
Ondansetron is de eerste vertegenwoordiger uit de groep 
der selectieve serotonine type 3 (5-HT3) receptor anta-
gonisten. In dit proefschrift worden de resultaten be-
schreven betreffende de anti-emetische werking en het 
toxiciteitsprofiel van ondansetron, verkregen in studies 
bij oncologische patiënten die behandeld werden met cyto-
toxische chemotherapie. 
De ontdekking dat 5-HT3 receptor antagonisten de mis-
selijkheid en braken veroorzaakt door chemo- en radio-
therapie konden onderdrukken, veroorzaakte een stroom-
versnelling in het pathofysiologisch onderzoek betreffende 
deze effecten. Dit leidde tot nieuwe inzichten in de neuro-
farmacologie en een herevaluatie van de opeenvolging van 
gebeurtenissen in de "braakreflex" waarvan in hoofdstuk 1 
een overzicht wordt gegeven. De braakreflex is opgebouwd 
uit aanvoerende en afvoerende informatiebanen, en een 
centraal coördinatiecentrum: het braakcentrum. Tegenwoordig 
neemt men aan dat het braakcentrum eerder een funktioneel 
concept is en het anatomische substraat gevormd wordt door 
een netwerk van interacties tussen nabijgelegen centra in 
de hersenstam. De belangrijkste detectoren van emetische 
stimuli zijn de chemoreceptor trigger zone (centraal) en de 
maagdarmtractus (perifeer), waarbij vooral laatsgenoemde in 
vergelijking met vroeger een belangrijkere rol heeft toe-
bedeeld gekregen. Beide organen worden direkt of indirekt 
geaktiveerd door de toegediende chemotherapie en sturen 
impulsen naar het braakcentrum. Vele gegevens bevestigen 
dat serotonine via de 5-HT3 receptor in deze informatie-
overdracht een belangrijke rol als neurotransmitter speelt. 
Hoogstwaarschijnlijk zijn ook andere neurotransmitters 
hierbij betrokken, ofschoon nog niet bekend is welke en 
evenmin welke hun interakties zijn. 
In hoofdstuk 2 wordt een overzicht gegeven van de voor-
en nadelen van anti-emetica en hun bruikbaarheid bij de 
preventie van chemotherapie-geinduceerde misselijkheid en 
braken. Voorts worden de methodologische valkuilen van 
anti-emetica trials belicht evenals de faktoren die mede-
bepalend zijn voor de ernst van de emetische klachten. 
Vooralsnog was metoclopramide (MCP) in hoge dosering (3-6 
mg/kg) het meest effektieve anti-emeticum tegen de acute 
vorm van misselijkheid en braken na chemotherapie. Dit 
schema kan echter extrapyramidale reakties veroorzaken, die 
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voornamelijk bij adolescenten optreden en een groot nadeel 
zijn bij het gebruik van MCP. De toevoeging van dexa-
methason en/of lorazepam vermindert de frequentie van de 
extrapyramidale symptomen en verbetert bovendien de anti-
emetische effektiviteit. De beste resultaten bij de be-
handeling van verlate ("delayed") misselijkheid en braken 
worden verkregen met een combinatie van metoclopramide en 
dexamethason, ofschoon maar bescherming geboden wordt bij ± 
50% van de patiënten. Anticipatoire klachten van mis-
selijkheid en braken worden nog minder door de bestaande 
medicijnen beïnvloed. Anti-emetica met een amnestische 
werking zoals lorazepam, evenals gedragstherapie kunnen 
soms enig effekt hebben. 
De beschikbare literatuur van preklinische en vroege fase 
I studies met de 5-HT3 receptor antagonisten ondansetron, 
granisetron en tropisetron wordt in hoofdstuk 3 samengevat. 
Deze middelen hebben waarschijnlijk zowel een perifeer als 
een centraal aangrijpingspunt. Plasma concentraties van 
ondansetron en granisetron zijn meestal evenredig met de 
toegediende dosis, maar de spiegels zijn voor verschillende 
patiënten bij eenzelfde dosis erg ver uiteenlopend. Voor 
zover bekend verloopt de farmacokinetiek lineair. De elimi-
natie halfwaardetijd van granisetron is bij patiënten 
verlengd in vergelijking met die van gezonde vrijwilligers. 
De piekconcentratie, beschikbaarheid en halfwaardetijd van 
ondansetron zijn toegenomen bij oudere patiënten, doch dit 
leidde niet tot accumulatie. De 3 geneesmiddelen worden na 
uitgebreide metabolisatie voornamelijk via de urine uit-
gescheiden. Het staat vast dat serotonine door middel van 
de 5-HT3 receptor een rol speelt in de contractiliteit en 
ontlediging van de maag-darmtractus, maar de gegevens van 
"in vivo" studies zijn niet altijd consistent. Resultaten 
van dierexperimenteel onderzoek suggereren een rol voor de 
5-HT3 receptor antagonisten bij psychiatrische aandoeningen 
(angst, psychose, verslaving- en ontwennings-verschijn-
selen), doch concrete klinische gegevens ontbreken nog. 
Belangrijke bijwerkingen werden enkel gezien bij erg hoge 
doseringen. 
In de volgende hoofdstukken worden onze eigen onder-
zoeksresultaten met ondansetron beschreven. In alle studies 
werd zowel de acute anti-emetische (eerste 24 uur) effek-
tiviteit als de toxiciteit van ondansetron onderzocht. Het 
aan- of afwezig zijn van verlate misselijkheid en braken 
(dag 2-6) werd niet steeds bestudeerd. De wijze waarop 
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misselijkheid en braken gescoord en beoordeeld werden was 
in alle studies gelijk. Intensiteit van misselijkheid werd 
door de patient gescoord m.b.v. een visuele schaal (VAS, Ο­
Ι 00 mm) of een graderingsschaal (geen, mild, matig, 
ernstig). De respons criteria voor braken waren: compleet 
(CR): geen episode van braken, redelijk (MR): 1-2 episodes, 
matig (mR): 3-5 en slecht (F): >5 episodes of noodzaak tot 
het gebruik van andere anti-emetische medikatie. 
In een eerste studie onderzochten we de effektiviteit en 
toxiciteit van 3 oplopende ondansetron doseringen ten 
aanzien van de preventie van zowel de acute als verlate 
symptomen bij patiënten die behandeld werden met cisplatine 
(70-120 mg/m ), voor een eerste of een volgende keer 
(hoofdstuk 4 en 5). Gedurende de eerste 24 uur werd ondan-
setron intraveneus gegeven (oplaaddosis + continue infusie) 
aan 45 patiënten, en 28 patiënten gebruikten ondansetron 
oraal gedurende de daaropvolgende 5 dagen. De continue 
infusie werd gekozen om een continue plasmaspiegel te 
krijgen, in de veronderstelling dat dit tot betere anti-
emetische resultaten zou leiden zoals eerder was aangetoond 
voor MCP. Acute symptomen werden volledig voorkomen bij 40% 
van de patiënten, 23% braakte 1-2 keer. Verlate klachten 
waren afwezig of redelijk bestreden bij 32%. Hoofdpijn en 
obstipatie waren de meest gemelde bijwerkingen gerelateerd 
aan ondansetron. Extrapyramidale symptomen werden niet 
waargenomen. 
Van 37 patiënten uit deze populatie werd op geregelde 
tijdstippen over de eerste 24 uur bloed afgenomen voor 
bepaling van de ondansetron concentratie. Bij eenzelfde 
ondansetron dosering waren de plasmaspiegels bij verschil-
lende patiënten erg uiteenlopend, een duidelijke verklaring 
hiervoor werd niet gevonden. Er bestond geen dosis-respons 
relatie, noch een drempelwaarde waarboven complete be-
scherming geboden werd. We vonden wel aanwijzingen voor een 
plasma-respons relatie die het meest uitgesproken was op 3 
en 6 uur na de start van de anti-emetische infusie. We 
concludeerden dat ondansetron veilig en effektief is in het 
voorkomen van acute chemotherapie-geinduceerde mis-
selijkheid en braken na cisplatine, onafhankelijk van de 
ondansetron dosis. Patienten die onvoldoende beschermd 
worden zouden alsnog baat kunnen hebben bij een hogere 
dosis ondansetron over de eerste 6-8 uur na de cisplatine 
toediening. De laagste ondansetron dosering (8 mg + 1 
mg/h/24h) werd gekozen voor verdere vergelijkende studies. 
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Vijfendertig patiënten die na niet-cisplatine chemo-
therapie ondanks standaard anti-emetica meer dan 5 keer 
braakten werden behandeld met 1 van de 2 orale ondansetron 
schema's (8 mg, gevolgd door 4 χ 4 mg of 3 χ θ mg), even­
tueel te herhalen in daaropvolgende kuren (hoofdstuk 6). 
Negenentachtig en eenentachtig procent van de patiënten 
braakte of niet of hoogstens 2 keer gedurende de eerste 24 
uur, verlaat braken werd compleet en redelijk bestreden bij 
respektievelijk 94% en 76%. De goede anti-emetische werking 
bleef aanwezig bij de 3 daaropvolgende chemotherapiekuren. 
Bijwerkingen waren opnieuw hoofdpijn en obstipatie. Oraal 
genomen biedt ondansetron (dagdosis 16-24 mg) een goede 
anti-emetische bescherming bij niet-cisplatine chemo-
therapie. 
In hoofdstuk 7 wordt verslag gedaan van de resultaten van 
een gerandomiseerde, dubbel-blinde, crossover studie waar-
bij de effektiviteit, zowel wat acute als verlate symptomen 
betreft, en de toxiciteit van ondansetron en MCP met elkaar 
vergeleken werden bij 125 niet-chemotherapeutisch voor-
behandelde (naive) patiënten die cisplatine (50-120 mg/m ) 
chemotherapie kregen. Op de eerste dag werd ondansetron als 
een continue infusie gegeven (zie boven), MCP (3 mg/kg + 4 
mg/kg) werd over de eerste θ uur toegediend. Gedurende de 
daaropvolgende dagen werden beide middelen oraal ingenomen 
(ondansetron 3 x 8 mg, MCP 3 χ 20 mg). In de acute fase 
werd braken volledig of redelijk voorkomen met ondansetron 
bij 72% van de patiënten, dit was het geval bij 41% met 
MCP. Acute misselijkheid werd eveneens beter bestreden met 
ondansetron. Wat betreft de verlate symptomen was het 
effekt van beide middelen teleurstellend, terwijl mis-
selijkheid in die periode beduidend minder voorkwam bij 
MCP. Hoofdpijn werd meer gezien bij het gebruik van 
ondansetron; extrapyramidale symptomen/rusteloosheid/angst 
kwamen alleen voor bij MCP. Obstipatie werd vaker genoteerd 
bij ondansetron, terwijl MCP vaker gepaard ging met 
diarree. De conclusie hier was eenduidig: ondansetron is 
duidelijk superieur in de bescherming van de acute cis-
platine-geinduceerde misselijkheid en braken, terwijl 
metoclopramide in de bestudeerde dosis een betere be-
scherming biedt tegen het optreden van verlate mis-
selijkheid. De meeste patiënten verkozen ondansetron. 
Aangezien in andere studies aangetoond werd dat een 
eenmalige dosis van een antibraakmiddel een goede be-
scherming bood tegen misselijkheid en braken veroorzaakt 
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door cytostatica, rees de vraag of de continue infusie van 
ondansetron dan wel een extra bijdrage leverde aan de anti-
emetische bescherming. Om dit te beantwoorden werd een 
gerandomiseerde, dubbel-blinde, parallel studie verricht 
waarin het effekt van drie doseringsschema's van 
ondansetron werd vergeleken bij 535 patiënten die voor de 
eerste keer cisplatine chemotherapie (50-120 mg/m ) kregen. 
Een groep patiënten kreeg de continue infusie van 
ondansetron, een andere groep een eenmalige dosis van 32 
mg, en een derde groep kreeg eenmalig 8 mg ondansetron. De 
resultaten waren opvallend gelijk in de 3 groepen. Acute 
misselijkheid werd voorkomen bij respektievelijk 53%, 51% 
en 48% van de patiënten, acuut braken was afwezig bij 
respektievelijk 54%, 57% en 54%. Dit bevestigt dat een 
goede anti-emetische bescherming gedurende de eerste 8 uur 
na de cisplatine toediening bepalend is voor de uit-
eindelijke respons na 24 uur. Waarom vrouwen signifikant 
minder goed beschermd worden dan mannen (CR:43% versus 67%) 
kon vooralsnog niet verklaard worden. Het aantal complete 
responders was lager als de cisplatine dosis hoger was dan 
70 mg/m , en eveneens als andere cytostatica samen met 
cisplatine werden toegediend. De bijwerkingen waren niet 
verschillend in de 3 groepen. Samenvattend werd uit deze 
studie duidelijk dat een eenmalige dosis van 8 mg 
ondansetron even effektief is als een dagdosis van 32 mg, 
waarbij een continue infusie van 1 mg/h niet bijdraagt tot 
een grotere effektiviteit. Voorts is het belangrijk dat 
verder onderzoek verricht wordt naar prognostische faktoren 
en hun etiologie, om het anti-emetische beleid hierop 
individueel te kunnen afstemmen. 
In hoofdstuk 9 wordt een overzicht gegeven van de resul-
taten verkregen met de 5-HT3 receptor antagonisten in 
klinische studies bij cisplatine- en niet-cisplatine bevat-
tende chemotherapie. In de meeste vergelijkende studies 
zijn de 5-HT3 receptor antagonisten superieur ten opzichte 
van standaard anti-emetica bij de bescherming van acute 
chemotherapie-geinduceerde misselijkheid en braken. Ze zijn 
evenwel niet het uiteindelijke antwoord bij de bestrijding 
van de verlate symptomen na cisplatine chemotherapie. Milde 
bijwerkingen zijn hoofdpijn en obstipatie. De passagere 
leverfunktiestoornissen die gemeld zijn worden waarschijn-
lijk eerder veroorzaakt door de chemotherapie, dan door de 
5-HT3 receptor antagonisten. 
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Op grond van onze eigen onderzoeksresultaten kunnen we 
stellen dat ondansetron een effektief anti-emeticum is bij 
de preventie van acute misselijkheid en braken na cis-
platine en niet-cisplatine chemotherapie, terwijl de effek-
tiviteit en de juiste dosering bij de preventie van de 
verlate symptomen nog nader onderzoek behoeft. Bij cis-
platine chemotherapie (>50 mg/m ) is een eenmalige 
ondansetron dosis van 8 mg even effektief als een hogere 
dosering. Bij patiënten die met deze dosis onvoldoende 
beschermd worden is het zinvol een hogere dosis over de 
eerste 6-Θ uur te proberen. Ondansetron veroorzaakt geen 
extrapyramidale symptomen, maar kan gepaard gaan met hoofd­
pijn en obstipatie. 
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NAWOORD 
Terugblikkend op de periode dat ik me bezighield met dit 
proefschrift, komen vele gebeurtenissen, het enthousiasme 
en de twijfels, naast gedachten over de relativiteit hier-
van opnieuw bovendrijven. Dat dit boekje desondanks toch 
geschreven is heb ik aan een groot aantal mensen te danken, 
die achter de schermen inspirerend en stimulerend hebben 
meegewerkt en zonder wiens hulp dit werk nooit zijn 
premiere zou hebben beleefd. Hoewel woorden tekortschieten 
wil ik hierbij toch graag sommigen noemen. 
De betrokken patiënten hebben er door hun aktieve bijdrage 
bij het invullen van de dagboekkaarten voor gezorgd dat we 
met de gegevens verder konden werken. 
Zonder de nauwgezette medewerking van de verpleegkundigen 
op de afdelingen in Rotterdam, Nijmegen en de andere be-
trokken centra bij het verzamelen van de gegevens zou dit 
proefschrift niet geschreven zijn. Catharien, Maureen, 
Marjon, Yvonne, Lydia, Joop, Liesbeth, Katinka, Lucia, 
Marianne en vele anderen zorgden er niet alleen voor dat 
alle checklisten/dagboekkaarten nauwkeurig werden ingevuld, 
maar ook dat ze opgeborgen werden als ik ze (weer eens) 
vergeten was mee te nemen. Bovendien stonden ze in voor de 
benodigde bloedafnames. 
Rob Oosterom en de laboratorium medewerkers stonden borg 
voor een goede verwerking en opslag van de diverse bloed-
monsters. 
Mevr. E. Vonk-Neele en mevr. M. Westerhout-Kersten bezorg-
den stipt alle recente publicaties en verbaasden me steeds 
weer door hun vriendelijke hulp als ik nog een nieuwe lijst 
referenties bij ze bracht. 
J. Vuik gaf nuttige adviezen voor het gebruik van het 
grafisch computerprogramma, en D. van de Wel, S. Sliwa en 
M. Polak werkten mee aan de foto's, dia's en figuren. 
Zonder de medewerking van onderzoekers uit andere centra 
(P.A. van Liessum, S. Mols-Jevdevic) zouden de hier be-
schreven studies nog lang niet afgerond zijn. Aan de dis-
cussies op weg naar of bij symposia bewaar ik een goede 
herinnering. 
De junioren en senioren van de afdeling Medische Oncologie 
(hoofd: dr. G. Stoter) hielpen elk op hun eigen manier bij 
het tot stand komen van dit proefschrift. Enkel en alleen 
al de extra gecreëerde schrijftijd was een behoorlijke 
steun. Mijn verschillende kamergenoten P. Stolk, W. Kruit, 
en D. de Gooyer hielpen mee het dagdagelijkse werk in een 
ontspannen sfeer te verrichten waaraan de leerzame en 
157 
onderhoudende discussies, al of niet onder het genot van 
een drankje, zeker toe bijdroegen. H. Goey was wel ver-
wonderd, doch vond het steeds weer vanzelfsprekend als hij 
me op de meest onverwachte momenten achter zijn personal 
computer aantrof. Dr. P.I.M. Schmitz was behulpzaam bij de 
statistische analyse van sommige gegevens. 
Door de correcties van zowel mijn gesproken als geschreven 
engels maakten Diane Batchelor en Liz Lane-Allman me al-
lengs meer vertrouwd met een derde taal. 
De secretariële hulp en betrokkenheid van Annelies Zorge-
van der Heiden heb ik al die tijd erg gewaardeerd, terwijl 
de inzet van Rafaela Luikens bij het klaar stomen van de 
definitieve versie van dit proefschrift onmisbaar was. 
Belangstelling en steun van buiten de Daniel den Hoed 
Kliniek zijn even onontbeerlijk geweest bij de tot stand 
koming van dit werkje. Mijn ouders hebben me, zoals al 
eerder, ook nu weer de mogelijke hulp en steun geboden. 
Marjan Kaljouw hielp een en ander steeds opnieuw te rela-
tiveren en te versnellen; en zij en Astrid Koeter waren 
vriendinnen door dik en dun. En tenslotte brachten mijn 
vrienden en familie al die tijd ongevraagd en onvoor-
waardelijk geduld en begrip op voor mijn (gebrek aan) 
levensstijl. 
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1. Gezien het verschil in patroon van braken na cisplatine 
bij de profylactische toediening van metoclopramide of 
ondansetron is het aannemelijk dat, naast serotonine en 
de 5-HT3 receptor, nog andere, onbekende faktoren 
betrokken zijn bij de informatie- overdracht bij het 
ontstaan van misselijkheid en braken na chemo- en 
radiotherapie, (dit proefschrift) 
2. De relatief mindere effektiviteit van serotonine3 
antagonisten bij de preventie van vertraagde 
misselijkheid en braken, in tegenstelling tot de effek-
tiviteit in de acute fase, suggereert een verschillend 
ontstaansmechanisme van beide fenomenen. 
(dit proefschrift) 
3. De tegenstrijdige waarnemingen bij het gebruik van 5-
HT3 receptor antagonisten ten aanzien van een dosis-
plasmaspiegel-effekt relatie lijkt mede te berusten op 
interpatient variabiliteit ter hoogte van de 5-HT3 
receptor (affiniteit, serotonine release). 
(dit proefschrift) 
4. Ter preventie van misselijkheid en braken gedurende de 
eerste 24 uur na cisplatine toediening is een eenmalige 
dosis van 8 mg ondansetron even effektief als een 
dagdosis van 32 mg. (dit proefschrift) 
5. Bij een langdurig gebruik van ondansetron moeten 
maatregelen genomen worden ter voorkoming van 
obstipatie. (dit proefschrift) 
6. Het feit dat vrouwen zichtbaar gevoeliger zijn dan 
mannen gaat ook op voor de emetogeniciteit van 
chemotherapie; de laatstgenoemde gevoeligheid dient 
echter bestreden te worden, (dit proefschrift) 
7. De WHO criteria voor weergave van de ernst van 
misselijkheid en braken dienen grondig aangepast te 
worden, waarbij misselijkheid en braken afzonderlijk en 
numeriek gegradeerd moeten worden. 
8. In tegenstelling tot eerdere bevindingen (Atkins et al, 
N Engl J Med 1988, 1557-63) is het optreden van dys-
thyreoidie bij IL2 behandeling niet positief 
gecorreleerd aan tumorrespons (Kruit et al, submitted). 
9. Binnen de huidige behandelingsstrategie van de appen-
dicitis acuta met infiltraat dient voor personen < 40 
jaar plaats ingeruimd te worden voor een conservatief 
beleid. (Devilee NTvG 1990, 851-3) 
10. Bescheidenheid is geen substituut voor een grote per-
soonlijkheid, verbaal geweld evenmin. 
11. Als geld even vergankelijk zou zijn als fruit, zou de 
wereld er heel anders uit zien. 
12. Stelling: korte bewering die aan het langste eind wil 
trekken. 
Nijmegen, juni 1991 Carolien Seynaeve 


